<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27965576</article-id>
<article-id pub-id-type="pmc">5127835</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2016.00449</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gentile</surname>
<given-names>Giulia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/386382/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ceccarelli</surname>
<given-names>Manuela</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/49746/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Micheli</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/49740/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tirone</surname>
<given-names>Felice</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/49703/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cavallaro</surname>
<given-names>Sebastiano</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn002">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/76890/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Institute of Neurological Sciences, National Research Council</institution>
<country>Catania, Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia</institution>
<country>Rome, Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Daniele Tibullo, University of Catania, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Stefano Forte, IOM Ricerca, Italy; Giuseppe Alberto Palumbo, Azienda Ospedaliero - Universitaria “Policlinico - Vittorio Emanuele”, Italy</p>
</fn>
<corresp id="fn001">*Correspondence: Felice Tirone <email xlink:type="simple">felice.tirone@cnr.it</email></corresp>
<corresp id="fn002">Sebastiano Cavallaro <email xlink:type="simple">sebastiano.cavallaro@cnr.it</email></corresp>
<fn fn-type="other" id="fn003">
<p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>7</volume>
<elocation-id>449</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 Gentile, Ceccarelli, Micheli, Tirone and Cavallaro.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Gentile, Ceccarelli, Micheli, Tirone and Cavallaro</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>We have recently generated a novel medulloblastoma (MB) mouse model with activation of the Shh pathway and lacking the MB suppressor Tis21 (<italic>Patched1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup>). Its main phenotype is a defect of migration of the cerebellar granule precursor cells (GCPs). By genomic analysis of GCPs <italic>in vivo</italic>, we identified as drug target and major responsible of this defect the down-regulation of the promigratory chemokine Cxcl3. Consequently, the GCPs remain longer in the cerebellum proliferative area, and the MB frequency is enhanced. Here, we further analyzed the genes deregulated in a <italic>Tis21</italic>-dependent manner (<italic>Patched1</italic><sup>+/−</sup><italic>/Tis21</italic> wild-type vs. <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic> knockout), among which are a number of down-regulated tumor inhibitors and up-regulated tumor facilitators, focusing on pathways potentially involved in the tumorigenesis and on putative new drug targets. The data analysis using bioinformatic tools revealed: (i) a link between the Shh signaling and the <italic>Tis21</italic>-dependent impairment of the GCPs migration, through a Shh-dependent deregulation of the clathrin-mediated chemotaxis operating in the primary cilium through the Cxcl3-Cxcr2 axis; (ii) a possible lineage shift of Shh-type GCPs toward retinal precursor phenotype, i.e., the neural cell type involved in group 3 MB; (iii) the identification of a subset of putative drug targets for MB, involved, among the others, in the regulation of Hippo signaling and centrosome assembly. Finally, our findings define also the role of Tis21 in the regulation of gene expression, through epigenetic and RNA processing mechanisms, influencing the fate of the GCPs.</p>
</abstract>
<kwd-group>
<kwd>medulloblastoma model</kwd>
<kwd>cerebellar precursor cell</kwd>
<kwd>drug target</kwd>
<kwd>Sonic Hedgehog</kwd>
<kwd>primary cilium</kwd>
<kwd>neural migration</kwd>
<kwd>retina</kwd>
<kwd>chemokines</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Ministero Economia e Finanze</funding-source>
<award-id rid="cn001">Project FaReBio</award-id>
</award-group>
<award-group>
<funding-source id="cn002">Fondazione Santa Lucia</funding-source>
</award-group>
<award-group>
<funding-source id="cn003">Associazione Italiana per la Ricerca sul Cancro<named-content content-type="fundref-id">10.13039/501100005010</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="7"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="232"></ref-count>
<page-count count="30"></page-count>
<word-count count="21419"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>About 30% of medulloblastomas (MBs), the pediatric tumor of the cerebellum, originates from the granule neuron precursor cells (GCPs) located in the external granular layer (EGL), at the surface of the developing cerebellum, in consequence of hyperactivation of the Sonic Hedgehog (Shh) pathway (Kadin et al., <xref ref-type="bibr" rid="B94">1970</xref>; Schüller et al., <xref ref-type="bibr" rid="B180">2008</xref>; Yang et al., <xref ref-type="bibr" rid="B220">2008</xref>; Gibson et al., <xref ref-type="bibr" rid="B63">2010</xref>; Northcott et al., <xref ref-type="bibr" rid="B152">2012</xref>). Other MB subtypes may originate from neural precursors of the cerebellar embryonic anlage, different from GCPs and dependent on Wnt signaling, or from GCPs with activation of different pathways (group 3), or also from neural precursors of unknown origin (group 4; Northcott et al., <xref ref-type="bibr" rid="B152">2012</xref>). GCPs intensely proliferate postnatally in the EGL, before exiting the cell cycle and migrating inward to form the mature internal granular layer (IGL; Hatten, <xref ref-type="bibr" rid="B75">1999</xref>). GCPs in the EGL are forced to divide by the proliferative molecule Shh, secreted by Purkinje neurons (Dahmane and Ruiz i Altaba, <xref ref-type="bibr" rid="B40">1999</xref>; Wallace, <xref ref-type="bibr" rid="B202">1999</xref>; Wechsler-Reya and Scott, <xref ref-type="bibr" rid="B211">1999</xref>). It is believed that the prolonged mitotic activity of the GCPs, consequent to hyperactivation of the Shh pathway, makes them potential targets of transforming insults (Wang and Zoghbi, <xref ref-type="bibr" rid="B205">2001</xref>).</p>
<p>We have previously shown that mice lacking one allele of <italic>Ptch1</italic>, which develop MB with low frequency as result of the activation of the Shh pathway (Hahn et al., <xref ref-type="bibr" rid="B71">1998</xref>), when crossed with mice knockout for the MB suppressor <italic>Tis21</italic> develop MB with very high frequency (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>,<xref ref-type="bibr" rid="B55">b</xref>). We identified as responsible for this effect a defect of migration of the GCPs that, remaining for a longer period in the EGL under the proliferative influence of Shh, developed tumor more frequently. Whole-genome analyses of expression and function indicated that the key molecule responsible for the lack of migration of GCPs is the chemokine Cxcl3 (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). Together with <italic>Cxcl3</italic>, we identified other 187 gene sequences, 163 of which have a functional product, whose expression in double mutant <italic>Ptch1</italic> heterozygous/<italic>Tis21</italic> knockout mice was modified, relative to <italic>Ptch1</italic> heterozygous mice in <italic>Tis21</italic> wild-type background (single mutants; Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). The set of genes whose expression significantly differs in the comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic> wild-type vs. <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> will be hereafter defined as Set A (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>A Venn diagram showing four genotype pairwise comparisons and the intersection of their differentially expressed gene/sequences set A–D</bold>. Set A corresponds to the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> vs. <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup>; Set B refers to <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> vs. wild type; Set C concerns <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> vs. <italic>Ptch1</italic><sup>+/+</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup>; Set D represents the double-knockout contribution in background wild type.</p>
</caption>
<graphic xlink:href="fphar-07-00449-g0001"></graphic>
</fig>
<p>Here, we aimed to expand the functional investigation of the previous whole-genome analysis of gene expression alterations occurring at the onset of tumorigenesis in the GCPs, in order to further examine the set of genes whose expression is modified in <italic>Ptch1</italic> heterozygous/<italic>Tis21</italic> knockout double mutant mice relative to <italic>Ptch1</italic> heterozygous/<italic>Tis21</italic> wild-type mice (Set A).</p>
<p>Given that <italic>Tis21</italic> mutation has a strong tumorigenic effect in <italic>Ptch1</italic> heterozygous background, with a high increase of MB frequency, we assumed that the transcriptional changes occurring in the Set A of 163 genes after <italic>Tis21</italic> ablation in <italic>Ptch1</italic> background were at the origin of the increased tumorigenicity observed. These genes, referred to as <italic>Tis21</italic>-dependent—given that their expression is by definition modified by the ablation of <italic>Tis21</italic> in <italic>Ptch1</italic> heterozygous background—will be divided in up-regulated and down-regulated, relative to <italic>Ptch1</italic> heterozygous/<italic>Tis21</italic> wild-type mice. It is worth noting that among the genes in Set A whose expression is down-regulated abound those with tumor-inhibitory activity (e.g., <italic>Pag1, PadI4, Lats2</italic>, and <italic>Cxcl3</italic>), while among the up-regulated genes are present tumor facilitators (e.g., <italic>Rab18, Dek</italic>).</p>
<p>Phenotypically, our genomic data refer to GCPs at a very early pre-neoplastic stage, having been isolated from 7 day-old mice, i.e., when the neoplastic lesions have not yet emerged.</p>
<p>The data analyzed interestingly lead to: (i) a link between the Shh signaling and the impairment of the GCPs migration, through a Shh-dependent deregulation of the receptor-mediated endocytosis pathway; (ii) a possible lineage shift of Shh-type GCPs toward retinal precursor phenotype/toward the neural cell type involved in group 3 MB; (iii) the identification of a subset of putative drug targets for MB involved in the regulation of cell cycle, Pdgf, Rapamycin target protein 1 and Hippo signaling pathways. Finally, our findings indicate a role of <italic>Tis21</italic> in the regulation of gene expression, through epigenetic and RNA processing mechanisms.</p>
</sec>
<sec id="s2" sec-type="materials and methods">
<title>Materials and methods</title>
<sec>
<title>Gene expression array</title>
<p>Genome-wide expression study design and experimental procedures, of GCPs isolated from the EGL of P7, mice were previously performed with Whole Mouse Genome Microarrays (Agilent Technologies), as described in Farioli-Vecchioli et al. (<xref ref-type="bibr" rid="B54">2012a</xref>). GCPs were isolated from Ptch1 heterozygous/Tis21 knockout double mutant and Ptch1 heterozygous/Tis21 wild-type mice of either sex (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). In order to extract the mRNA from GCPs for microarray analysis, for each of the four genotypes were used 4 replicates of GCPs isolated from 3-4 mice each, for a total of about 64 mice (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). The experiments and all animal procedures were completed in accordance with the current European (directive 2010/63/EU) Ethical Committee guidelines and approved by the Ethical Committee of the Italian Ministry of Health (authorized protocol number 14/2009 dated 14/12/2009, expiry date 14/12/2012, according to Law Decree 116/92). Experiments performed after 14/12/2012 are authorized by the Ethical Committee of the Italian Ministry of Health by protocols 307/2013-B and 193/2015-PR expiring 30/03/2020.</p>
</sec>
<sec>
<title>Functional data analysis</title>
<p>Raw data from microarrays experiments were processed and analyzed using GeneSpringGX 12.5 (Agilent Technologies), as already described (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). Pathway enrichment analysis of Set B and Set D genes was performed with MetaCore™ by Thomson Reuters (Ekins et al., <xref ref-type="bibr" rid="B49">2007</xref>). Pathways with corrected enrichment <italic>p</italic>-value <italic>p</italic> &lt; 0.05 were considered significant. MetaCore™ integrated software for functional analysis and its manually curated database have also been used for functional annotation of Tis21-dependent Set A genes, together with DAVID Bioinformatics Resources version 6.7 public database by the National Center for Biotechnology Information (NIH) (Huang da et al., <xref ref-type="bibr" rid="B88">2009a</xref>,<xref ref-type="bibr" rid="B89">b</xref>), Mouse Genome Database (MGD) by The Jackson Laboratory, Bar Harbor, Maine (Blake et al., <xref ref-type="bibr" rid="B20">2014</xref>), Cerebellar Development Transcriptome Data Base (CDT-DB) by NIJC, RIKEN-BSI, Japan (Sato et al., <xref ref-type="bibr" rid="B179">2008</xref>) and Universal Protein Resource (UniProt) by the UniProt Consortium (Consortium, <xref ref-type="bibr" rid="B35">2014</xref>).</p>
</sec>
<sec>
<title>Drug target analysis</title>
<p>To identify potential drug targets among the Set A differentially expressed genes, we have used the drug target selection tool via gene list analysis by MetaCore™ (Thomson Reuters) (Ekins et al., <xref ref-type="bibr" rid="B49">2007</xref>) and Thomson Reuters Cortellis Drug Viewer tool (also available on MetaCore™ platform) via pathway analysis. The search has been performed among human primary/direct (Table <xref ref-type="table" rid="T3">3</xref>) and secondary/indirect (Table <xref ref-type="table" rid="T4">4</xref>) drug targets (see OrthoDB Kriventseva et al., <xref ref-type="bibr" rid="B105">2015</xref>, for the comparison between human and mouse orthologs). The drugs have been taken into account for their targets and not for their use, so not only anti-neoplastic agents are listed in Tables <xref ref-type="table" rid="T3">3</xref>–<xref ref-type="table" rid="T6">6</xref>. Cortellis™ drugs results were compared with records contained in public databases such as DrugBank version 4.2 (Knox et al., <xref ref-type="bibr" rid="B101">2011</xref>; Law et al., <xref ref-type="bibr" rid="B108">2014</xref>), PubChem Compound by NIH (Bolton et al., <xref ref-type="bibr" rid="B21">2010</xref>) and Naturally Occurring Plant based Anticancerous Compound-Activity-Target (Mangal et al., <xref ref-type="bibr" rid="B125">2013</xref>). Finally, to further annotate Set A list genes with respect to known drug-gene interactions and potential druggability, in both mouse and human, we have used the search tools on The Drug Gene Interaction Database (DGIdb) (Griffith et al., <xref ref-type="bibr" rid="B68">2013</xref>) via gene list (Figure <xref ref-type="fig" rid="F3">3</xref>, Tables <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Results and discussion</title>
<sec>
<title>Whole-genome expression changes underlying <italic>Tis21</italic>-dependent activity in GCPs during cerebellum development</title>
<p>By using oligonucleotide microarrays, we monitored the transcriptomic profiles belonging to GCPs isolated at postnatal day 7 (P7), i.e., cells under the proliferative and tumorigenic influence of Shh deregulated signaling in EGL. When expression profiles of genes from either Ptch1 heterozygous GCPs in Tis21 wild-type background (<italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup>) or double mutant (<italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup>) GCPs were compared with the control wild-type (<italic>Ptch1</italic><sup>+/+</sup><italic>/Tis21</italic><sup>+/+</sup>), a consistent subset of genes showed a significant change in expression level, i.e., 2599 in <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> (Figure <xref ref-type="fig" rid="F1">1</xref> Set B) and 3525 in <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> (Figure <xref ref-type="fig" rid="F1">1</xref> Set D). Instead, the contribution of <italic>Ptch1</italic><sup>+/−</sup> in <italic>Tis21</italic> Knockout background was exemplified by 5381 differentially expressed genes (Figure <xref ref-type="fig" rid="F1">1</xref> Set C; <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> vs. <italic>Ptch1</italic><sup>+/+</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup>).</p>
<p>Here we analyze and discuss mainly those genes that were differentially expressed in the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> vs. <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> (Set A; Figure <xref ref-type="fig" rid="F1">1</xref>; Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>), to identify the contribution by <italic>Tis21</italic> in <italic>Ptch1</italic> heterozygous background. These genes are critical as they underlie the great increase of MB frequency observed in <italic>Ptch1</italic> heterozygous mice ablated of <italic>Tis21</italic> (<italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup>), relative to <italic>Ptch1</italic> heterozygous mice in a wild-type background (<italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup>). <italic>Tis21</italic>-dependent mechanisms underlying the onset of Shh-type MB in GCPs during pre-neoplastic development involve a set of 188 sequences (Figure <xref ref-type="fig" rid="F1">1</xref> Set A). Among them, about 170 encode for proteins with a known function. In particular, 13 genes belonging to a subset of set A (Figure <xref ref-type="fig" rid="F1">1</xref>) showed a change of expression that was influenced exclusively by the ablation of <italic>Tis21</italic>: <italic>Tigar, Dsc2, Padi4, Serbp1, Lnx1, Pag1, Olfr670, Mcemp1, Cldn22, Slc25a15, Pth, Pdgfd</italic> and <italic>Cxcl3</italic>.</p>
<p>The validation of some of these genes has already been performed by quantitative real-time PCR (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>).</p>
</sec>
<sec>
<title>Functional analysis of Ptch1 heterozygous/Tis21-null mouse model deregulated genes</title>
<p>Deregulated genes in our pre-neoplastic model mainly belong to developmental pathways that affect different cellular processes such as cell cycle regulation, proliferation, cell adhesion, cytoskeleton remodeling, apoptosis, survival and differentiation (Table <xref ref-type="table" rid="T1">1</xref>). In particular, genes belonging to developmental signaling cascades, differentially expressed in our Shh-deregulated model, depend on the Ptch1 mutation contribution as inferred by set B vs. set D data analysis (Figure <xref ref-type="fig" rid="F2">2</xref>). As well known in the literature, in fact, developmental cascades, when deregulated, acquire oncogenic effect. Neuronal development and tumorigenesis rely on cell communication via identical signaling pathways, resulting in a complex signaling network that creates a breeding ground for tumor-initiating events (Peifer and Polakis, <xref ref-type="bibr" rid="B161">2000</xref>; Schwartz and Ginsberg, <xref ref-type="bibr" rid="B181">2002</xref>; Clark et al., <xref ref-type="bibr" rid="B33">2007</xref>; Katoh, <xref ref-type="bibr" rid="B95">2007</xref>; Neth et al., <xref ref-type="bibr" rid="B150">2007</xref>; Guo and Wang, <xref ref-type="bibr" rid="B70">2009</xref>; Rodini et al., <xref ref-type="bibr" rid="B173">2010</xref>; Mimeault and Batra, <xref ref-type="bibr" rid="B140">2011</xref>; Roussel and Hatten, <xref ref-type="bibr" rid="B176">2011</xref>; Akhurst and Hata, <xref ref-type="bibr" rid="B5">2012</xref>; Manoranjan et al., <xref ref-type="bibr" rid="B126">2012</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p><bold>The most informative deregulated genes belonging to the Set A and associated with the influence of Tis21 gene in background <italic><bold>Ptch1</bold></italic> heterozygous (GCPs at P7)</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Process</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Text type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Down-regulated in Set A</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Up-regulated in Set A</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Enrichment probability</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Wtap, Sik2, Rab11fip4, Lats2, Zc3h12d, Sema4b, Tigar</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pa2g4, Srpk2, Eif3a, Eif3c, Eif2c1, Taok2, Mphosph10, Rrp1, Ipo7, Taf7, Cdc27, Ckap5</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.000004</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cytoskeleton</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cdc42bpb, Sik2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ehbp1, Akap2, Rab18, Ckap5, Emd</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Protein Ubiquitination</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lnx1, Nfx1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ube2o, Cdc27, Smurf2, Usp36</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.03787</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pag1, Gcnt3, Sema4b</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agtr2, Eif2c1, Gtpbp4, Rps12, Slc6a6</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.69694</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Apoptotic Process</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tigar, Ppp1r13l, Serpina3g</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vdac1, Ripk3, Rbm5, Isoc2b, Sltm, Cxcl12</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.32304</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Adhesion</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Col4a6, Col23a1, Dsc2, Cldn22, Egflam</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.39940</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cell differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">NS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Zfhx2os, Dazl</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deptor, Foxf2, Lhx5</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.45675</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Primary Cilium</td>
<td align="left" colspan="1" rowspan="1" valign="top">MT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ccdc157, Ccdc171, Rab11fip2, Rab11fip4, Cxcl3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Syne2, Rgs5</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vescicle-mediated transport</td>
<td align="left" colspan="1" rowspan="1" valign="top">MT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rab11fip4, Rab11fip2, Cxcl3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ehbp1, Zfyve20, Cxcl12, Sgsm2, Ckap5, Vps35, Rab18, Smurf2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00574</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retinal Development</td>
<td align="left" colspan="1" rowspan="1" valign="top">MT</td>
<td align="left" colspan="1" rowspan="1" valign="top">H19, Col4a6, Rab11fip4, Bsn, Efna4, Egflam</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vdac1, Taf7, Emd, 9130401M01Rik, Taok2, Hist3h2ba, Tomm22, Vps35, Slc6a6, Pafah1b1, Akap2, Raly, Rps12, Nlk, Pa2g4, Srpk2, Dgkq, Cdc27, Syne2, Ripk3</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.000000</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Developmental Process</td>
<td align="left" colspan="1" rowspan="1" valign="top">SD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gpr82, Smg1, H19, Mettl14, Fat4, Sema4b, Lats2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rgs5, Sgsm2, Emd, Rab18, Vps35, Nlk, Gigyf2, Kctd5, Ankrd11, Cxcl12, Pdgfd</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00007</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Migration</td>
<td align="left" colspan="1" rowspan="1" valign="top">MT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cxcl3, Jmy, Efna4, Timp1, Frk, Prrx1, Rab11Fip2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cxcl12, Pdgfd, Pafah1b1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00008</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Epigenetic Modulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">SD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hist2h2bb, Cbx3, Padi4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hist3h2ba, Ankrd11, Ankrd24, Ankrd26, Brwd1, Dek, Anp32a, Taf7, Pa2g4, Emd, Ipo7</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.000000</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RNA Processing</td>
<td align="left" colspan="1" rowspan="1" valign="top">SD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Wtap, Mettl14</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rbm5, Raly, Srpk2, Ddx23, Dek, Htatsf1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00312</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nonsense-mediated mRNA decay</td>
<td align="left" colspan="1" rowspan="1" valign="top">SD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smg1, Upf3b</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00755</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ribonucleoprotein complex biogenesis and assembly</td>
<td align="left" colspan="1" rowspan="1" valign="top">SD</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">Eif3a, Eif3c, Eif2c1, Rmnd1, Rrp1, Gtpbp4, Rps12, Mphosph10, Ipo7</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Shh-type MB genes</td>
<td align="left" colspan="1" rowspan="1" valign="top">MT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gli1<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">Pdgfd</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.0164</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Group 3 MB genes</td>
<td align="left" colspan="1" rowspan="1" valign="top">MT</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Nlk, Ppp2r2b<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref>, Raf1<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td>
<td align="center" colspan="1" rowspan="1" valign="top">0.0161</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>The genes are clustered in pathways of involvement, according to the functional analysis methods following described. Many genes overlap different clusters. We divide the genes into two categories: down-regulated and up-regulated, depending on whether the mutation of Tis21 causes in double mutant mice an increase or decrease of expression, respectively, relative to Ptch1 heterozygous/Tis21 wild-type mice</italic>.</p>
<fn id="TN1">
<label>*</label>
<p><italic>Genes whose levels are changed in Set A although not significantly accordingly to the statistical analysis performed. The functional classes involved in our study have been discussed in the main text (MT), in the <xref ref-type="supplementary-material" rid="SM1">Supplementary Data</xref> (SD) or are not shown (NS). The enrichment probability of the deregulated genes in each functional class has been calculated using the Fisher Exact Text</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>A molecular overview of our Shh-deregulated mouse model, characterized by the genetic disruption of hedgehog signaling resulting from a heterozygous mutation in the negative regulators <italic><bold>Ptch1</bold></italic>, whose effects are enhanced by the homozygous deletion of the <italic><bold>Tis21</bold></italic> tumor suppressor gene</bold>. The figure shows the proteins mainly involved in neural developmental pathways, encoded by the differentially expressed genes of set B and set D and shown in their subcellular compartments. Each differentially expressed pathway object is labeled with a thermometer that indicates the gene expression changes: downward thermometers have a blue color and indicate down-regulated expression, whereas upward thermometers have a red color and indicate up-regulated expression. The thermometer number 1 is related to the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> vs. wild type Set B, while the thermometer number 2 is related to the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>−/−</sup> vs. wild type Set D. Signaling cross-talks between developmental pathways involved in pre-neoplastic GCPs development are initiated by different growth factors and cytokines, the most part of which interacts with G-protein coupled receptors. This is supported by a strong up-regulation of many members of heterotrimeric G-proteins, their target molecules and regulators (data not shown in figure). Among those reported in literature as involved in MB (Roussel and Hatten, <xref ref-type="bibr" rid="B176">2011</xref>), developmental signaling pathways appear to be up-reregulated in our experimental data, according to the far fewer percentages of negative signature genes (Chen et al., <xref ref-type="bibr" rid="B30">2013</xref>) and the over-representation of WNT and axonal guidance genes present in human MB Shh-type (Northcott et al., <xref ref-type="bibr" rid="B153">2011</xref>). Interestingly, a β-Catenin-Gli1 balanced interaction has been recently reported to regulate Shh-driven MB tumor growth in <italic>Ptch1</italic> heterozygous mice <italic>in vitro</italic> (Zinke et al., <xref ref-type="bibr" rid="B229">2015</xref>), while Sox7, a transcription factor that is known to reduce Wnt/β-Catenin stimulated transcription in a dose-dependent manner (Takash et al., <xref ref-type="bibr" rid="B190">2001</xref>), is up-regulated in Set B and <italic>Tis21</italic> ablation enhances its up-regulation in Set D (data not shown in figure). Furthermore, Smo-dependent non-canonical Shh pathways (Jenkins, <xref ref-type="bibr" rid="B91">2009</xref>), which have been reported to modulate cytoskeleton-dependent processes and fluctuation of Ca<sup>2+</sup> through the plasma membrane in mammalian neurons (Brennan et al., <xref ref-type="bibr" rid="B22">2012</xref>) and suggested in possible association with MB (Briscoe and Therond, <xref ref-type="bibr" rid="B23">2013</xref>), are put in light here for the first time as related to the MB Shh-type mouse model. Evidences of a deregulated Slit-Robo pathway, which is implicated in neuronal migration (Wong et al., <xref ref-type="bibr" rid="B215">2001</xref>; Marillat et al., <xref ref-type="bibr" rid="B128">2004</xref>), are present in our data with the up-regulation of the axon guidance receptor <italic>Robo4</italic>. The ligand of Robo4, Slit2, has been linked to the inhibition of MB cell invasion (Werbowetski-Ogilvie et al., <xref ref-type="bibr" rid="B213">2006</xref>). Proteins belonging to the ubiquitin-dependent degradation of GCPs cell cycle regulators [24] have their genes up-regulated in our model, in particular a number of ubiquitin-conjugating enzymes and some constituents of the SCF (Skip1, Cullin1, F-box)-E3 ubiquitin ligase complex. Among them, a substrate recognition component of the SCF-type E3 ubiquitin ligase, the F-box protein Fbw7, which has been linked to a premature migration of GCPs in conditional <italic>Fbw7</italic>-knockout mice [30]. An up-regulation genes coding for proteins involved in palmitoylation (i.e., HHAT) and transport of Shh (i.e., DISP1) is noticed in in Set D, where Ptch1 sterol-sensing domain seems to control Smoothened activity through Ptch1 vesicular trafficking [34]. Retinoblastoma-associated protein (Rb), as well as its downstream effectors E2F3 and E2F5, has its correspondent gene up-regulated in set D, where the deregulation of the Rb/E2F tumor suppressor complex in MB Shh-driven has been already associated to the E2F1-dependent regulation of lipogenic enzymes in primary cerebellar granule neuron precursors (Bhatia et al., <xref ref-type="bibr" rid="B18">2011</xref>). Figure <xref ref-type="fig" rid="F4">4</xref> below shows the set of symbols whereby network objects and interactions between objects are indicated in this figure.</p>
</caption>
<graphic xlink:href="fphar-07-00449-g0002"></graphic>
</fig>
<p>At the same time, <italic>Tis21</italic> ablation is responsible for the delayed migration of pre-neoplastic precursors outside the EGL, which corresponds to a delayed cell differentiation and represents the key step for MB Shh-type formation. In fact, where GCPs proliferate for a prolonged period in EGL, they became the target of neoplastic transforming insults (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>,<xref ref-type="bibr" rid="B55">b</xref>).</p>
<p>Moreover, we have noticed evidence for the involvement of the primary cilium in our GCPs pre-neoplastic model, mainly in Set B but also in Set A data (Figure <xref ref-type="fig" rid="F3">3</xref>), and also evidence of Smo-dependent non-canonical Shh pathways. A link between Shh signaling at primary cilium and clathrin-mediated endocytotic trafficking/cytoskeletal remodeling will also be discussed.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p><bold>Drug targets belonging to the Set A discussed in the main text</bold>. Each gene product is labeled with a thermometer indicating the gene expression changes: downward thermometers have a blue color showing down-regulated expression, whereas upward thermometers have a red color showing up-regulated expression. The most part of the figure objects are deregulated also in other two pair comparisons. For this reason, the thermometer number 1 is related to the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> vs. wild type or Set B, the thermometer number 2 is related to the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>−/−</sup> vs. wild type or Set D, while the thermometer number 3 is related to the pairwise comparison <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> vs. <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> or Set A. See Figure <xref ref-type="fig" rid="F4">4</xref> for the set of symbols, objects and interactions between objects indicated in this figure.</p>
</caption>
<graphic xlink:href="fphar-07-00449-g0003"></graphic>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p><bold>The figure shows symbols, objects and interactions between objects indicated in Figures <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref></bold>.</p>
</caption>
<graphic xlink:href="fphar-07-00449-g0004"></graphic>
</fig>
<p>Another observation is related to the mitogen role of Shh signaling, not only in the developing cerebellum but also in the neuronal tube and overall in the retinal cell specification. In fact, a large number of deregulated genes in our Set A are also involved in the delayed differentiation of retinal cell types. Notably, it has been previously shown a parallelism between MB and retinal development; in fact, the analysis of cell populations in MB-derived from GCPs (particularly the group 3) suggests the occurrence of a potential aberrant trans-lineage differentiation into retinal neuronal precursors (Kool et al., <xref ref-type="bibr" rid="B104">2008</xref>; Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>). Here, given the large number of genes comprised in set A that is deregulated during the retinal cell development, we want to focus our attention on the timing of exit from the cell cycle, a crucial step in retinal cell development and differentiation, which is under the influence of Shh signaling, as it occurs in the development of MB Shh-type (Dyer, <xref ref-type="bibr" rid="B48">2004</xref>). These considerations will be taken into account for a parallel comparison with our model data.</p>
<p>Finally, a fine regulation at RNA processing, ribosomes and vesicle trafficking level but also an epigenetic modulation were noticed in set A deregulated genes (Table <xref ref-type="table" rid="T1">1</xref>). In the following paragraphs, we will discuss the most informative deregulated coding genes belonging to the set A according to their functional clusters (Figure <xref ref-type="fig" rid="F3">3</xref> and Table <xref ref-type="table" rid="T1">1</xref>), the most of which overlap different clusters. Among them, there is a large number of already known genes as oncogenes and tumor suppressors. In doing this, we have also taken into account the genes which are deregulated in consequence of the <italic>Ptch1</italic> heterozygous.</p>
<sec>
<title>Primary cilium roles in GPCs proliferation and differentiation</title>
<p>Primary cilia are sensory non-motile microtubule-based organelles (Lee and Gleeson, <xref ref-type="bibr" rid="B109">2010</xref>) protruding from the surface of GCPs in the EGL at early post-natal stages (Del Cerro and Snider, <xref ref-type="bibr" rid="B42">1972</xref>), whose requirement for Shh-induced expansion and cerebellar development has been proved using mutants of genes involved in the ciliary formation and maintenance (Chizhikov et al., <xref ref-type="bibr" rid="B31">2007</xref>; Spassky et al., <xref ref-type="bibr" rid="B186">2008</xref>). Among them, the genetic ablation of primary cilia by removing <italic>Kif3a</italic> (which encodes the microtubule plus end-directed kinesin motor 3A protein), blocked MB formation driven by a constitutively active Smoothened protein (Han et al., <xref ref-type="bibr" rid="B72">2009</xref>). Therefore, <italic>Kif3a</italic> down-regulation blocks MB Shh-type formation in a primary cilia-dependent manner; moreover, its activity is not required for GCPs differentiation (Chizhikov et al., <xref ref-type="bibr" rid="B31">2007</xref>). In our model, we observe that <italic>Kif3a</italic> is up-regulated in <italic>Ptch1</italic> heterozygous mice, irrespective of the presence or absence of <italic>Tis21</italic>, which is therefore not involved in the Kif3a-dependent phenotype (Figure <xref ref-type="fig" rid="F2">2</xref>). This is consistent with the finding that Kif3a is required for the proliferation of the GCPs (Chizhikov et al., <xref ref-type="bibr" rid="B31">2007</xref>) and with our observation that <italic>Tis21</italic> in cerebellum regulates the migration of the GCPs but not their proliferation, while the opposite occurs for <italic>Ptch1</italic>.</p>
<p>Nevertheless, in our model, several genes encoding for the coiled-coil domain containing proteins are deregulated in Set A, and thus are dependent on <italic>Tis21</italic>, i.e., <italic>Ccdc157</italic> and <italic>Ccdc171</italic> (Table <xref ref-type="table" rid="T1">1</xref>). One-fourth of the deregulated genes in Set A corresponds to coiled-coils proteins (data not shown), whose highly versatile protein folding motif is related to different biological processes, from subcellular infrastructure maintenance to trafficking control (Burkhard et al., <xref ref-type="bibr" rid="B24">2001</xref>; Rose et al., <xref ref-type="bibr" rid="B175">2005</xref>) and cilia-related (McClintock et al., <xref ref-type="bibr" rid="B132">2008</xref>; Munro, <xref ref-type="bibr" rid="B146">2011</xref>). A coiled-coil containing protein is also Rab11 family-interacting protein 4 encoded by <italic>Rab11fip4</italic> (Muto et al., <xref ref-type="bibr" rid="B148">2006</xref>, <xref ref-type="bibr" rid="B147">2007</xref>), whose role in our model will be discussed more in detail in other paragraphs together with the functional product of <italic>Rab11fip2</italic>, and their wide implication in Shh signaling at primary cilium as a protein involved in microtubule-based vesicle trafficking. Another protein, Nesprin-2 encoded by <italic>Syne2</italic>, is known to mediate centrosome migration and is essential for early ciliogenesis and formation of the primary cilia by the interaction with the coiled-coil domain of Meckelin protein (Dawe et al., <xref ref-type="bibr" rid="B41">2009</xref>). Notably, <italic>Ccdc157, Ccdc171, Rab11fip2</italic>, and <italic>Rab11fip4</italic> are significantly down-regulated in Set A, while <italic>Syne2</italic> is up-regulated. Also a novel repressor of hedgehog signaling, whose gene <italic>Rgs5</italic> is up-regulated in set A, has been proven to be present with Smo in primary cilia (Mahoney et al., <xref ref-type="bibr" rid="B123">2013</xref>). This would suggest that <italic>Tis21</italic>-dependent tumorigenesis in a (proliferation-independent) way involves ciliogenesis. This latter may be also enhanced by <italic>Syne2</italic> after <italic>Tis21</italic> ablation.</p>
<p>Evidences of direct involvement of Shh signaling on the increase of Ca<sup>2+</sup> levels (Ca<sup>2+</sup> spikes) have been shown at the primary cilium of chicken embryonic spinal neurons. In this system has been observed that Shh (a recombinant N-terminal molecule) may recruit second messengers (i.e., calcium—Ca<sup>2+</sup>—and inositol triphosphate) by a non-canonical pathway, through the activation of the Smoothened protein, which translocates to the cilium and becomes activated by phosphorylation at its C-terminal from a G-protein-coupled receptor kinase 2 (Riobo et al., <xref ref-type="bibr" rid="B171">2006</xref>; Belgacem and Borodinsky, <xref ref-type="bibr" rid="B14">2011</xref>; Brennan et al., <xref ref-type="bibr" rid="B22">2012</xref>). Belgacem and Borodinsky (<xref ref-type="bibr" rid="B14">2011</xref>) proposed a model in which the primary cilium acts as a subcellular compartment for Shh signaling allowing the spatiotemporal integration of the second messengers through a Smoothened-dependent recruitment of G<sub>i</sub> proteins and Phospholipase C that in turn increases inositol triphosphate levels. The opening of Inositol triphosphate receptors-operated stores and the following activation of Transient receptor potential cation channel 1 (Trpc1) results in an increased Ca<sup>2+</sup> spike activity. This model could fit with our data (Figure <xref ref-type="fig" rid="F3">3</xref>) in which <italic>Plc-gamma2, Ip3r3, Trpc1, Trpc2</italic>, and <italic>Trpc3</italic> are up-regulated in <italic>Ptch1</italic> heterozygous mice (but independently from <italic>Tis21</italic>). Notably, this is the first time that such regulation is observed directly in a mouse model of Shh-type MB, as it had been previously only suggested (Briscoe and Therond, <xref ref-type="bibr" rid="B23">2013</xref>). Furthermore, the authors suggested that the Smoothened-dependent Ca<sup>2+</sup> spike activity is necessary for Shh-induced differentiation of spinal postmitotic neuron. Moreover, the role of second messenger signaling in the regulation of cerebellar granule cell migration has been studied in different mouse models (Komuro et al., <xref ref-type="bibr" rid="B103">2015</xref>), which highlighted the direct evidence of the role of Ca<sup>2+</sup> signaling in granule cell turning and modulation of their migration rate. The revision of these studies, performed by Komuro et al. (<xref ref-type="bibr" rid="B103">2015</xref>), suggested the role of Ca<sup>2+</sup> as potential therapeutic target for some deficits in granule cell migration since its downstream effectors control the assembly and disassembly of cytoskeletal elements.</p>
<p>In the last years, the discovery of the role of the primary cilium in Shh signaling captured the attention of the scientific community, leading to test a large number of molecules that modulate SMO cilial translocation acting on different therapeutic potential targets in different types of cancer among which MB (Amakye et al., <xref ref-type="bibr" rid="B6">2013</xref>). Loss of cilia in cancer has been suggested to be responsible for an insensitivity of cancer cells to environmental repressive signals, based in part on derangement of cell cycle checkpoints governed by cilia and centrosomes (Plotnikova et al., <xref ref-type="bibr" rid="B165">2008</xref>). The importance of the role of cilia in Shh-driven medulloblastoma allografts derived from <italic>Ptch1</italic><sup>+/−</sup><italic>P53</italic><sup>−/−</sup> mice has been shown using a Shh antagonist, i.e., arsenic trioxide (a therapeutic agent for acute promyelocytic leukemia), which inhibits the growth of tumor through the prevention of Shh ciliary accumulation and the reduction of the stability of the Gli2 transcriptional effector (Kim et al., <xref ref-type="bibr" rid="B97">2010</xref>).</p>
</sec>
<sec>
<title>Receptor-mediated endocytosis mechanisms, microtubule-based vesicle recycling and intracellular membrane trafficking</title>
<p>Other genes deregulated in Set A are involved in endocytic trafficking clathrin-dependent (Figure <xref ref-type="fig" rid="F5">5</xref>), and a certain number is related to cytoskeletal remodeling and primary cilium that could be very interesting for their implications for target therapy.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p><bold>Drug targets percentage per functional class of the Set A deregulated genes</bold>. The drug targets identified in Set A are showed as percentage with respect to the functional classes to which they belong.</p>
</caption>
<graphic xlink:href="fphar-07-00449-g0005"></graphic>
</fig>
<p>The clathrin-dependent endocytic mechanism is a receptor-mediated endocytosis type, which involves clathrin-coated vesicles, early endosomes, microtubule-based vesicle trafficking, lysosomes and recycling transport vesicles in its pathway (Le Roy and Wrana, <xref ref-type="bibr" rid="B113">2005</xref>). Evidences of a deregulated clathrin-mediated endocytosis pattern have been reported for MB group 4 during early human neurogenesis (Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>), and detected in our Set B (data not shown) as well as in Set A, where a large number of deregulated genes belongs to this signaling: <italic>Rab11fip4</italic> (Horgan and McCaffrey, <xref ref-type="bibr" rid="B83">2009</xref>), <italic>Ehbp1</italic> (Guilherme et al., <xref ref-type="bibr" rid="B69">2004</xref>), <italic>Rab11fip2</italic> (Fan et al., <xref ref-type="bibr" rid="B52">2004</xref>), <italic>Zfyve20</italic> (de Renzis et al., <xref ref-type="bibr" rid="B44">2002</xref>; Naslavsky et al., <xref ref-type="bibr" rid="B149">2004</xref>), <italic>Cxcl12</italic> (Fan et al., <xref ref-type="bibr" rid="B52">2004</xref>; Teicher and Fricker, <xref ref-type="bibr" rid="B195">2010</xref>; Zhu et al., <xref ref-type="bibr" rid="B227">2012</xref>), <italic>Sgsm2</italic> (Yang et al., <xref ref-type="bibr" rid="B218">2007</xref>), <italic>Ckap5</italic> (Foraker et al., <xref ref-type="bibr" rid="B57">2012</xref>), <italic>Vps35</italic> (Foraker et al., <xref ref-type="bibr" rid="B57">2012</xref>), and <italic>Rab18</italic> (Foraker et al., <xref ref-type="bibr" rid="B57">2012</xref>).</p>
<p><italic>Rab11fip4</italic> is known to interact with Rab11 (a Rab GTPase involved in the regulation of intracellular membrane trafficking), which in turn interacts with Rab-coupling protein, a protein involved in the formation of lamellipodia, which facilitates invasive cancer cell migration (Kelly et al., <xref ref-type="bibr" rid="B96">2012</xref>). <italic>Ehbp1</italic> gene product is involved in actin reorganization coupled to endocytosis clathrin-mediated (Guilherme et al., <xref ref-type="bibr" rid="B69">2004</xref>). <italic>Zfyve20</italic> is known to regulate structure, sorting, endocytic/recycling pathway of the early endosomal compartment by the interaction with Rab4 and Rab5 (de Renzis et al., <xref ref-type="bibr" rid="B44">2002</xref>; Naslavsky et al., <xref ref-type="bibr" rid="B149">2004</xref>). <italic>Vps35</italic>, among other genes involved in intracellular membrane trafficking, is deregulated in Set A. It encodes for the vacuolar protein sorting-associated protein 35, a component of the trimeric cargo-selective retromer complex, required for the efficient endosome-to-Golgi recycling of many membrane proteins among which Wntless. It is also known to regulate endosomal tubule dynamics (Harbour et al., <xref ref-type="bibr" rid="B73">2010</xref>; Berwick and Harvey, <xref ref-type="bibr" rid="B16">2014</xref>). The oncogene <italic>Rab18</italic> is required for normal ER structure and the regulation of endocytic traffic (Lütcke et al., <xref ref-type="bibr" rid="B122">1994</xref>; Gerondopoulos et al., <xref ref-type="bibr" rid="B62">2014</xref>). This Rab GTPasi is also known as a MB antigen (Behrends et al., <xref ref-type="bibr" rid="B13">2003</xref>). Interestingly, Rab18 has been localized at lipid droplets (LDs) level (Martin et al., <xref ref-type="bibr" rid="B130">2005</xref>), and its overexpression causes close apposition of LDs to membrane cisternae connected to the rough ER (LD-associated membrane or LAM) (Ozeki et al., <xref ref-type="bibr" rid="B158">2005</xref>). Indeed, <italic>de novo</italic> lipid synthesis has been found in certain highly proliferative and aggressive tumors such as MB Shh-type, suggesting that the Shh-E2F1-FASN axis regulating <italic>de novo</italic> lipid synthesis in cancers could be used as therapeutic target in hedgehog-dependent tumors (Bhatia et al., <xref ref-type="bibr" rid="B18">2011</xref>). Remarkably, <italic>Rab11fip2</italic> encodes for a Rab11 family-interacting protein 2, which directly interacts with the actin-based myosin Vb motor protein regulating Cxcr2 recycling and receptor-mediated chemotaxis; hence, Rab11fip2 links Rab11 to molecular motor proteins and cell migration (Jones et al., <xref ref-type="bibr" rid="B93">2006</xref>; Horgan and McCaffrey, <xref ref-type="bibr" rid="B83">2009</xref>). Moreover, the passage of the internalized Cxcr2 through the Rab11-recycling system appears to have a key role in the physiological response to a chemokine that follows to the formation of clathrin-coated vesicles; in fact, Rab11 family-interacting protein 2 can form a complex with AP-2 that is a major clathrin adaptor complex in cells (Cullis et al., <xref ref-type="bibr" rid="B39">2002</xref>; Fan et al., <xref ref-type="bibr" rid="B52">2004</xref>; Le Roy and Wrana, <xref ref-type="bibr" rid="B113">2005</xref>). Furthermore, the Rab11 involvement into the regulation of vesicular trafficking during primary ciliogenesis has been already put in light (Knödler et al., <xref ref-type="bibr" rid="B100">2010</xref>; Hsiao et al., <xref ref-type="bibr" rid="B85">2012</xref>). A consequence of the above findings, indicating an interaction between Cxcr2 and the clathrin pathway, is that, since Cxcl3 binds the Cxcr2 receptor (Zlotnik et al., <xref ref-type="bibr" rid="B230">2006</xref>), we can infer that this chemokine receptor-mediated chemotaxis mechanism is clathrin-dependent and linked through Rab11fip2 to the primary cilium, in which the Shh signaling takes part. Other evidence of an involvement of Rab11fips and Shh signaling derives from Rab11fip4 (see the retina development section). This protein seems to be involved in the regulation of the membrane trafficking system through interaction with other small GTPases, among which could be Ras-related protein Rab-23, and in the negative regulation of Shh signaling at the primary cilium (Muto et al., <xref ref-type="bibr" rid="B147">2007</xref>; Hsiao et al., <xref ref-type="bibr" rid="B85">2012</xref>).</p>
<p>All this points to an important link between Shh signaling, operating through the primary cilium, and GCPs impaired cell migration, through a clathrin-Cxcl3-Cxcr2-mediated chemotaxis and microtubule-based endocytic vesicle recycling trafficking. Furthermore, the findings of a study about the role of endosomes around mother centriole appendages, and their Rab11-dependent recycling activity that requires centrosome-associated endosome proteins (Hehnly et al., <xref ref-type="bibr" rid="B78">2012</xref>), seem to be in line with our data (see drug target section). Interestingly, they showed that (i) the appendages of the mother centriole and recycling endosomes are in intimate contact, as first evidence for a novel centrosome-anchored molecular pathway and regulation of endosome recycling; (ii) there is a structural association between the endosome and the centrosome with new and unexpected implications for recycling endosome functions, such us that one related to cilia formation; (iii) it is also possible that Rab11, and other endosome-associated molecules bound to the centrosome, may play dual roles in endosome and centrosome function (Hehnly et al., <xref ref-type="bibr" rid="B78">2012</xref>).</p>
</sec>
<sec>
<title>Retinal development</title>
<p>In mice, retinal development occurs between E11.5 and P8, as uncommitted neuroblasts leave the cell cycle and commit to retinal cell fates (Mu et al., <xref ref-type="bibr" rid="B144">2001</xref>). Thanks to mice models, it is known that aberrant proliferation during the development of the neural tube, of cerebellum and retina, leads to embryonal and early postnatal tumors (Dyer, <xref ref-type="bibr" rid="B48">2004</xref>). The potent mitogen Shh positively controls the proliferation of their neuronal precursor cells (Martí and Bovolenta, <xref ref-type="bibr" rid="B129">2002</xref>). In particular, Shh signaling plays a pivotal role in regulating the proliferation of retinal progenitor cells (RPCs) and the differentiation of retinal ganglion cells (RGCs) during vertebrate retinal development, acting in a cell-specific manner; namely, in mouse Shh is required as positive regulator of RPCs proliferation and as negative regulator of RGCs production, by inhibiting cell-cycle exit (Wang et al., <xref ref-type="bibr" rid="B207">2005</xref>; Wallace, <xref ref-type="bibr" rid="B203">2008</xref>).</p>
<p>A further molecular target which may be responsible for the regulation of retinal cell proliferation and hence for cancer cell proliferation was suggested to be Rb; in fact, the levels of Rb protein appear critical for the development of retinal tumors (Sicinski et al., <xref ref-type="bibr" rid="B185">1995</xref>). The rationale for this is that Rb, when active, inhibits the cycle at the G1 checkpoint, prior to cell differentiation, whereas its inactivation, exerted by phosphorylation from cyclinD1/CDK4, is known to start the cell cycle progression. Thus, high levels of Rb may be more difficult to inactivate and vice-versa, thus critically linking the Rb-dependent developmental regulation of proliferation during neurogenesis to cancer cell proliferation for certain types of tissues (Sicinski et al., <xref ref-type="bibr" rid="B185">1995</xref>). Indeed, in our model we observe that in GCPs heterozygous for <italic>Ptch1</italic> (set B: <italic>Ptch1</italic><sup>+/−</sup><italic>/Tis21</italic><sup>+/+</sup> vs. <italic>Ptch1</italic><sup>+/+</sup><italic>/Tis21</italic><sup>+/+</sup>) cyclin D1 expression does not change while Rb does increase. This suggests that in Shh-driven neoplastic GCPs the increase of Rb protein is compensatory.</p>
<p>In the case of MB, a parallel between developmental neurobiology and oncology was suggested for the proliferating progenitor cells of the retina and cerebellar granule neurons, where the failure to exit the cell cycle leads to aberrant cell proliferation during development in mice (Romer and Curran, <xref ref-type="bibr" rid="B174">2004</xref>). Notably, MB-types Cluster D and E (also referred to as groups 4 and 3, respectively) have been found to be marked by a deregulated expression of retinal photoreceptor genes suggesting a distinct origin (i.e., non-cerebellar) from stem cells during the embryonic development, with respect to MB Shh-type in human (Kool et al., <xref ref-type="bibr" rid="B104">2008</xref>).</p>
<p>In this context, concerning the contribution of Tis21 deletion to the MB development, in Set A we noticed a great number of deregulated genes that have been previously described as involved in retinal development. This comparison could be useful to suggest some common mechanisms related to the progenitor cells cell-cycle exit failure. A consistent subset of Set A genes has been previously described as being involved in cellular expression patterns of mouse early retinal development; these gene were previously recognized by analyzing the outer retinal neuroblastic layer, which in early developmental stages consists almost entirely of mitotic progenitor cells: <italic>Vdac1, Taf7, Emd, 9130401M01Rik, Taok2, Hist3h2ba, Tomm22, Vps35, H19, Slc6a6, Pafah1b1, Akap2, Raly, Rps12, Nlk, Pa2g4</italic> and <italic>Srpk2</italic> (Blackshaw et al., <xref ref-type="bibr" rid="B19">2004</xref>). These genes are all up-regulated in Set A except for <italic>H19</italic>. Furthermore, a number of other genes that were identified in other studies as being involved in retinal development, are down-regulated in set A: <italic>Col4a6</italic> (Bai et al., <xref ref-type="bibr" rid="B10">2009</xref>), <italic>Rab11fip4</italic> (Muto et al., <xref ref-type="bibr" rid="B147">2007</xref>), <italic>Bsn</italic> (Dick et al., <xref ref-type="bibr" rid="B45">2003</xref>), <italic>Efna4</italic> (Marcus et al., <xref ref-type="bibr" rid="B127">1996</xref>; Poliakov et al., <xref ref-type="bibr" rid="B166">2004</xref>; Triplett and Feldheim, <xref ref-type="bibr" rid="B198">2012</xref>), <italic>Egflam</italic> (whose product is also known as Pikachurin) (Omori et al., <xref ref-type="bibr" rid="B157">2012</xref>); conversely, other retinal genes up-regulated in set A are: <italic>Dgkq</italic> (Pilz et al., <xref ref-type="bibr" rid="B163">1995</xref>), <italic>Cdc27</italic> (Leung et al., <xref ref-type="bibr" rid="B114">2008</xref>), <italic>Syne2</italic> (Yu et al., <xref ref-type="bibr" rid="B222">2011</xref>), <italic>Slc6a6</italic> (Vinnakota et al., <xref ref-type="bibr" rid="B201">1997</xref>; Warskulat et al., <xref ref-type="bibr" rid="B210">2007</xref>), <italic>Ripk3</italic> (Trichonas et al., <xref ref-type="bibr" rid="B197">2010</xref>).</p>
<p>The genes listed above belong to different functional clusters, and some of them will be discussed more in detail in their paragraph of pertinence. Interestingly, the mouse <italic>Rab11fip4</italic>, whose product regulates the Rab GTPases and is predominantly expressed in the developing neural tissues, among which retina, acts as regulator of RPCs cell-cycle exit and their subsequent differentiation (Muto et al., <xref ref-type="bibr" rid="B147">2007</xref>). Rab11fip4 seems to be involved in the regulation of membrane trafficking system through interaction with other small GTPases and in the negative regulation of Shh signaling (Muto et al., <xref ref-type="bibr" rid="B147">2007</xref>). Moreover, the <italic>Syne2</italic> gene product is known to mediate nuclear migration during mammalian retinal development connecting the nucleus with dynein/dynactin and kinesin proteins (Yu et al., <xref ref-type="bibr" rid="B222">2011</xref>).</p>
<p>This comparison is in line with the evidence that progenitors from the developing cerebral cortex, cerebellum and retina share a common expression program, suggesting a common evolutionary origin of the different progenitors cells (Livesey et al., <xref ref-type="bibr" rid="B120">2004</xref>), and implying a possible common differentiation program. Our data suggest that this developmental process, possibly at the steps of migration and differentiation, is regulated by <italic>Tis21</italic>.</p>
</sec>
<sec>
<title>Migration</title>
<p>The migration of the GCPs is known to be induced by responses to local environmental cues. However, the alterations of migratory behavior may also depend on intrinsic programs (Komuro et al., <xref ref-type="bibr" rid="B102">2013</xref>). In our study, we observed in Set A the differential expression of a great number of genes belonging to migration, cell adhesion and differentiation mechanisms. Among the genes implicated in migration seven are down-regulated after ablation of <italic>Tis21</italic> in Shh-activated background, namely, <italic>Cxcl3, Jmy, Efna4, Timp1, Frk, Prrx1</italic>, and <italic>Rab11fip2</italic>, and three are up-regulated: <italic>Cxcl12, Pdgfd</italic>, and <italic>Pafah1b</italic>.</p>
<p><italic>Cxcl3</italic> is a chemokine known to have chemotactic activity for neutrophils (Wuyts et al., <xref ref-type="bibr" rid="B216">1999</xref>). Chemotaxis but also angiogenesis seems to be activated by the interaction with its receptor (Addison et al., <xref ref-type="bibr" rid="B1">2000</xref>; Zlotnik et al., <xref ref-type="bibr" rid="B230">2006</xref>). In our previously published data, <italic>Cxcl3</italic> has been identified as a gene whose transcription is regulated positively by Tis21 (which directly associates to the <italic>Cxcl3</italic> promoter), suggesting that the evident role played <italic>in vivo</italic> by <italic>Tis21</italic> as inducer of the migration of the GCPs out of the EGL might occur through its functional product; this implies Cxcl3 as a new pharmacological target for medulloblastoma therapy, also considering that MB lesions were reduced using this chemokine as treatment (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>,<xref ref-type="bibr" rid="B55">b</xref>). Recently, the anti-cancer role of this chemokine has also been recognized for non-small lung cancer, mediated by the activity of interleukin-27 (Airoldi et al., <xref ref-type="bibr" rid="B4">2015</xref>). Jmy, a junction mediating and regulatory protein, is known to induce cell motility by promoting actin assembly and regulating cadherins in the cytoplasm; in DNA damage conditions it undergoes nuclear accumulation, where acts as p53-cofactor promoting apoptosis (Shikama et al., <xref ref-type="bibr" rid="B184">1999</xref>; Coutts et al., <xref ref-type="bibr" rid="B37">2007</xref>; Zuchero et al., <xref ref-type="bibr" rid="B232">2009</xref>). Together, these findings suggest that the ability of Jmy to regulate actin and cadherin, by coordinating cell motility with the p53 response, could underlie a common pathway (Coutts et al., <xref ref-type="bibr" rid="B38">2009</xref>). Furthermore, actin assembly has been found to regulate the nuclear import of Jmy in response to DNA damage (Zuchero et al., <xref ref-type="bibr" rid="B231">2012</xref>). Thus, an abnormal activity and/or localization of Jmy could contribute to tumor invasion, thus making this gene as a potential tumor therapeutic target (Wang, <xref ref-type="bibr" rid="B206">2010</xref>). In theory, the down-regulation of <italic>Jmy</italic> may contribute to enhance the rate of MB in our mouse model, possibly by controlling the migration of the GCPs as shown for Cxcl3. Regarding <italic>Efna4</italic>, this gene encodes for the EphrinA4 protein that has been linked with the migration of neuronal cells during development (Poliakov et al., <xref ref-type="bibr" rid="B166">2004</xref>). A recent study showed that EphrinA4 and the Ephrin type-B receptor 4 are almost exclusively expressed in Shh MBs, while other Ephrins are expressed in non–Shh MBs; furthermore, a strategy of overexpression and silencing, applied specifically to EphrinB1, showed its ability to control the migration of MB cell lines (McKinney et al., <xref ref-type="bibr" rid="B135">2015</xref>). Further evidence of the migration-promoting activity of EphrinA4 has been observed in human glioma cells, where it acts by accelerating a canonical FGFR signaling pathway (Fukai et al., <xref ref-type="bibr" rid="B58">2008</xref>). <italic>Timp1</italic> protein product is a metalloproteinase inhibitor known to be involved in cell adhesion and migration of human neural stem cells (hNSCs). In fact, through its cell surface receptor CD63, TIMP-1 activates β1 integrin, FAK (focal adhesion kinase) and the PI3K (phosphoinositide 3-kinase) signal transduction pathway, resulting in the migration of hNSCs (Lee et al., <xref ref-type="bibr" rid="B112">2014</xref>). Due to its chemoattractant properties, TIMP-1 has been identified in the same study as a therapeutic target for human glioma. The <italic>Frk</italic> gene product is a Src kinase known as Tyrosine-protein kinase FRK, which controls the migration and invasion of human glioma cells by regulating JNK/c-Jun signaling (Zhou et al., <xref ref-type="bibr" rid="B226">2012</xref>). Moreover, the Tyrosine-protein kinase FRK acts as a tumor suppressor in breast cancer by regulating the stability of PTEN, as the loss of <italic>Rak</italic> (i.e., <italic>Frk</italic>) induced tumorigenicity in immortalized normal mammary epithelial cells (Yim et al., <xref ref-type="bibr" rid="B221">2009</xref>). In mouse brain, <italic>Pten</italic> is known to be expressed starting at approximately postnatal day 0 (Lachyankar et al., <xref ref-type="bibr" rid="B107">2000</xref>) and has also been correlated with the regulation of neuronal precursor cell migration (Li et al., <xref ref-type="bibr" rid="B118">2002</xref>). In Set B Pten is up-regulated. The paired-related homeobox transcription factor 1, which is encoded by <italic>Prrx1</italic>, is an epithelial-mesenchymal transition (EMT) inducer in embryos, where this process is required for the formation of tissues for which cells originate far from their final destination (Ocaña et al., <xref ref-type="bibr" rid="B155">2012</xref>). EMT is modified and exploited by cancer cells for metastatic dissemination and also in cancer cells. In particular, the loss of <italic>Prrx1</italic> has been related to the ability of cancer cells to acquire tumor-initiating abilities concomitantly with stem cells properties (Ocaña et al., <xref ref-type="bibr" rid="B155">2012</xref>). Furthermore, paired-related homeobox transcription factor 1 has been found to promote tenascin-C–dependent fibroblast migration when its expression was induced by Focal adhesion kinase 1 (McKean et al., <xref ref-type="bibr" rid="B134">2003</xref>). <italic>Fak</italic> is up-regulated in both Set B and Set D. Very interesting is the down-regulation of <italic>Rab11fip2</italic>, whose role in the endocytic recycling pathway has been linked to cell migration (Jones et al., <xref ref-type="bibr" rid="B93">2006</xref>) as previously discussed (Section Receptor-Mediated Endocytosis Mechanisms, Microtubule-Based Vesicle Recycling and Intracellular Membrane Trafficking).</p>
<p>Among the genes up-regulated in Set A related to migration there is <italic>Cxcl12</italic>, which encodes for a deeply studied chemokine involved in different mechanisms in cancer development and metastatic invasion (Duda et al., <xref ref-type="bibr" rid="B47">2011</xref>; Hattermann and Mentlein, <xref ref-type="bibr" rid="B76">2013</xref>), but also described as involved in the migration of neuronal cells through both its receptor, C-X-C chemokine receptor type 4 and Atypical chemokine receptor 3 (Tiveron and Cremer, <xref ref-type="bibr" rid="B196">2008</xref>; Memi et al., <xref ref-type="bibr" rid="B137">2013</xref>; Yang et al., <xref ref-type="bibr" rid="B219">2013</xref>). Cxcl12 appears to exert an action opposite to Cxcl3, as it promotes the localization of the GCPs to the EGL by chemoattraction, being released from meninges (Klein et al., <xref ref-type="bibr" rid="B98">2001</xref>; Zhu et al., <xref ref-type="bibr" rid="B228">2002</xref>). Thus, the upregulation of <italic>Cxcl12</italic>, consequent to the ablation of <italic>Tis21</italic>, synergizes with the downregulation of <italic>Cxcl3</italic> in preventing the migration of the GCPs from the EGL. Notably, the chemoattraction of cerebellar granule cells by Cxcl12, whose receptor C-X-C chemokine receptor type 4 is coupled to a G protein, is selectively inhibited by the soluble EphB receptor; this inhibition is blocked by a truncated PDZ-RGS3 lacking the RGS domain, which activates the G-proteins. Therefore, this points to the existence of a pathway connecting B ephrins and Cxcl12 to the regulation of G protein–coupled chemoattraction, and leads to a model for regulation of migration in cerebellar development (Lu et al., <xref ref-type="bibr" rid="B121">2001</xref>). In this regard, in our model (Set A) we have detected not only a down-regulation of <italic>Efna4</italic>, which is a cell surface GPI-bound ligand for Eph receptors, but also the up-regulation of a regulator of heterotrimeric G protein signaling, i.e., <italic>Rgs5</italic>. Therefore, in our model the decrease of <italic>Cxcl3</italic> and <italic>Efna4</italic> and the increase of <italic>Cxcl12</italic> after ablation of <italic>Tis21</italic> in <italic>Ptch1</italic> heterozygous mice would synergize in impairing the migration of GCPs from the EGL. As mentioned above, the increase of <italic>Cxcl12</italic> in the <italic>Tis21</italic>-null EGL GCPs would prevent their migration by chemoattraction (Zhu et al., <xref ref-type="bibr" rid="B228">2002</xref>). Moreover, the PDGFR pathway members have been recently studied in correlations with MB Shh-driven and MB cell migration, and an upregulation of PDGFRA (receptor for PDGF-A), PDGF-D (ligand for PDGFRB) and Cxcl12 has been observed in Shh-type MB (vs. non Shh MBs). In particular, the activation of the PDGFR pathway has been shown to activate the Cxcl12 receptor (i.e., CXCR4, via inhibition of GRK6) and thus cell migration (Yuan et al., <xref ref-type="bibr" rid="B223">2013</xref>). A relevant caveat of that study is that the direction of cell migration, relative to the EGL, was not assessed, having the analysis been conducted only <italic>in vitro</italic> (Yuan et al., <xref ref-type="bibr" rid="B223">2013</xref>). In our model, we noticed an up-regulation of <italic>Pdgfd</italic> and <italic>Cxcl12</italic> genes in Set A, while both <italic>Pdgfra</italic> and <italic>Pdgfrb</italic> and also <italic>Cxcl12</italic> are up-regulated in Set B and D (see Figure <xref ref-type="fig" rid="F3">3</xref>). This indicates that the heterozygosity of <italic>Ptch1</italic> is in itself a condition inducing the expression of both the Cxcr4 and Pdgfr pathways, and that the additional ablation of <italic>Tis21</italic> further enhances their activation. Finally, <italic>Pafah1b1</italic>, up-regulated in Set A, encodes for Lis1, a microtubule regulator that is required for correct neuronal migration during development (Hippenmeyer et al., <xref ref-type="bibr" rid="B81">2010</xref>; Escamez et al., <xref ref-type="bibr" rid="B51">2012</xref>).</p>
</sec>
<sec>
<title>Epigenetic modulation</title>
<p>The transcriptional reprogramming of the epigenetic patterns is among the causes of tumorigenesis. Nowadays, the epigenetic regulation of transcription and genome organization in MB Shh-type pathogenesis is extensively studied (Batora et al., <xref ref-type="bibr" rid="B11">2014</xref>; Hovestadt et al., <xref ref-type="bibr" rid="B84">2014</xref>; Shi et al., <xref ref-type="bibr" rid="B183">2014</xref>). We have previously provided a first functional genomic analysis of epigenetically regulated genes or interacting proteins for our mouse model <italic>Tis21</italic> KO, identified in background either <italic>Ptch1</italic> heterozygous or wild-type (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B55">2012b</xref>). We also have recently shown that the Tis21 protein binds to histone deacetylases (HDAC1/4/9) in GCPs, where they are required for the Tis21-dependent inhibition of cyclin D1 expression (Micheli et al., <xref ref-type="bibr" rid="B139">2016</xref>). In the present analysis, a great number of genes encoding proteins involved in epigenetic regulation appear to be deregulated in Set A (three <italic>down-regulated</italic> and 12 <italic>up-regulated)</italic>. They mostly belong to the category of the Histone modification rather than to the Chromatin remodeling one (Table <xref ref-type="table" rid="T2">2</xref>), which categories are described in (Arrowsmith et al., <xref ref-type="bibr" rid="B8">2012</xref>; Plass et al., <xref ref-type="bibr" rid="B164">2013</xref>). Our data are in line with those previously published highlighting a great number of deregulated or mutated histone modifiers involved in medulloblastoma (Northcott et al., <xref ref-type="bibr" rid="B152">2012</xref>) and their importance as oncogenes or as tumor suppressors (Cohen et al., <xref ref-type="bibr" rid="B34">2011</xref>). Furthermore, we highlight also the deregulation of five Histone modifier Regulators, up-regulated in Set A, namely: <italic>Emd</italic> (Berk et al., <xref ref-type="bibr" rid="B15">2013</xref>), <italic>Anp32a</italic> (Seo et al., <xref ref-type="bibr" rid="B182">2001</xref>; Fan et al., <xref ref-type="bibr" rid="B53">2006</xref>; Kular et al., <xref ref-type="bibr" rid="B106">2009</xref>), <italic>Taf7</italic> (Gegonne et al., <xref ref-type="bibr" rid="B61">2001</xref>, <xref ref-type="bibr" rid="B60">2013</xref>; Kloet et al., <xref ref-type="bibr" rid="B99">2012</xref>), <italic>Pag2g4</italic> (Zhang et al., <xref ref-type="bibr" rid="B225">2003</xref>), <italic>Ipo7</italic> (Jäkel et al., <xref ref-type="bibr" rid="B90">1999</xref>; Mühlhäusser et al., <xref ref-type="bibr" rid="B145">2001</xref>). A detailed description of Set A genes involved in epigenetic modulation is presented in <xref ref-type="supplementary-material" rid="SM1">Supplementary Data</xref>, at section “Epigenetic modulation.”</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p><bold>Regulators of the epigenome identified in Set A</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Functional Groups</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Subgroups</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Down-regulated in Set A</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Up-regulated in Set A</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Histone modification</td>
<td align="left" colspan="1" rowspan="1" valign="top">Histones</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hist2h2bb (Marzluff et al., <xref ref-type="bibr" rid="B131">2002</xref>; González-Romero et al., <xref ref-type="bibr" rid="B66">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hist3h2ba (Marzluff et al., <xref ref-type="bibr" rid="B131">2002</xref>; González-Romero et al., <xref ref-type="bibr" rid="B66">2010</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Writers</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cbx3 (Takanashi et al., <xref ref-type="bibr" rid="B189">2009</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Editors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Padi4 (Wang et al., <xref ref-type="bibr" rid="B209">2004</xref>, <xref ref-type="bibr" rid="B208">2012</xref>; Chang et al., <xref ref-type="bibr" rid="B29">2009</xref>; Tanikawa et al., <xref ref-type="bibr" rid="B193">2012</xref>; Christophorou et al., <xref ref-type="bibr" rid="B32">2014</xref>; Deplus et al., <xref ref-type="bibr" rid="B43">2014</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ankrd11 (Behrends et al., <xref ref-type="bibr" rid="B13">2003</xref>; Zhang et al., <xref ref-type="bibr" rid="B224">2004</xref>; Plass et al., <xref ref-type="bibr" rid="B164">2013</xref>; Gallagher et al., <xref ref-type="bibr" rid="B59">2015</xref>), Ankrd24 (Plass et al., <xref ref-type="bibr" rid="B164">2013</xref>), Ankrd26 (Plass et al., <xref ref-type="bibr" rid="B164">2013</xref>)</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Readers</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cbx3 (Arney and Fisher, <xref ref-type="bibr" rid="B7">2004</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brwd1 (Huang et al., <xref ref-type="bibr" rid="B87">2003</xref>; Bai et al., <xref ref-type="bibr" rid="B9">2011</xref>; Arrowsmith et al., <xref ref-type="bibr" rid="B8">2012</xref>; Filippakopoulos and Knapp, <xref ref-type="bibr" rid="B56">2012</xref>; Plass et al., <xref ref-type="bibr" rid="B164">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chromatin remodeling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleosome remodeling factor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Padi4 (Christophorou et al., <xref ref-type="bibr" rid="B32">2014</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Chromatin remodeling factor</td>
<td align="left" colspan="1" rowspan="1" valign="top">-</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dek (Cavellán et al., <xref ref-type="bibr" rid="B26">2006</xref>; Hu et al., <xref ref-type="bibr" rid="B86">2007</xref>; Privette Vinnedge et al., <xref ref-type="bibr" rid="B167">2013</xref>; Saha et al., <xref ref-type="bibr" rid="B177">2013</xref>; Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Histones and enzymes involved in histone modification and chromatin remodeling are showed in the table. They have been classified in subgroups according to their function and divided in enzymes that transfer the modification or writers, enzymes that modify or revert a modification also called editors or erasers and enzymes that mediate the interactions of proteins or protein complexes with the modification known as readers (Arrowsmith et al., <xref ref-type="bibr" rid="B8">2012</xref>; Plass et al., <xref ref-type="bibr" rid="B164">2013</xref>)</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Drug targets</title>
<p>The increasing recognition of the heterogeneity of molecular basis underlying cancer allows the identification and development of molecularly targeted agents and their transfer to the patients (Rask-Andersen et al., <xref ref-type="bibr" rid="B170">2011</xref>; Saletta et al., <xref ref-type="bibr" rid="B178">2014</xref>). Here we provide a drug target identification through the genomic analysis of deregulated MB Shh-type <italic>Tis21</italic> knockout-dependent genes in Set A and, where possible, the identification of potentially druggable targets (Figure <xref ref-type="fig" rid="F3">3</xref>, Tables <xref ref-type="table" rid="T3">3</xref>–<xref ref-type="table" rid="T5">5</xref>), performed using the methods described in the appropriate section. This analysis has given as a result 20 primary, 31 secondary, 53 druggable targets and 18 gene targets among Set A elements (Tables <xref ref-type="table" rid="T3">3</xref>–<xref ref-type="table" rid="T6">6</xref>). Their distribution within the functional classes is showed in Figure <xref ref-type="fig" rid="F5">5</xref>. and the putative drug targets identified in SetA, here discussed, are shown in Figure <xref ref-type="fig" rid="F3">3</xref>.</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p><bold>A list containing the direct targets and their drugs obtained using MetaCore™ (i.e., ATP1A1) and Cortellis™ db</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-bottom: thin solid #000000;">
<th align="center" colspan="5" rowspan="1" valign="top">
<bold>MetaCore™/Cortellis™ Therapeutic Drug-target direct Interactions</bold>
</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene Symbol</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Target</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Drug</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Effect</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Pubmed</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Trichlormethiazide intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Istaroxime</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12904068, 12388640, 17239702</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">11 beta-Hydroxysteroid dehydrogenase</td>
<td align="left" colspan="1" rowspan="1" valign="top">Enoxolone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">8504732, 16012754, 16309197, 16391818, 17566745, 18721818, 18600055, 19949310, 24613819</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">H19</td>
<td align="left" colspan="1" rowspan="1" valign="top">H19</td>
<td align="left" colspan="1" rowspan="1" valign="top">BC-822</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PDGF</td>
<td align="left" colspan="1" rowspan="1" valign="top">PDGF</td>
<td align="left" colspan="1" rowspan="1" valign="top">CR002</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">17308324, 16510766, 12937299</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">XR-510</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PD-123319</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">MP-157</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">EMA401</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">23489258</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Acetyl-CoA carboxylase 1 isoform 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">CP-640186</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12842871, 15341732, 23358327, 15934915</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CP-610431</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12842871</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPIN340</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">16840555, PMC2916360</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GBF1</td>
<td align="left" colspan="1" rowspan="1" valign="top">GBF1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brefeldin A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">3192548, PMC160661, 2004424</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>The Cortellis™ drugs list has been compared and expanded using others public databases as described in Materials and Methods section</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p><bold>A list containing the indirect drug-target interactions obtained using MetaCore™</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-bottom: thin solid #000000;">
<th align="center" colspan="5" rowspan="1" valign="top"><bold>MetaCore</bold>™<bold>Secondary Drug-target Interactions</bold></th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Drug</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene Symbol</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Target</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Effect</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Pubmed</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lestaurtinib extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Midostaurin intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">19654408</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">19654408</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">19654408</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">19654408</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ca('2+) cytosol</td>
<td align="left" colspan="1" rowspan="1" valign="top">DGKB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diacylglycerol kinase, beta</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">9003401, 16288460, 10206945, 12832407</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PADI4</td>
<td align="left" colspan="1" rowspan="1" valign="top">PAD4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">11798170, 15247907</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DGKA</td>
<td align="left" colspan="1" rowspan="1" valign="top">DGK-alpha</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">9003401, 16288460, 10206945, 12832407</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DGKG</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diacylglycerol kinase, gamma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">9003401, 16288460, 10206945, 12832407</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">VDAC1</td>
<td align="left" colspan="1" rowspan="1" valign="top">VDAC 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">12022949, 16597621</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Estradiol extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">BTG2</td>
<td align="left" colspan="1" rowspan="1" valign="top">BTG2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12959972</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">RGS5</td>
<td align="left" colspan="1" rowspan="1" valign="top">RGS5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">17374850</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL12</td>
<td align="left" colspan="1" rowspan="1" valign="top">SDF-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">17362937, 17555868</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">9623596, 10503719</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dabrafenib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vandetanib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037377, 22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tozasertib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">18183025,22037378</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">18183025,22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retinoic acid extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">PADI4</td>
<td align="left" colspan="1" rowspan="1" valign="top">PAD4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">10488123</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Aggrecanase-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">17255106</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Uprosertib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dexamethasone extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15 (ORC1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">12055339, 11997094</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">16872738</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zn('2+) nucleus</td>
<td align="left" colspan="1" rowspan="1" valign="top">ZNF286A</td>
<td align="left" colspan="1" rowspan="1" valign="top">ZNF286A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">11347906</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BSN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bassoon</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">9806829, 9679147, 9679147</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pazopanib extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Masitinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pyridoxal Phosphate intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15 (ORC1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12807890</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">16249179</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fedratinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nilotinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Epigallocatechin-3-gallate extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL1</td>
<td align="left" colspan="1" rowspan="1" valign="top">GRO-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TAK-901 intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">INK128 intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">QIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ibrutinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zn('2+) extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS10</td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAM-TS10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">11867212</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Aggrecanase-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">11867212</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TG100115 intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Perphenazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pamapimod intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Eprosartan extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2016730, 8515425</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Aclarubicin intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">12118337</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Promazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Phenoxybenzamine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Carbenoxolone intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10566667, 10664531, 12190302</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anisindione intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">4067989</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Maprotiline extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Irbesartan extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2329553</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Prazepine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">lorcainide extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10593659</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pirfenidone intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">17086734</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NO extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">11698241, 14992266, 15166008</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Taurine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">9130593, 10936171, 12437590</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fenoprofen intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">1347398</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Meloxicam extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">16536903</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Promethazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Biotin intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">12421859, 14749229, 15539280</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Furosemide intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">9724039</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dimethyl sulfoxide intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">PADI4</td>
<td align="left" colspan="1" rowspan="1" valign="top">PAD4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">10488123</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Thiram intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12901862</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Disopyramide extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10593659</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fluoxymesterone intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Digitoxin extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">11525233</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Methylene blue intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">GUCY1A3</td>
<td align="left" colspan="1" rowspan="1" valign="top">GUCY1A3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12031394, 12729841</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heparin extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL12</td>
<td align="left" colspan="1" rowspan="1" valign="top">SDF-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10570220, 15741341, 17264079, 17726466</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Atenolol extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">11201505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hg('2+) extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15 (ORC1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12807890</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Procainamide extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10593659</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Trazodone extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nicotinic acid intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">8857918, 10195935, 11171611, 12873710, 15030302</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Imatinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">15711537, 18183025, 22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sotalol extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">11201505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tocainide extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TRV-120027 extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ruxolitinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ruboxistaurin intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cisplatin extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Trifluoperazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Doxycycline intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">20874665, 17122880, 17145119, 19442784</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Losartan extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">1469703, 1875348, 1920360, 7473594, 7562905, 7606390, 7990105, 8064808, 8246245, 8277505, 8277506, 8340920, 8421274, 11310611, 11749394, 12213451, 16039125, 7990105, 14761190</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Silmitasertib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chlorpromazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">R547 intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">22037378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">17alpha-Hydroxyprogesterone extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10566667</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Alprazolam extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Digoxin extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">11072868</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CFI-400945 intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Clotiapine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Indenolol extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">1685314, 11201505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Testosterone extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">16579987</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Aldosterone extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">16767692, 10718622</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Encainide extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2168576, 10593659</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Regorafenib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cholic acid intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12015312</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">BMS-387032 intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAO2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Angiotensin II extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">16570916, 2362273</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tivozanib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Clofilium extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">15637453</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Amoxapine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tranilast intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">16393468</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zn('2+) cytosol</td>
<td align="left" colspan="1" rowspan="1" valign="top">RBM5</td>
<td align="left" colspan="1" rowspan="1" valign="top">RBM5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">10352938</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Androstanolone extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">RPS12</td>
<td align="left" colspan="1" rowspan="1" valign="top">RPS12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">15525599</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ketoconazole intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10664531</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Thioridazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retinoic acid intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">GCNT3</td>
<td align="left" colspan="1" rowspan="1" valign="top">GCNT3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">15591039</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Prochlorperazine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">6167716</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Latanoprost extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">12454040</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Piperacillin intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">LACTB</td>
<td align="left" colspan="1" rowspan="1" valign="top">LACTB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Afatinib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Afuresertib intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Topiramate intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">16415917</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nebentan extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Celiprolol intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">1685314, 11201505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Disulfiram intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12901862</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cimetidine intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">PADI4</td>
<td align="left" colspan="1" rowspan="1" valign="top">PAD4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Candesartan extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unspecified</td>
<td align="left" colspan="1" rowspan="1" valign="top">16039125</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Progesterone intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">9623596, 10566667, 10664531, 12915667, 9055382</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Loxapine extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">2576298</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nadolol extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">11201505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hydrochlorothiazide intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10334975</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Deoxycholic acid intracellular</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">12015312</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Metoprolol extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">11201505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">D-Glucose extracellular region</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">10516137, 12870156</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Paricalcitol</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTH</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">9697664, 16797393</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>The only exception is the record related to the PTH gene that has been taken from Cortellis Drug Viewer list and compared with others public databases, as described in Materials and Methods section</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T5" position="float">
<label>Table 5</label>
<caption>
<p><bold>A drug-target interactions list and the correspondent source of information obtained using the Search Drug-Target Interactions tool on DGIdb, where a drug-gene interaction is a known interaction between a known drug compound and a target gene</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-bottom: thin solid #000000;">
<th align="center" colspan="6" rowspan="1" valign="top">
<bold>DGIdB Drug-Gene Interactions</bold>
</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Search Term</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Drug</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Interaction Type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Source</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Source Version</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>ACACA</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA-acetyl-CoA carboxylase alpha</td>
<td align="left" colspan="1" rowspan="1" valign="top">TOFA</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BIOTIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS5</td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS5-ADAM metallopeptidase with thrombospondin type 1 motif, 5</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BATIMASTAT</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2-angiotensin II receptor, type 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">PD123319</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">[125I]CGP42112</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">COMPOUND 21 [PMID: 22802221]</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CGP42112</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ANGIOTENSIN III</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ANGIOTENSIN II</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">NOVOKININ</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ANGIOTENSIN A</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CANDESARTAN CILEXETIL</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TAK-491</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PS433540</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">AZILSARTAN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">AZILSARTAN MEDOXOMIL</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TAK-591</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TASOSARTAN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1-ATPase, Na/K transporting, alpha 1 polypeptide</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALMITRINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BEPRIDIL</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ACETYLDIGITOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">OUABAIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIGOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIGITOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DESLANOSIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">TEND</td>
<td align="left" colspan="1" rowspan="1" valign="top">01-Aug-2011</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ACETYLDIGITOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DESLANOSIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIGITOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIGOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">GuideToPharmacologyInteractions</td>
<td align="left" colspan="1" rowspan="1" valign="top">04-mar-15</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">OUABAIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">LUMEFANTRINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CICLOPIROX</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ALUMINIUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CHLOROPROCAINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Blocker</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ARTEMETHER</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ALMITRINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DESLANOSIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIGITOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HYDROFLUMETHIAZIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Other/Unknown</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BEPRIDIL</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIGOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ACETYLDIGITOXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ALUMINIUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">MAGNESIUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ETHACRYNIC ACID</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DIAZOXIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Other/Unknown</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRICHLORMETHIAZIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">POTASSIUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DESLANOSIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ALMITRINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">OUABAIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BRETYLIUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CEACAM3</td>
<td align="left" colspan="1" rowspan="1" valign="top">CEACAM3-carcinoembryonic antigen-related cell adhesion molecule 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">ARCITUMOMAB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antibody</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTD</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.3.02 (2011.08.25)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL12</td>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL12-chemokine (C-X-C motif) ligand 12</td>
<td align="left" colspan="1" rowspan="1" valign="top">TINZAPARIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binder</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DEPTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">DEPTOR - DEP domain containing MTOR-interacting protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">AZD8055</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">MyCancerGenome</td>
<td align="left" colspan="1" rowspan="1" valign="top">13-mar-13</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">MLN0128</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">MyCancerGenome</td>
<td align="left" colspan="1" rowspan="1" valign="top">13-mar-13</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">OSI-027</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">MyCancerGenome</td>
<td align="left" colspan="1" rowspan="1" valign="top">13-mar-13</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ERLOTINIB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK-fyn-related kinase</td>
<td align="left" colspan="1" rowspan="1" valign="top">REGORAFENIB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">MyCancerGenomeClinicalTrial</td>
<td align="left" colspan="1" rowspan="1" valign="top">30-Feburary-2014</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2-hydroxysteroid (11-beta) dehydrogenase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">NADH</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LARS</td>
<td align="left" colspan="1" rowspan="1" valign="top">LARS-leucyl-tRNA synthetase</td>
<td align="left" colspan="1" rowspan="1" valign="top">L-LEUCINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PADI4</td>
<td align="left" colspan="1" rowspan="1" valign="top">PADI4-peptidyl arginine deiminase, type IV</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-[(1S)-1-(AMINOCARBONYL)-4-(ETHANIMIDOYLAMINO)BUTYL]BENZAMIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">L-CITRULLINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PDGFD</td>
<td align="left" colspan="1" rowspan="1" valign="top">PDGFD-platelet derived growth factor D</td>
<td align="left" colspan="1" rowspan="1" valign="top">SUNITINIB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">MyCancerGenomeClinicalTrial</td>
<td align="left" colspan="1" rowspan="1" valign="top">30-Feburary-2014</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PPP1R13L</td>
<td align="left" colspan="1" rowspan="1" valign="top">PPP1R13L-protein phosphatase 1, regulatory subunit 13 like</td>
<td align="left" colspan="1" rowspan="1" valign="top">CISPLATIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">PharmGKB</td>
<td align="left" colspan="1" rowspan="1" valign="top">12-Jul-2012</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CYCLOPHOSPHAMIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">PharmGKB</td>
<td align="left" colspan="1" rowspan="1" valign="top">12-Jul-2012</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">THALIDOMIDE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">PharmGKB</td>
<td align="left" colspan="1" rowspan="1" valign="top">12-Jul-2012</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PLATINUM COMPOUNDS</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">PharmGKB</td>
<td align="left" colspan="1" rowspan="1" valign="top">12-Jul-2012</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PLATINUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">PharmGKB</td>
<td align="left" colspan="1" rowspan="1" valign="top">12-Jul-2012</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PTH</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTH-parathyroid hormone</td>
<td align="left" colspan="1" rowspan="1" valign="top">NORLEUCINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15-solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15</td>
<td align="left" colspan="1" rowspan="1" valign="top">L-ORNITHINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2-SRSF protein kinase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PURVALANOL</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ADENINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ADENOSINE-5′-DIPHOSPHATE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2-TAO kinase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">PHOSPHONOSERINE</td>
<td align="left" colspan="1" rowspan="1" valign="top">n/a</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">VDAC1</td>
<td align="left" colspan="1" rowspan="1" valign="top">VDAC1-voltage-dependent anion channel 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">DIHYDROXYALUMINIUM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">DrugBank</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T6" position="float">
<label>Table 6</label>
<caption>
<p><bold>A sub-list of Set A genes with the correspondent selected druggable gene category and source of information obtained using the Search Druggable Gene Categories tool on DGIdb, where a druggable gene category is a group of genes that are thought to be potentially druggable by various methods of prediction</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-bottom: thin solid #000000;">
<th align="center" colspan="4" rowspan="1" valign="top">
<bold>DGIdB Druggable Targets</bold>
</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Search term</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Druggable Gene Category</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sources</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACACA-acetyl-CoA carboxylase alpha</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom RussLampel</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUG RESISTANCE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS10</td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS10-ADAM metallopeptidase with thrombospondin type 1 motif, 10</td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">NEUTRAL ZINC METALLOPEPTIDASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS5</td>
<td align="left" colspan="1" rowspan="1" valign="top">ADAMTS5-ADAM metallopeptidase with thrombospondin type 1 motif, 5</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">NEUTRAL ZINC METALLOPEPTIDASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AGTR2-angiotensin II receptor, type 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">G PROTEIN COUPLED RECEPTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene RussLampel HopkinsGroom</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AKAP2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AKAP2-A kinase (PRKA) anchor protein 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP1A1-ATPase, Na/K transporting, alpha 1 polypeptide</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ION CHANNEL</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ABC TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUG RESISTANCE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">BTG2</td>
<td align="left" colspan="1" rowspan="1" valign="top">BTG2-BTG family, member 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">DNA REPAIR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CDC27</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC27-cell division cycle 27 homolog (S. cerevisiae)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB</td>
<td align="left" colspan="1" rowspan="1" valign="top">CDC42BPB-CDC42 binding protein kinase beta (DMPK-like)</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel dGene HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO HopkinsGroom</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL1</td>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL1-chemokine (C-X-C motif) ligand 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">GROWTH FACTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL12</td>
<td align="left" colspan="1" rowspan="1" valign="top">CXCL12-chemokine (C-X-C motif) ligand 12</td>
<td align="left" colspan="1" rowspan="1" valign="top">CELL SURFACE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">EXTERNAL SIDE OF PLASMA MEMBRANE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">GROWTH FACTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DAZL</td>
<td align="left" colspan="1" rowspan="1" valign="top">DAZL-deleted in azoospermia-like</td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DEK</td>
<td align="left" colspan="1" rowspan="1" valign="top">DEK - DEK oncogene</td>
<td align="left" colspan="1" rowspan="1" valign="top">DNA REPAIR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DGKQ</td>
<td align="left" colspan="1" rowspan="1" valign="top">DGKQ-diacylglycerol kinase, theta 110 kDa</td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR BINDING</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DPP10</td>
<td align="left" colspan="1" rowspan="1" valign="top">DPP10-dipeptidyl-peptidase 10 (non-functional)</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel HopkinsGroom dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom GO dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">EFNA4</td>
<td align="left" colspan="1" rowspan="1" valign="top">EFNA4-ephrin-A4</td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TYROSINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ERG</td>
<td align="left" colspan="1" rowspan="1" valign="top">ERG-v-ets erythroblastosis virus E26 oncogene homolog (avian)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CLINICALLY ACTIONABLE</td>
<td align="left" colspan="1" rowspan="1" valign="top">FoundationOneGenes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FOXF2</td>
<td align="left" colspan="1" rowspan="1" valign="top">FOXF2-forkhead box F2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR COMPLEX</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR BINDING</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FRK</td>
<td align="left" colspan="1" rowspan="1" valign="top">FRK-fyn-related kinase</td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TYROSINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom dGene RussLampel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GPR82</td>
<td align="left" colspan="1" rowspan="1" valign="top">GPR82-G protein-coupled receptor 82</td>
<td align="left" colspan="1" rowspan="1" valign="top">G PROTEIN COUPLED RECEPTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene RussLampel HopkinsGroom</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GTPBP4</td>
<td align="left" colspan="1" rowspan="1" valign="top">GTPBP4-GTP-binding protein 4</td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GUCY1A3</td>
<td align="left" colspan="1" rowspan="1" valign="top">GUCY1A3-guanylate cyclase 1, soluble, alpha 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom RussLampel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSD11B2-hydroxysteroid (11-beta) dehydrogenase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUG RESISTANCE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SHORT CHAIN DEHYDROGENASE REDUCTASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IPO7</td>
<td align="left" colspan="1" rowspan="1" valign="top">IPO7-importin 7</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">JMY</td>
<td align="left" colspan="1" rowspan="1" valign="top">JMY-junction mediating and regulatory protein, p53 cofactor</td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DNA REPAIR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LARS</td>
<td align="left" colspan="1" rowspan="1" valign="top">LARS-leucyl-tRNA synthetase</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom RussLampel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2</td>
<td align="left" colspan="1" rowspan="1" valign="top">LATS2-LATS, large tumor suppressor, homolog 2 (Drosophila)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom dGene RussLampel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NAPEPLD</td>
<td align="left" colspan="1" rowspan="1" valign="top">NAPEPLD - N-acyl phosphatidylethanolamine phospholipase D</td>
<td align="left" colspan="1" rowspan="1" valign="top">PHOSPHOLIPASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NLK</td>
<td align="left" colspan="1" rowspan="1" valign="top">NLK-nemo-like kinase</td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom dGene RussLampel</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR BINDING</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PA2G4</td>
<td align="left" colspan="1" rowspan="1" valign="top">PA2G4-proliferation-associated 2G4, 38 kDa</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PAFAH1B1</td>
<td align="left" colspan="1" rowspan="1" valign="top">PAFAH1B1-platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45 kDa)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PDGFD</td>
<td align="left" colspan="1" rowspan="1" valign="top">PDGFD-platelet-derived growth factor D</td>
<td align="left" colspan="1" rowspan="1" valign="top">GROWTH FACTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PPP1R13L</td>
<td align="left" colspan="1" rowspan="1" valign="top">PPP1R13L-protein phosphatase 1, regulatory subunit 13 like</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR BINDING</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PTH</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTH-parathyroid hormone</td>
<td align="left" colspan="1" rowspan="1" valign="top">HORMONE ACTIVITY</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RBM5</td>
<td align="left" colspan="1" rowspan="1" valign="top">RBM5-RNA binding motif protein 5</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom RussLampel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RIPK3</td>
<td align="left" colspan="1" rowspan="1" valign="top">RIPK3-receptor-interacting serine-threonine kinase 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SENP7</td>
<td align="left" colspan="1" rowspan="1" valign="top">SENP7-SUMO1/sentrin specific peptidase 7</td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SIK2-salt-inducible kinase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel HopkinsGroom dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A15-solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLC6A6-solute carrier family 6 (neurotransmitter transporter, taurine), member 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO HopkinsGroom</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SMG1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SMG1-smg-1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PHOSPHATIDYLINOSITOL 3 KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom RussLampel dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DNA REPAIR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SRPK2-SRSF protein kinase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">RussLampel dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SYT11</td>
<td align="left" colspan="1" rowspan="1" valign="top">SYT11-synaptotagmin XI</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TAF7</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAF7-TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 55 kDa</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR COMPLEX</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HISTONE MODIFICATION</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSCRIPTION FACTOR BINDING</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TAOK2-TAO kinase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">HopkinsGroom RussLampel dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SERINE THREONINE KINASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TIMP1-TIMP metallopeptidase inhibitor 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE INHIBITOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO dGene</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TOMM22</td>
<td align="left" colspan="1" rowspan="1" valign="top">TOMM22-translocase of outer mitochondrial membrane 22 homolog (yeast)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">UPF3B</td>
<td align="left" colspan="1" rowspan="1" valign="top">UPF3B-UPF3 regulator of nonsense transcripts homolog B (yeast)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">USP36</td>
<td align="left" colspan="1" rowspan="1" valign="top">USP36-ubiquitin specific peptidase 36</td>
<td align="left" colspan="1" rowspan="1" valign="top">PROTEASE</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DRUGGABLE GENOME</td>
<td align="left" colspan="1" rowspan="1" valign="top">dGene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">VDAC1</td>
<td align="left" colspan="1" rowspan="1" valign="top">VDAC1-voltage-dependent anion channel 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRANSPORTER</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ION CHANNEL</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ZC3H12D</td>
<td align="left" colspan="1" rowspan="1" valign="top">ZC3H12D-zinc finger CCCH-type containing 12D</td>
<td align="left" colspan="1" rowspan="1" valign="top">TUMOR SUPPRESSOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">GO</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Among the Set A genes showing a change of expression influenced exclusively by the ablation of <italic>Tis21</italic>, there is <italic>Pdgfd</italic> that has been discussed in developmental (see <xref ref-type="supplementary-material" rid="SM1">Supplemtary Data</xref>) and migration processes as up-regulated gene. Since the overactivity of PDGF signaling can drive tumorigenesis (Pietras et al., <xref ref-type="bibr" rid="B162">2003</xref>), and since PDGF-D in particular has been found to be a potent transforming and angiogenic growth factor (Li et al., <xref ref-type="bibr" rid="B116">2003</xref>) highly expressed in Shh-type medulloblastoma (Yuan et al., <xref ref-type="bibr" rid="B223">2013</xref>), we propose targeting PDGF-D as therapeutic strategy for medulloblastoma Shh-type, as already studied in other tumors (Heldin, <xref ref-type="bibr" rid="B80">2013</xref>). Another very interesting drug target could be the phosphatidylinositol 3-kinase-related kinase Smg1, which here has been discussed in developmental and nonsense-mediated decay processes (Supplementary Material) as down-regulated in Set A (up-regulated in Set D). This protein seems to act antagonistically with mTOR signaling (González-Estévez et al., <xref ref-type="bibr" rid="B65">2012</xref>; Du et al., <xref ref-type="bibr" rid="B46">2014</xref>), and this is in functional synergy with the up-regulation in Set A of <italic>Deptor</italic>, which negatively regulates mTOR signaling (Beauchamp and Platanias, <xref ref-type="bibr" rid="B12">2013</xref>). Also Deptor is one of the druggable target identified in our study. Taken together, these findings seem to support the importance of mTOR pathway and its upstream PDGF signaling in the pathogenesis of medulloblastoma (Mohan et al., <xref ref-type="bibr" rid="B141">2012</xref>).</p>
<p>Other two druggable targets are regulators of cell cycle and developmental processes: <italic>Sik2</italic> and <italic>Lats2</italic>. The functional product of <italic>Sik2</italic> is localized at the centrosome where its absence leads to a delay of G1/S transition (Ahmed et al., <xref ref-type="bibr" rid="B3">2010</xref>), while <italic>Lats2</italic> encodes for a centrosomal protein (a serin threonin kinase) whose loss leads to centrosome fragmentation (Yabuta et al., <xref ref-type="bibr" rid="B217">2007</xref>), also involved in the regulation of cell cycle G1/S checkpoint, for its relevance to MB tumorigenesis due to its influence in the reduction of expression of cyclin-D1 and N-CoR (Park et al., <xref ref-type="bibr" rid="B159">2012</xref>; Lit et al., <xref ref-type="bibr" rid="B119">2013</xref>). The deregulation of centrosome and cilia biogenesis have been already described in different human diseases, in particular, in cancer where a derangement of cell cycle checkpoints is governed by cilia and centrosomes (Plotnikova et al., <xref ref-type="bibr" rid="B165">2008</xref>; Nigg and Raff, <xref ref-type="bibr" rid="B151">2009</xref>; Bettencourt-Dias et al., <xref ref-type="bibr" rid="B17">2011</xref>). In addition to that, Sik2 has been characterized as negative regulator of Hippo signaling in Drosophila (Wehr et al., <xref ref-type="bibr" rid="B212">2013</xref>). In our data, other two regulators of Hippo signaling appear to be down-regulated after ablation of <italic>Tis21, Lats2</italic>, and <italic>Fat4</italic> that we discuss for their role in the developmental process (<xref ref-type="supplementary-material" rid="SM1">Supplementary Data</xref>); both act also as tumor suppressors. This evidence supports the involvement of Hippo signaling (Roussel and Hatten, <xref ref-type="bibr" rid="B176">2011</xref>) and centrosome assembly in the pathogenesis of MB.</p>
<p>Another putative drug target belonging to developmental processes, <italic>Rgs5</italic>, encodes for an endogenous repressor of Shh signaling and has been proposed in a recent study as potential therapeutic target in Hh-mediated diseases. In fact, it was shown that (i) Rgs5 inhibits the Shh-mediated signaling by activating the GTP-bound Gαi downstream of Smo and (ii) a physical complex between Rgs5 with Smo is present in primary cilia (Mahoney et al., <xref ref-type="bibr" rid="B123">2013</xref>).</p>
<p>The apoptosis is not the only form of cellular death in which the deregulated genes in Set A are involved. In fact, the <italic>Ripk3</italic> functional product, a receptor-interacting protein kinase 3, has been reported to contribute to both apoptotic and necroptotic cell death, depending on target availability (Cook et al., <xref ref-type="bibr" rid="B36">2014</xref>; Vanden Berghe et al., <xref ref-type="bibr" rid="B200">2014</xref>). Since many anti-cancer drugs are inducers of apoptosis, the induction of RIP3-dependent necrosis is an attractive strategy to circumvent apoptosis resistance of cancer cells (Moriwaki and Chan, <xref ref-type="bibr" rid="B143">2013</xref>) that is currently under investigation (Moriwaki et al., <xref ref-type="bibr" rid="B142">2015</xref>). As <italic>Ripk3</italic> expression is induced after knockout of <italic>Tis21</italic> in Shh-activated background, we may hypothesize that <italic>Ripk3</italic> plays in our model a tumor suppressor role.</p>
<p>The therapeutic advantage of targeting the ubiquitin-proteasome system has already being successfully investigated with proteasomal inhibitors in Shh-type MB with <italic>in vivo</italic> preclinical studies (Ohshima-Hosoyama et al., <xref ref-type="bibr" rid="B156">2011</xref>) and in a preliminary study with personalized targeted therapy for pediatric brain tumors among which MB (Wolff et al., <xref ref-type="bibr" rid="B214">2012</xref>). However, the targeting of specific enzymes regulating the ubiquitylation process, e.g., SKP2, a SCF ubiquitin ligase, up-regulated in Set D (Figure <xref ref-type="fig" rid="F3">3</xref>), has been recently proposed as a more specific approach than the previous one (Hede et al., <xref ref-type="bibr" rid="B77">2014</xref>). Two genes belonging to the ubiquitin-dependent degradation processes are up-regulated in Set A and have been identified in this study as putative drug target: <italic>Ups36</italic> and <italic>Cdc27</italic>. <italic>Usp36</italic>, encoding for a deubiquitinating enzyme (Quesada et al., <xref ref-type="bibr" rid="B168">2004</xref>), has been detected as overexpresed in human ovarian cancer compared to normal ovaries (Li et al., <xref ref-type="bibr" rid="B117">2008</xref>). An Usp36 homolog, recently detected in Drosophila stem cells, has been linked to the deubiquitylation of histone H2B and to the silencing of key differentiation genes, including genes target of Notch (Buszczak et al., <xref ref-type="bibr" rid="B25">2009</xref>). Whereas the anaphase-promoting complex component Cdc27 is an E3 ubiquitin ligase able to control cell cycle progression at the G1 to S transition, and also to induce the non-proteolytic disassembly of the spindle checkpoint during mitosis (Jin et al., <xref ref-type="bibr" rid="B92">2008</xref>; Manchado et al., <xref ref-type="bibr" rid="B124">2010</xref>; Pawar et al., <xref ref-type="bibr" rid="B160">2010</xref>). For these reasons, <italic>Cdc27</italic> functional product has been identified as a molecular target of the curcumin-induced cell cycle arrest and apoptosis in Shh-type MB (Lee and Langhans, <xref ref-type="bibr" rid="B110">2012</xref>). The therapeutic properties of this natural substance were already shown in Shh-driven MB models, highlighting its ability to inhibit the Shh signaling, to reduce the level of β-catenin and to inhibit HDAC4 (Elamin et al., <xref ref-type="bibr" rid="B50">2010</xref>; Lee et al., <xref ref-type="bibr" rid="B111">2011</xref>). Thus, the up-regulation of <italic>Cdc27</italic> after ablation of <italic>Tis21</italic> may be a tumorigenic factor.</p>
<p>Of interest as drug target among the genes belonging to the migration processes is <italic>Timp1</italic>. Its signal trasduction pathway results in the migration of hNSCs, showing chemoattractant properties and being identified in the same study as a therapeutic target for human glioma (Lee et al., <xref ref-type="bibr" rid="B112">2014</xref>). Here we suggest the same prospective use of Timp1 in MB Shh-type.</p>
<p>The <italic>Cdc42bpb</italic> produces a Rho GTPase activated serine/threonine kinase, which, by regulating the (non-muscle) cytoskeletal actomyosin, influences cell shape and promotes motility and migration (Tan et al., <xref ref-type="bibr" rid="B192">2008</xref>, <xref ref-type="bibr" rid="B191">2011</xref>), thus acting also as a key regulator of tumor cell invasion. Cdc42bpb is therefore an interesting drug target (Heikkila et al., <xref ref-type="bibr" rid="B79">2011</xref>; Unbekandt et al., <xref ref-type="bibr" rid="B199">2014</xref>). It's down-regulation in our Set A data is in line with the GCPs migration failure, consistently with the deregulation of others migration regulators discussed above.</p>
<p>Genes involved in the RNA processing are <italic>Smg1</italic> and <italic>Upf3b</italic>, respectively down- and up-regulated in Set A. Interestingly, both genes encode for proteins involved in alternative splicing (AS) coupled with Nonsense-Mediated Decay (NMD) mechanism by which NMD controls transcript abundance by regulating AS; in fact, the SURF complex, which includes the SMG1–UPF1–eRF1–eRF3 proteins, forms a bridge between the ribosome and the downstream exon-junction complex (EJC) associated with UPF3b and UPF2 (Chamieh et al., <xref ref-type="bibr" rid="B28">2008</xref>; McIlwain et al., <xref ref-type="bibr" rid="B133">2010</xref>). Moreover, <italic>Smg1</italic> has been showed to be involved in the predisposition to tumor formation and inflammation in <italic>Smg1</italic> heterozygous mice; this mouse model presents elevated basal tissue and serum cytokine levels—indicating low-level inflammation—and can progress to chronic inflammation or enhanced cancer development. Therefore, this is a model of inflammation-enhanced cancer development (Roberts et al., <xref ref-type="bibr" rid="B172">2013</xref>), also suggesting that <italic>Smg1</italic> is a tumor suppressor (Du et al., <xref ref-type="bibr" rid="B46">2014</xref>). To our knowledge, the possibility to target inflammation through Smg1 has never been applied to medulloblastoma until now. Furthermore, in our data <italic>Il1b</italic>, for example, is up-regulated in Set D and B (See Figure <xref ref-type="fig" rid="F2">2</xref>); also <italic>Cxcl12</italic> is up-regulated in Set D, B, and also in Set A, as mentioned previously, while <italic>Cxcl3</italic> is down-regulated in Set A. It is also worth noting the existence of an anticoagulant inhibitor of CXCL12/CXCR4 axis, the Tinzaparin, as well as other heparinoids that have been studied in brest cancer models for their heparinoid-mediated inhibition of chemotaxis activity (Harvey et al., <xref ref-type="bibr" rid="B74">2007</xref>; Mellor et al., <xref ref-type="bibr" rid="B136">2007</xref>). As Cxcl12 favors the localization of the GCPs to the EGL by chemoattraction, an inhibitor of Cxcl12 might achieve an opposite effect, similar to the promigratory effect exerted by Cxcl3.</p>
</sec>
</sec>
</sec>
<sec id="s4">
<title>Summary and conclusions</title>
<p>During cerebellar development, Shh is expressed in Purkinje cells and regulates the proliferation of GCPs acting as mitogen (Dahmane and Ruiz i Altaba, <xref ref-type="bibr" rid="B40">1999</xref>; Wallace, <xref ref-type="bibr" rid="B202">1999</xref>; Wechsler-Reya and Scott, <xref ref-type="bibr" rid="B211">1999</xref>). GPCs undergo a prolonged mitotic activity in the EGL during the early postnatal period in the mouse. After this intense proliferative phase, around the second postnatal week in mouse, GPCs exit the cell cycle and migrate radially to the IGL, along the Bergmann glia. During this inward migration, differentiation of post-mitotic GPCs takes place, allowing the mature granule neurons to expand the IGL, where they extend dendrites (Dyer, <xref ref-type="bibr" rid="B48">2004</xref>; Rodini et al., <xref ref-type="bibr" rid="B173">2010</xref>; Wang and Wechsler-Reya, <xref ref-type="bibr" rid="B204">2014</xref>). As a consequence of a hyperactivation of the Shh pathway occurring in the <italic>Ptch1</italic><sup>+/−</sup> MB mouse model, the prolonged mitotic activity of GCPs makes them potential targets for transforming insults, leading to MB (Wang and Zoghbi, <xref ref-type="bibr" rid="B205">2001</xref>).</p>
<p>Mutations in <italic>Ptch1</italic> occur in sporadic human MB and promote the tumor in <italic>Ptch1</italic> heterozygous mouse models at a rate of approximately 8% within 12 weeks of age and up to 30% between 12 and 25 weeks of age (Goodrich et al., <xref ref-type="bibr" rid="B67">1997</xref>). As previously described (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>), the ablation of <italic>Tis21</italic> in our mouse model strikingly enhances, from 25 to 80%, the incidence of MB spontaneously occurring in <italic>Ptch1</italic> heterozygous mice. We observe that the whole balance between division, differentiation and death is disrupted in <italic>Ptch1</italic> heterozygous GCPs lacking <italic>Tis21</italic>, leading to an increase in tumor incidence (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). In particular, Tis21 seems to act on the timing of migration of GPCs from EGL to IGL, causing an extended period of localization in the proliferative region, decrease of differentiation and increase of apoptosis (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>,<xref ref-type="bibr" rid="B55">b</xref>). These cellular changes are mirrored in gene expression changes occurring in Set A, shown in Table <xref ref-type="table" rid="T1">1</xref>. We observe that the most significant enrichments of genes whose expression is altered in Set A, fall in the functional pathways of developmental signaling, retinal development, cell migration, epigenetic modulation, and primary cilium-related activities. We will summarize some consideration on these functions and also about the ubiquitin-dependent degradation (Table <xref ref-type="table" rid="T1">1</xref>), in relation to the possible drug targets available.</p>
<sec>
<title>Cell cycle regulation and cell proliferation of the GCPs (Set A)</title>
<p>We have shown that no change in the proliferation of GCPs occurs after ablation of <italic>Tis21</italic> (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). Moreover, in a recent study, we have demonstrated that the proliferation of the GCPs is not ruled by <italic>Tis21</italic> but by the family-related gene <italic>Btg1</italic> (Ceccarelli et al., <xref ref-type="bibr" rid="B27">2015</xref>). Indeed, if we analyze the type of expression changes occurring in the whole array of genes of Set A that either directly or indirectly regulate the proliferation and/or the cell cycle of the GCPs (Table <xref ref-type="table" rid="T7">7</xref>) we find that there is upregulation as well downregulation of genes that affect either positively or negatively this process, evidently resulting in no net change of proliferation of the GCPs. Nonetheless, the defect of migration of the <italic>Tis21</italic>-null GCPs forces them to stay a longer period in the EGL under the control of Shh influence, possibly leading to different types of alterations in cell division, including the control of centrosome assembly (see below).</p>
<table-wrap id="T7" position="float">
<label>Table 7</label>
<caption>
<p><bold>The table shows a sub-set of Set A deregulated genes which can influence proliferation in a direct or indirect manner</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Genes</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Functional classes</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Expression level</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Effect on proliferation</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Oncosuppressor gene</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gtpbp4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ipo7</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Eif3a</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Eif3c</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cdc27</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ckap5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ankrd11</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epigenetic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Mphosph10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rps12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rrp1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Srpk2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Taf7</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Taok2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Slc6a6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Agtr2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pa2g4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Eif2c1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle; Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Up</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td align="left" colspan="1" rowspan="1" valign="top">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pag1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td align="left" colspan="1" rowspan="1" valign="top">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rab11fip4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lats2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td align="left" colspan="1" rowspan="1" valign="top">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tigar (9630033F20Rik)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sema4b</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle; Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zc3h12d</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">−</td>
<td align="left" colspan="1" rowspan="1" valign="top">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gcnt3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sik2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Wtap</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cell Cycle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Down</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Cilium, GCPs migration, clathrin motility, and centrosome assembly (Set A)</title>
<p>We have shown a link between the Shh signaling, operating through the primary cilium, and the impairment of cell migration, i.e., the main phenotype observed in <italic>Ptch</italic><sup>+/−</sup><italic>/Tis21</italic><sup><italic>KO</italic></sup> mice [17]. In fact, the primary cilium, as mentioned above, is a sensory non-motile microtubule-based organelle which acts as a subcellular compartment for Shh signaling through a Smoothened-dependent recruitment of G<sub>i</sub> proteins (Belgacem and Borodinsky, <xref ref-type="bibr" rid="B14">2011</xref>). These include the Rab11 family, which impacts on cell motility, and whose components Fip4 and Fip2 are down-regulated in Set A. Remarkably, Rab11Fip2 interacts with the myosin Vb motor protein (Horgan and McCaffrey, <xref ref-type="bibr" rid="B83">2009</xref>) that regulates the recycling of C-X-C chemokine receptor type 2, the receptor of Cxcl3, and the receptor-mediated chemotaxis, as confirmed by Raman et al. (<xref ref-type="bibr" rid="B169">2014</xref>). As we have pointed out previously, Cxcl3 induces the migration of GCPs out of the EGL and its decrease in Set A is at the origin of the increase of tumorigenesis in Tis21 KO model (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B54">2012a</xref>). All this points to a link between the decrease of the Cxcl3-Cxcr2 function in Set A and the clathrin-mediated chemotaxis and microtubule-based migration. Such type of reasoning could be extended to the whole set of coiled coil molecules present in the cilium whose expression is altered in Set A, further suggesting that the ablation of <italic>Tis21</italic> in Set A could trigger an impairment of GCPs migration acting at more than one level.</p>
<p>Another interesting connection is with the cilium-based GTPase Rab11Fip4; in fact, since Rab11Fip4 induces Gli3 (Muto et al., <xref ref-type="bibr" rid="B147">2007</xref>) which is a negative regulator of Shh signaling, the ablation of <italic>Tis21</italic>, by down-regulating <italic>Rab11fip4</italic>, may enhance the Shh pathway activity, thus conferring more penetrance to the Shh stimulus. Moreover, the presence of cilia is in itself necessary for the development of Shh-type MB, and the formation of cilia might be enhanced by the upregulation in Set A of <italic>Syne2</italic> (Chizhikov et al., <xref ref-type="bibr" rid="B31">2007</xref>).</p>
<p>We also noticed several deregulated genes in Set A related to an evident deregulation of centrosome assembly (<italic>Akap2, Syne2, Ckap5, Sik2, Emd</italic>, and <italic>Lats2</italic>). Since the basal bodies, microtubule-based structures, are required for the formation of cilia (also non-motile ones) but also for the pericentriolar material at the core of the centrosome (Nigg and Raff, <xref ref-type="bibr" rid="B151">2009</xref>), our results could confirm the previously reported evidences of a deregulation of centrosome and cilia biogenesis that have been described in different types of cancer, where a derangement of cell cycle checkpoints is governed by cilia and centrosomes (Plotnikova et al., <xref ref-type="bibr" rid="B165">2008</xref>; Nigg and Raff, <xref ref-type="bibr" rid="B151">2009</xref>; Bettencourt-Dias et al., <xref ref-type="bibr" rid="B17">2011</xref>).</p>
</sec>
<sec>
<title>Primary cilium (Set B)</title>
<p>In reference to set B (comparison of <italic>Ptch1</italic> heterozygous mice vs. wild-type, thus without involvement of Tis21) our attention was captured by mechanisms that could regulate cell cycle machinery in a primary cilia-dependent fashion. These are suggestive of a possible involvement of Smo-dependent non-canonical Shh-pathways, namely concerning our data showing for the first time that Plc-gamma2, Ip3r3, Trpc1, Trpc2, and Trpc3 are up-regulated in <italic>Ptch1</italic> heterozygous mice. These genes belong to the described Smo-dependent non-canonical Shh pathways (Figure <xref ref-type="fig" rid="F3">3</xref>) that have been reported to modulate cytoskeleton-dependent processes (Jenkins, <xref ref-type="bibr" rid="B91">2009</xref>) and Ca<sup>2+</sup> spikes (Brennan et al., <xref ref-type="bibr" rid="B22">2012</xref>). In particular, a model in which the subcellular compartment (i.e., primary cilium) for Shh signaling allows the spatiotemporal integration of second messengers has been proposed (Belgacem and Borodinsky, <xref ref-type="bibr" rid="B14">2011</xref>), and the role of Ca<sup>2+</sup> signaling in granule cell turning and in modulation of their migration rate has been suggested as potential therapeutic target for some deficits in granule cell migration, since its downstream effectors control the assembly and disassembly of cytoskeletal elements (Komuro et al., <xref ref-type="bibr" rid="B103">2015</xref>).</p>
<p>The presence of the key components of the Shh pathway in cilia has been assessed, as well as the anterograde and retrograde traffic regulating its signaling (Goetz and Anderson, <xref ref-type="bibr" rid="B64">2010</xref>). We have taken in consideration the role of primary cilia in GCPs, where their presence has been assessed in the EGL at early post-natal stages (Del Cerro and Snider, <xref ref-type="bibr" rid="B42">1972</xref>), as well as their requirement for Shh-induced expansion and cerebellar development (Chizhikov et al., <xref ref-type="bibr" rid="B31">2007</xref>; Spassky et al., <xref ref-type="bibr" rid="B186">2008</xref>). Exploring this scenario, in our MB mouse model we have highlighted some other cilia-related protein targets modified in Set B—but not in Set A—such as Tctex-1, identified as a novel “checkpoint” for G1-S transition controlling ciliary resorption, cell cycle S-phase entry and fate of neural progenitors of developing neocortex (Li et al., <xref ref-type="bibr" rid="B115">2011</xref>; Sung and Li, <xref ref-type="bibr" rid="B188">2011</xref>).</p>
</sec>
<sec>
<title>Possible lineage switch of pGCPs in Set A and retinal development</title>
<p>An intriguing observation concerns the fact that three genes in Set A whose expression is significantly modified - namely, <italic>Nlk, Raf1</italic>, and <italic>Ppp2r2b</italic>—are markers for group 3 medulloblastoma (Kool et al., <xref ref-type="bibr" rid="B104">2008</xref>; Gibson et al., <xref ref-type="bibr" rid="B63">2010</xref>; Northcott et al., <xref ref-type="bibr" rid="B153">2011</xref>, <xref ref-type="bibr" rid="B154">2012c</xref>; Taylor et al., <xref ref-type="bibr" rid="B194">2012</xref>; Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>). Moreover, <italic>Nlk</italic> is among the genes of Set A modified in retinal development, and it has been suggested that cerebellar and retinal progenitor cells have common evolutionary origin [76]. It is also worth noting that, according to references (Kool et al., <xref ref-type="bibr" rid="B104">2008</xref>; Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>), among the markers for group 3 MB there are many genes involved in retinal development; in our Set A many genes as well are involved in this process, <italic>Nlk</italic> being common. Additionally, in Set A there are at least two genes whose expression is modified, <italic>Gli1</italic> and <italic>Pdgfd</italic>, which are markers of Shh-type medulloblastoma (Kool et al., <xref ref-type="bibr" rid="B104">2008</xref>; Gibson et al., <xref ref-type="bibr" rid="B63">2010</xref>; Northcott et al., <xref ref-type="bibr" rid="B153">2011</xref>, <xref ref-type="bibr" rid="B154">2012c</xref>; Taylor et al., <xref ref-type="bibr" rid="B194">2012</xref>; Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>). Hence, the ablation of Tis21 causes changes in the <italic>Ptch1</italic> heterozygous Shh-type model of two Shh-type MB marker genes (increased expression) and of three group 3 MB marker genes (Table <xref ref-type="table" rid="T1">1</xref>). As a whole, these data may suggest the possibility that the ablation of <italic>Tis21</italic>, by altering the expression of important Shh marker genes such <italic>Pdgfd</italic> and <italic>Gli1</italic>, may increase the penetrance of the Shh-type tumor phenotype, but also the possibility of a shift of the Shh phenotype toward the group 3 MB. A possible shift toward group 3, associated with retinal development control, may underlie the intriguing novel concept that the inactivation of a gene—in this case <italic>Tis21</italic>, which is known to be required for the terminal differentiation of neural stem cells (Micheli et al., <xref ref-type="bibr" rid="B138">2015</xref>)—may favor in Shh-activated GCPs a lineage shift toward other neural cell types involved in group 3 MB onset. Further analyses will be necessary to clarify this possibility.</p>
<p>A further correlation concerns the up-regulation of <italic>Deptor</italic> in Set A: this gene has been remarkably associated with reduced differentiation and increase of regenerative potential of pluripotent stem cells (Agrawal et al., <xref ref-type="bibr" rid="B2">2014</xref>). <italic>Deptor</italic> functional product also inhibits the TOR pathway, whose activation results in a more penetrant phenotype in Shh-type MB, with enhanced survival of cancer stem cells (Beauchamp and Platanias, <xref ref-type="bibr" rid="B12">2013</xref>). Thus, we can further suppose that the ablation of <italic>Tis21</italic> enhances the stem cell character of the Shh–activated GCPs as a preliminary step to possible lineage shifts.</p>
</sec>
<sec>
<title>Epigenetic changes in GCPs of Set A</title>
<p>The most significant enrichment in Set A is probably observed for genes that regulate transcription epigenetically. We have previously performed a functional genomic analysis where we identified more than 30 genes altered by the <italic>Tis21</italic> KO genotype relative to <italic>Tis21</italic> wild-type, (in background either <italic>Ptch1</italic> wild-type or heterozygous) and involved in epigenetic control, being regulated by DNA methylation or histone deacetylation, or being able to associate with HDAC1 or HDAC4 (Farioli-Vecchioli et al., <xref ref-type="bibr" rid="B55">2012b</xref>). We limited the present analysis within Set A to genes acting as histone modifier and their regulators or involved in chromatin remodeling, finding several of the first class and one of the second. Among them, is relevant <italic>PadI4</italic>, which by demethylating histones may act as a tumor suppressor (Tanikawa et al., <xref ref-type="bibr" rid="B193">2012</xref>); thus, its down-regulation in Set A could enhance tumorigenesis. Remarkable is also the series of histone modification editors ANKRDs, whose genes are down-regulated in SetA. Among the chromatin modifiers, we find <italic>Dek</italic>, up-regulated in Set A and also up-regulated in group 4 MB (Hooper et al., <xref ref-type="bibr" rid="B82">2014</xref>), which is a known oncogene that can confer stem cell-like qualities and is thus potentially enhancing the probability of cancer (Privette Vinnedge et al., <xref ref-type="bibr" rid="B167">2013</xref>). Altogether, the alteration in Set A of genes involved in histone modification and chromatin remodeling fits with the idea that the ablation of <italic>Tis21</italic> may reduce in the <italic>Tis21</italic>-null GCPs the restraint toward a lineage shift, as exposed in the previous section.</p>
</sec>
<sec>
<title>RNA processing in Set A</title>
<p>The role of <italic>Tis21</italic> in the cell proliferation control has been recently associated in human cells to RNA deadenylation, by which it influences mRNA poly(A) tail shortening (Stupfler et al., <xref ref-type="bibr" rid="B187">2016</xref>). Nevertheless, in Set A we detect the deregulation of genes related to AS or to NMD, but not to mRNA deadenylation.</p>
</sec>
<sec>
<title>Drug targets</title>
<p>This is a very interesting topic for therapy, that will need preclinical experimental studies for evaluation. Among the Set A genes that could be targeted by a drug, are worth mentioning: (i) the inhibitor of Pdgfd (ligand for Pdgfrb), since the activation of the PDGFR pathway has been shown to activate the Cxcl12 receptor; (ii) the possibility to enhance the activity of the tumor suppressor phosphatidylinositol 3-kinase-related kinase Smg1, whose ablation favors inflammation and cancer development. This could also be obtained by negatively targeting mTOR, which is antagonistic to Smg1 (possibly also by enhancing Deptor activity, which negatively regulates mTOR signaling). Moreover, as mentioned above, the intracerebellar administration of Cxcl3 functional product, by controlling the timing of migration of pre-neoplastic pGCPS, may have therapeutic effects that still need to be fully tested <italic>in vivo</italic>. Since these genes are deregulated in a Shh-type MB whose frequency is enhanced by <italic>Tis21</italic> ablation, and since Tis21 has been shown to be down-regulated in human MBs (mainly Shh-type), it is plausible a benefit using Cxcl3 in MB therapy of at least the Shh-type.</p>
</sec>
</sec>
<sec id="s5">
<title>Author contributions</title>
<p>GG analyzed the data; SC, FT designed the experiments; GG, FT wrote the paper; MC, LM carried out experimental work; GG, FT, and SC are responsible for accuracy and integrity of any part of the work.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This work was supported by grants from the Italian Ministry of Economy and Finance (Project FaReBio) to FT, the CNR Project DSB.AD004.094 to FT, and by the Italian Ministry of Education, Universities and Research grant CTN01_00177_817708 to SC. MC is recipient of fellowships from the Italian Foundation for Cancer Research (FIRC; year 2014) and from Fondazione Santa Lucia (year 2015), while GG is recipient of the fellowship from the Italian Ministry of Education, Universities and Research grant CTN01_00177_817708 (2014–2015).</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. However, a patent was filed by the National Research Council on the possible use of the chemokine Cxcl3 in medulloblastoma therapy. No financial exploitation of the patent has occurred.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>We acknowledge Cristina Calì, Alfia Corsino, Maria Patrizia D'Angelo, and Francesco Marino for their administrative and technical support. We also appreciate the contribution of Maria Guarnaccia to the first release of the manuscript and figures.</p>
</ack>
<sec id="s7" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fphar.2016.00449/full#supplementary-material">http://journal.frontiersin.org/article/10.3389/fphar.2016.00449/full#supplementary-material</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<media xlink:href="DataSheet1.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addison</surname><given-names>C. L.</given-names></name><name><surname>Daniel</surname><given-names>T. O.</given-names></name><name><surname>Burdick</surname><given-names>M. D.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Ehlert</surname><given-names>J. E.</given-names></name><name><surname>Xue</surname><given-names>Y. Y.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity</article-title>. <source/>J. Immunol.
<volume>165</volume>, <fpage>5269</fpage>–<lpage>5277</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.165.9.5269</pub-id><pub-id pub-id-type="pmid">11046061</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>P.</given-names></name><name><surname>Reynolds</surname><given-names>J.</given-names></name><name><surname>Chew</surname><given-names>S.</given-names></name><name><surname>Lamba</surname><given-names>D. A.</given-names></name><name><surname>Hughes</surname><given-names>R. E.</given-names></name></person-group> (<year>2014</year>). <article-title>DEPTOR is a stemness factor that regulates pluripotency of embryonic stem cells</article-title>. <source/>J. Biol. Chem.
<volume>289</volume>, <fpage>31818</fpage>–<lpage>31826</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.565838</pub-id><pub-id pub-id-type="pmid">25258312</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>A. A.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Jennings</surname><given-names>N. B.</given-names></name><name><surname>Etemadmoghadam</surname><given-names>D.</given-names></name><name><surname>Capalbo</surname><given-names>L.</given-names></name><name><surname>Jacamo</surname><given-names>R. O.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer</article-title>. <source/>Cancer Cell
<volume>18</volume>, <fpage>109</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2010.06.018</pub-id><pub-id pub-id-type="pmid">20708153</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Airoldi</surname><given-names>I.</given-names></name><name><surname>Tupone</surname><given-names>M. G.</given-names></name><name><surname>Esposito</surname><given-names>S.</given-names></name><name><surname>Russo</surname><given-names>M. V.</given-names></name><name><surname>Barbarito</surname><given-names>G.</given-names></name><name><surname>Cipollone</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer</article-title>. <source/>Oncotarget
<volume>6</volume>, <fpage>3694</fpage>–<lpage>3708</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2797</pub-id><pub-id pub-id-type="pmid">25638163</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhurst</surname><given-names>R. J.</given-names></name><name><surname>Hata</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting the TGFβ signalling pathway in disease</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>11</volume>, <fpage>790</fpage>–<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3810</pub-id><pub-id pub-id-type="pmid">23000686</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amakye</surname><given-names>D.</given-names></name><name><surname>Jagani</surname><given-names>Z.</given-names></name><name><surname>Dorsch</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Unraveling the therapeutic potential of the Hedgehog pathway in cancer</article-title>. <source/>Nat. Med.
<volume>19</volume>, <fpage>1410</fpage>–<lpage>1422</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3389</pub-id><pub-id pub-id-type="pmid">24202394</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arney</surname><given-names>K. L.</given-names></name><name><surname>Fisher</surname><given-names>A. G.</given-names></name></person-group> (<year>2004</year>). <article-title>Epigenetic aspects of differentiation</article-title>. <source/>J. Cell Sci.
<volume>117</volume>(<issue>Pt 19</issue>), <fpage>4355</fpage>–<lpage>4363</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.01390</pub-id><pub-id pub-id-type="pmid">15331660</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrowsmith</surname><given-names>C. H.</given-names></name><name><surname>Bountra</surname><given-names>C.</given-names></name><name><surname>Fish</surname><given-names>P. V.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><name><surname>Schapira</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Epigenetic protein families: a new frontier for drug discovery</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>11</volume>, <fpage>384</fpage>–<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3674</pub-id><pub-id pub-id-type="pmid">22498752</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>S. W.</given-names></name><name><surname>Herrera-Abreu</surname><given-names>M. T.</given-names></name><name><surname>Rohn</surname><given-names>J. L.</given-names></name><name><surname>Racine</surname><given-names>V.</given-names></name><name><surname>Tajadura</surname><given-names>V.</given-names></name><name><surname>Suryavanshi</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration</article-title>. <source/>BMC Biol.
<volume>9</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/1741-7007-9-54</pub-id><pub-id pub-id-type="pmid">21834987</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Dilworth</surname><given-names>D. J.</given-names></name><name><surname>Weng</surname><given-names>Y. C.</given-names></name><name><surname>Gould</surname><given-names>D. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Developmental distribution of collagen IV isoforms and relevance to ocular diseases</article-title>. <source/>Matrix Biol.
<volume>28</volume>, <fpage>194</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.matbio.2009.02.004</pub-id><pub-id pub-id-type="pmid">19275937</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batora</surname><given-names>N. V.</given-names></name><name><surname>Sturm</surname><given-names>D.</given-names></name><name><surname>Jones</surname><given-names>D. T.</given-names></name><name><surname>Kool</surname><given-names>M.</given-names></name><name><surname>Pfister</surname><given-names>S. M.</given-names></name><name><surname>Northcott</surname><given-names>P. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics</article-title>. <source/>Neuroscience
<volume>264</volume>, <fpage>171</fpage>–<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.07.030</pub-id><pub-id pub-id-type="pmid">23876321</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beauchamp</surname><given-names>E. M.</given-names></name><name><surname>Platanias</surname><given-names>L. C.</given-names></name></person-group> (<year>2013</year>). <article-title>The evolution of the TOR pathway and its role in cancer</article-title>. <source/>Oncogene
<volume>32</volume>, <fpage>3923</fpage>–<lpage>3932</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.567</pub-id><pub-id pub-id-type="pmid">23246968</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrends</surname><given-names>U.</given-names></name><name><surname>Schneider</surname><given-names>I.</given-names></name><name><surname>Rössler</surname><given-names>S.</given-names></name><name><surname>Frauenknecht</surname><given-names>H.</given-names></name><name><surname>Golbeck</surname><given-names>A.</given-names></name><name><surname>Lechner</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries</article-title>. <source/>Int. J. Cancer
<volume>106</volume>, <fpage>244</fpage>–<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.11208</pub-id><pub-id pub-id-type="pmid">12800201</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belgacem</surname><given-names>Y. H.</given-names></name><name><surname>Borodinsky</surname><given-names>L. N.</given-names></name></person-group> (<year>2011</year>). <article-title>Sonic hedgehog signaling is decoded by calcium spike activity in the developing spinal cord</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>108</volume>, <fpage>4482</fpage>–<lpage>4487</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1018217108</pub-id><pub-id pub-id-type="pmid">21368195</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>J. M.</given-names></name><name><surname>Tifft</surname><given-names>K. E.</given-names></name><name><surname>Wilson</surname><given-names>K. L.</given-names></name></person-group> (<year>2013</year>). <article-title>The nuclear envelope LEM-domain protein emerin</article-title>. <source/>Nucleus
<volume>4</volume>, <fpage>298</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.4161/nucl.25751</pub-id><pub-id pub-id-type="pmid">23873439</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berwick</surname><given-names>D. C.</given-names></name><name><surname>Harvey</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>The regulation and deregulation of Wnt signaling by PARK genes in health and disease</article-title>. <source/>J. Mol. Cell Biol.
<volume>6</volume>, <fpage>3</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1093/jmcb/mjt037</pub-id><pub-id pub-id-type="pmid">24115276</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettencourt-Dias</surname><given-names>M.</given-names></name><name><surname>Hildebrandt</surname><given-names>F.</given-names></name><name><surname>Pellman</surname><given-names>D.</given-names></name><name><surname>Woods</surname><given-names>G.</given-names></name><name><surname>Godinho</surname><given-names>S. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Centrosomes and cilia in human disease</article-title>. <source/>Trends Genet.
<volume>27</volume>, <fpage>307</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2011.05.004</pub-id><pub-id pub-id-type="pmid">21680046</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>B.</given-names></name><name><surname>Hsieh</surname><given-names>M.</given-names></name><name><surname>Kenney</surname><given-names>A. M.</given-names></name><name><surname>Nahlé</surname><given-names>Z.</given-names></name></person-group> (<year>2011</year>). <article-title>Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma</article-title>. <source/>Oncogene
<volume>30</volume>, <fpage>410</fpage>–<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.454</pub-id><pub-id pub-id-type="pmid">20890301</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackshaw</surname><given-names>S.</given-names></name><name><surname>Harpavat</surname><given-names>S.</given-names></name><name><surname>Trimarchi</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Kuo</surname><given-names>W. P.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Genomic analysis of mouse retinal development</article-title>. <source/>PLoS Biol.
<volume>2</volume>:<fpage>E247</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0020247</pub-id><pub-id pub-id-type="pmid">15226823</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>J. A.</given-names></name><name><surname>Bult</surname><given-names>C. J.</given-names></name><name><surname>Eppig</surname><given-names>J. T.</given-names></name><name><surname>Kadin</surname><given-names>J. A.</given-names></name><name><surname>Richardson</surname><given-names>J. E.</given-names></name></person-group> (<year>2014</year>). <article-title>The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse</article-title>. <source/>Nucleic Acids Res
<volume>42</volume>, <fpage>D810</fpage>–<lpage>D817</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1225</pub-id><pub-id pub-id-type="pmid">24285300</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>E. E.</given-names></name><name><surname>Wang</surname><given-names>Y. L.</given-names></name><name><surname>Thiessen</surname><given-names>P. A.</given-names></name><name><surname>Bryant</surname><given-names>S. H.</given-names></name></person-group> (<year>2010</year>). <article-title>PubChem: integrated platform of small molecules and biological activities</article-title>. <source/>Annu. Rep. Comput. Chem.
<volume>4</volume>, <fpage>217</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1016/S1574-1400(08)00012-1</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Mahoney</surname><given-names>M.</given-names></name><name><surname>Riobo</surname><given-names>N. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Noncanonical Hedgehog signaling</article-title>. <source/>Vitam. Horm.
<volume>88</volume>, <fpage>55</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-394622-5.00003-1</pub-id><pub-id pub-id-type="pmid">22391299</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briscoe</surname><given-names>J.</given-names></name><name><surname>Thérond</surname><given-names>P. P.</given-names></name></person-group> (<year>2013</year>). <article-title>The mechanisms of Hedgehog signalling and its roles in development and disease</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>14</volume>, <fpage>416</fpage>–<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3598</pub-id><pub-id pub-id-type="pmid">23719536</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhard</surname><given-names>P.</given-names></name><name><surname>Stetefeld</surname><given-names>J.</given-names></name><name><surname>Strelkov</surname><given-names>S. V.</given-names></name></person-group> (<year>2001</year>). <article-title>Coiled coils: a highly versatile protein folding motif</article-title>. <source/>Trends Cell Biol.
<volume>11</volume>, <fpage>82</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/S0962-8924(00)01898-5</pub-id><pub-id pub-id-type="pmid">11166216</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buszczak</surname><given-names>M.</given-names></name><name><surname>Paterno</surname><given-names>S.</given-names></name><name><surname>Spradling</surname><given-names>A. C.</given-names></name></person-group> (<year>2009</year>). <article-title>Drosophila stem cells share a common requirement for the histone H2B ubiquitin protease scrawny</article-title>. <source/>Science
<volume>323</volume>, <fpage>248</fpage>–<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1126/science.1165678</pub-id><pub-id pub-id-type="pmid">19039105</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavellán</surname><given-names>E.</given-names></name><name><surname>Asp</surname><given-names>P.</given-names></name><name><surname>Percipalle</surname><given-names>P.</given-names></name><name><surname>Farrants</surname><given-names>A. K.</given-names></name></person-group> (<year>2006</year>). <article-title>The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription</article-title>. <source/>J. Biol. Chem.
<volume>281</volume>, <fpage>16264</fpage>–<lpage>16271</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M600233200</pub-id><pub-id pub-id-type="pmid">16603771</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Micheli</surname><given-names>L.</given-names></name><name><surname>D'Andrea</surname><given-names>G.</given-names></name><name><surname>De Bardi</surname><given-names>M.</given-names></name><name><surname>Scheijen</surname><given-names>B.</given-names></name><name><surname>Ciotti</surname><given-names>M. T.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Altered cerebellum development and impaired motor coordination in mice lacking the Btg1 gene: involvement of cyclin D1</article-title>. <source/>Dev. Biol.
<volume>408</volume>, <fpage>109</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2015.10.007</pub-id><pub-id pub-id-type="pmid">26524254</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamieh</surname><given-names>H.</given-names></name><name><surname>Ballut</surname><given-names>L.</given-names></name><name><surname>Bonneau</surname><given-names>F.</given-names></name><name><surname>Le Hir</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>NMD factors UPF2 and UPF3 bridge UPF1 to the exon junction complex and stimulate its RNA helicase activity</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>15</volume>, <fpage>85</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb1330</pub-id><pub-id pub-id-type="pmid">18066079</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Pang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>Z.</given-names></name></person-group> (<year>2009</year>). <article-title>Increased PADI4 expression in blood and tissues of patients with malignant tumors</article-title>. <source/>BMC Cancer
<volume>9</volume>:<fpage>40</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-9-40</pub-id><pub-id pub-id-type="pmid">19183436</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P. K.</given-names></name><name><surname>Fan</surname><given-names>Y. B.</given-names></name><name><surname>Man</surname><given-names>T. K.</given-names></name><name><surname>Hung</surname><given-names>Y.</given-names></name><name><surname>Lau</surname><given-names>C. C.</given-names></name><name><surname>Wong</surname><given-names>S. T. C.</given-names></name></person-group> (<year>2013</year>). <article-title>A gene signature based method for identifying subtypes and subtype-specific drivers in cancer with an application to medulloblastoma</article-title>. <source/>BMC Bioinformatics
<volume>14</volume>:<fpage>S1</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-14-S18-S1</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chizhikov</surname><given-names>V. V.</given-names></name><name><surname>Davenport</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Shih</surname><given-names>E. K.</given-names></name><name><surname>Cabello</surname><given-names>O. A.</given-names></name><name><surname>Fuchs</surname><given-names>J. L.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Cilia proteins control cerebellar morphogenesis by promoting expansion of the granule progenitor pool</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>9780</fpage>–<lpage>9789</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5586-06.2007</pub-id><pub-id pub-id-type="pmid">17804638</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christophorou</surname><given-names>M. A.</given-names></name><name><surname>Castelo-Branco</surname><given-names>G.</given-names></name><name><surname>Halley-Stott</surname><given-names>R. P.</given-names></name><name><surname>Oliveira</surname><given-names>C. S.</given-names></name><name><surname>Loos</surname><given-names>R.</given-names></name><name><surname>Radzisheuskaya</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Citrullination regulates pluripotency and histone H1 binding to chromatin</article-title>. <source/>Nature
<volume>507</volume>, <fpage>104</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1038/nature12942</pub-id><pub-id pub-id-type="pmid">24463520</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>P. A.</given-names></name><name><surname>Treisman</surname><given-names>D. M.</given-names></name><name><surname>Ebben</surname><given-names>J.</given-names></name><name><surname>Kuo</surname><given-names>J. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Developmental signaling pathways in brain tumor-derived stem-like cells</article-title>. <source/>Dev. Dyn.
<volume>236</volume>, <fpage>3297</fpage>–<lpage>3308</lpage>. <pub-id pub-id-type="doi">10.1002/dvdy.21381</pub-id><pub-id pub-id-type="pmid">18000980</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>I.</given-names></name><name><surname>Poreba</surname><given-names>E.</given-names></name><name><surname>Kamieniarz</surname><given-names>K.</given-names></name><name><surname>Schneider</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Histone modifiers in cancer: friends or foes?</article-title>
<source/>Genes Cancer
<volume>2</volume>, <fpage>631</fpage>–<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1177/1947601911417176</pub-id><pub-id pub-id-type="pmid">21941619</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consortium</surname><given-names>T. U.</given-names></name></person-group> (<year>2014</year>). <article-title>Activities at the Universal Protein Resource (UniProt)</article-title>. <source/>Nucleic Acids Res.
<volume>42</volume>, <fpage>D191</fpage>–<lpage>D198</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1140</pub-id><pub-id pub-id-type="pmid">24253303</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>W. D.</given-names></name><name><surname>Moujalled</surname><given-names>D. M.</given-names></name><name><surname>Ralph</surname><given-names>T. J.</given-names></name><name><surname>Lock</surname><given-names>P.</given-names></name><name><surname>Young</surname><given-names>S. N.</given-names></name><name><surname>Murphy</surname><given-names>J. M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>RIPK1- and RIPK3-induced cell death mode is determined by target availability</article-title>. <source/>Cell Death Differ.
<volume>21</volume>, <fpage>1600</fpage>–<lpage>1612</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2014.70</pub-id><pub-id pub-id-type="pmid">24902899</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutts</surname><given-names>A. S.</given-names></name><name><surname>Boulahbel</surname><given-names>H.</given-names></name><name><surname>Graham</surname><given-names>A.</given-names></name><name><surname>La Thangue</surname><given-names>N. B.</given-names></name></person-group> (<year>2007</year>). <article-title>Mdm2 targets the p53 transcription cofactor JMY for degradation</article-title>. <source/>EMBO Rep.
<volume>8</volume>, <fpage>84</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/sj.embor.7400855</pub-id><pub-id pub-id-type="pmid">17170761</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutts</surname><given-names>A. S.</given-names></name><name><surname>Weston</surname><given-names>L.</given-names></name><name><surname>La Thangue</surname><given-names>N. B.</given-names></name></person-group> (<year>2009</year>). <article-title>A transcription co-factor integrates cell adhesion and motility with the p53 response</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>106</volume>, <fpage>19872</fpage>–<lpage>19877</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0906785106</pub-id><pub-id pub-id-type="pmid">19897726</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullis</surname><given-names>D. N.</given-names></name><name><surname>Philip</surname><given-names>B.</given-names></name><name><surname>Baleja</surname><given-names>J. D.</given-names></name><name><surname>Feig</surname><given-names>L. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Rab11-FIP2, an adaptor protein connecting cellular components involved in internalization and recycling of epidermal growth factor receptors</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>49158</fpage>–<lpage>49166</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M206316200</pub-id><pub-id pub-id-type="pmid">12364336</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahmane</surname><given-names>N.</given-names></name><name><surname>Ruiz i Altaba</surname><given-names>A.</given-names></name></person-group> (<year>1999</year>). <article-title>Sonic hedgehog regulates the growth and patterning of the cerebellum</article-title>. <source/>Development
<volume>126</volume>, <fpage>3089</fpage>–<lpage>3100</lpage>. <pub-id pub-id-type="pmid">10375501</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawe</surname><given-names>H. R.</given-names></name><name><surname>Adams</surname><given-names>M.</given-names></name><name><surname>Wheway</surname><given-names>G.</given-names></name><name><surname>Szymanska</surname><given-names>K.</given-names></name><name><surname>Logan</surname><given-names>C. V.</given-names></name><name><surname>Noegel</surname><given-names>A. A.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Nesprin-2 interacts with meckelin and mediates ciliogenesis via remodelling of the actin cytoskeleton</article-title>. <source/>J. Cell Sci.
<volume>122</volume>(<issue>Pt 15</issue>), <fpage>2716</fpage>–<lpage>2726</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.043794</pub-id><pub-id pub-id-type="pmid">19596800</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Cerro</surname><given-names>M. P.</given-names></name><name><surname>Snider</surname><given-names>R. S.</given-names></name></person-group> (<year>1972</year>). <article-title>Studies on the developing cerebellum. II. The ultrastructure of the external granular layer</article-title>. <source/>J. Comp. Neurol.
<volume>144</volume>, <fpage>131</fpage>–<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1002/cne.901440202</pub-id><pub-id pub-id-type="pmid">5029131</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deplus</surname><given-names>R.</given-names></name><name><surname>Denis</surname><given-names>H.</given-names></name><name><surname>Putmans</surname><given-names>P.</given-names></name><name><surname>Calonne</surname><given-names>E.</given-names></name><name><surname>Fourrez</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Citrullination of DNMT3A by PADI4 regulates its stability and controls DNA methylation</article-title>. <source/>Nucleic Acids Res.
<volume>42</volume>, <fpage>8285</fpage>–<lpage>8296</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku522</pub-id><pub-id pub-id-type="pmid">24957603</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Renzis</surname><given-names>S.</given-names></name><name><surname>Sonnichsen</surname><given-names>B.</given-names></name><name><surname>Zerial</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>). <article-title>Divalent Rab effectors regulate the sub-compartmental organization and sorting of early endosomes</article-title>. <source/>Nat. Cell Biol.
<volume>4</volume>, <fpage>124</fpage>–<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1038/ncb744</pub-id><pub-id pub-id-type="pmid">11788822</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>O.</given-names></name><name><surname>tom Dieck</surname><given-names>S.</given-names></name><name><surname>Altrock</surname><given-names>W. D.</given-names></name><name><surname>Ammermuller</surname><given-names>J.</given-names></name><name><surname>Weiler</surname><given-names>R.</given-names></name><name><surname>Garner</surname><given-names>C. C.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>The presynaptic active zone protein bassoon is essential for photoreceptor ribbon synapse formation in the retina</article-title>. <source/>Neuron
<volume>37</volume>, <fpage>775</fpage>–<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(03)00086-2</pub-id><pub-id pub-id-type="pmid">12628168</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Ji</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia</article-title>. <source/>Int. J. Mol. Sci.
<volume>15</volume>, <fpage>17065</fpage>–<lpage>17076</lpage>. <pub-id pub-id-type="doi">10.3390/ijms150917065</pub-id><pub-id pub-id-type="pmid">25257528</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duda</surname><given-names>D. G.</given-names></name><name><surname>Kozin</surname><given-names>S. V.</given-names></name><name><surname>Kirkpatrick</surname><given-names>N. D.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Fukumura</surname><given-names>D.</given-names></name><name><surname>Jain</surname><given-names>R. K.</given-names></name></person-group> (<year>2011</year>). <article-title>CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway inhibition: an emerging sensitizer for anticancer therapies?</article-title>
<source/>Clin. Cancer Res.
<volume>17</volume>, <fpage>2074</fpage>–<lpage>2080</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-10-2636</pub-id><pub-id pub-id-type="pmid">21349998</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Mouse models of childhood cancer of the nervous system</article-title>. <source/>J. Clin. Pathol.
<volume>57</volume>, <fpage>561</fpage>–<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.2003.009910</pub-id><pub-id pub-id-type="pmid">15166259</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekins</surname><given-names>S.</given-names></name><name><surname>Nikolsky</surname><given-names>Y.</given-names></name><name><surname>Bugrim</surname><given-names>A.</given-names></name><name><surname>Kirillov</surname><given-names>E.</given-names></name><name><surname>Nikolskaya</surname><given-names>T.</given-names></name></person-group> (<year>2007</year>). <article-title>Pathway mapping tools for analysis of high content data</article-title>. <source/>Methods Mol. Biol.
<volume>356</volume>, <fpage>319</fpage>–<lpage>350</lpage>. <pub-id pub-id-type="pmid">16988414</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elamin</surname><given-names>M. H.</given-names></name><name><surname>Shinwari</surname><given-names>Z.</given-names></name><name><surname>Hendrayani</surname><given-names>S.-F.</given-names></name><name><surname>Al-Hindi</surname><given-names>H.</given-names></name><name><surname>Al-Shail</surname><given-names>E.</given-names></name><name><surname>Khafaga</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells</article-title>. <source/>Mol. Carcinog.
<volume>49</volume>, <fpage>302</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1002/mc.20604</pub-id><pub-id pub-id-type="pmid">20025076</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escamez</surname><given-names>T.</given-names></name><name><surname>Bahamonde</surname><given-names>O.</given-names></name><name><surname>Tabares-Seisdedos</surname><given-names>R.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Martinez</surname><given-names>S.</given-names></name><name><surname>Echevarria</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Developmental dynamics of PAFAH1B subunits during mouse brain development</article-title>. <source/>J. Comp. Neurol.
<volume>520</volume>, <fpage>3877</fpage>–<lpage>3894</lpage>. <pub-id pub-id-type="doi">10.1002/cne.23128</pub-id><pub-id pub-id-type="pmid">22522921</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>G. H.</given-names></name><name><surname>Lapierre</surname><given-names>L. A.</given-names></name><name><surname>Goldenring</surname><given-names>J. R.</given-names></name><name><surname>Sai</surname><given-names>J.</given-names></name><name><surname>Richmond</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis</article-title>. <source/>Mol. Biol. Cell
<volume>15</volume>, <fpage>2456</fpage>–<lpage>2469</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E03-09-0706</pub-id><pub-id pub-id-type="pmid">15004234</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name></person-group> (<year>2006</year>). <article-title>Tumor suppressor pp32 represses cell growth through inhibition of transcription by blocking acetylation and phosphorylation of histone H3 and initiating its proapoptotic activity</article-title>. <source/>Cell Death Differ.
<volume>13</volume>, <fpage>1485</fpage>–<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4401825</pub-id><pub-id pub-id-type="pmid">16341127</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farioli-Vecchioli</surname><given-names>S.</given-names></name><name><surname>Cina</surname><given-names>I.</given-names></name><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Micheli</surname><given-names>L.</given-names></name><name><surname>Leonardi</surname><given-names>L.</given-names></name><name><surname>Ciotti</surname><given-names>M. T.</given-names></name><etal></etal></person-group>. (<year>2012a</year>). <article-title>Tis21 knock-out enhances the frequency of medulloblastoma in Patched1 heterozygous mice by inhibiting the Cxcl3-dependent migration of cerebellar neurons</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>15547</fpage>–<lpage>15564</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0412-12.2012</pub-id><pub-id pub-id-type="pmid">23115191</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farioli-Vecchioli</surname><given-names>S.</given-names></name><name><surname>Micheli</surname><given-names>L.</given-names></name><name><surname>Leonardi</surname><given-names>L.</given-names></name><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Cavallaro</surname><given-names>S.</given-names></name><name><surname>Tirone</surname><given-names>F.</given-names></name></person-group> (<year>2012b</year>). <article-title>Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration of cerebellar granule precursor cells, regulated by Nos2 and Tis21</article-title>. <source/>Front Neurosci.
<volume>6</volume>:<fpage>198</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2012.00198</pub-id><pub-id pub-id-type="pmid">23355800</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippakopoulos</surname><given-names>P.</given-names></name><name><surname>Knapp</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>The bromodomain interaction module</article-title>. <source/>FEBS Lett.
<volume>586</volume>, <fpage>2692</fpage>–<lpage>2704</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2012.04.045</pub-id><pub-id pub-id-type="pmid">22710155</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foraker</surname><given-names>A. B.</given-names></name><name><surname>Camus</surname><given-names>S. M.</given-names></name><name><surname>Evans</surname><given-names>T. M.</given-names></name><name><surname>Majeed</surname><given-names>S. R.</given-names></name><name><surname>Chen</surname><given-names>C. Y.</given-names></name><name><surname>Taner</surname><given-names>S. B.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Clathrin promotes centrosome integrity in early mitosis through stabilization of centrosomal ch-TOG</article-title>. <source/>J. Cell Biol.
<volume>198</volume>, <fpage>591</fpage>–<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201205116</pub-id><pub-id pub-id-type="pmid">22891263</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukai</surname><given-names>J.</given-names></name><name><surname>Yokote</surname><given-names>H.</given-names></name><name><surname>Yamanaka</surname><given-names>R.</given-names></name><name><surname>Arao</surname><given-names>T.</given-names></name><name><surname>Nishio</surname><given-names>K.</given-names></name><name><surname>Itakura</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line</article-title>. <source/>Mol. Cancer Ther.
<volume>7</volume>, <fpage>2768</fpage>–<lpage>2778</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-2263</pub-id><pub-id pub-id-type="pmid">18790757</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>D.</given-names></name><name><surname>Voronova</surname><given-names>A.</given-names></name><name><surname>Zander</surname><given-names>M. A.</given-names></name><name><surname>Cancino</surname><given-names>G. I.</given-names></name><name><surname>Bramall</surname><given-names>A.</given-names></name><name><surname>Krause</surname><given-names>M. P.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Ankrd11 is a chromatin regulator involved in autism that is essential for neural development</article-title>. <source/>Dev. Cell
<volume>32</volume>, <fpage>31</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2014.11.031</pub-id><pub-id pub-id-type="pmid">25556659</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gegonne</surname><given-names>A.</given-names></name><name><surname>Devaiah</surname><given-names>B. N.</given-names></name><name><surname>Singer</surname><given-names>D. S.</given-names></name></person-group> (<year>2013</year>). <article-title>TAF7: traffic controller in transcription initiation</article-title>. <source/>Transcription
<volume>4</volume>, <fpage>29</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.4161/trns.22842</pub-id><pub-id pub-id-type="pmid">23340207</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gegonne</surname><given-names>A.</given-names></name><name><surname>Weissman</surname><given-names>J. D.</given-names></name><name><surname>Singer</surname><given-names>D. S.</given-names></name></person-group> (<year>2001</year>). <article-title>TAFII55 binding to TAFII250 inhibits its acetyltransferase activity</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>98</volume>, <fpage>12432</fpage>–<lpage>12437</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.211444798</pub-id><pub-id pub-id-type="pmid">11592977</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerondopoulos</surname><given-names>A.</given-names></name><name><surname>Bastos</surname><given-names>R. N.</given-names></name><name><surname>Yoshimura</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>R.</given-names></name><name><surname>Carpanini</surname><given-names>S.</given-names></name><name><surname>Aligianis</surname><given-names>I.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Rab18 and a Rab18 GEF complex are required for normal ER structure</article-title>. <source/>J. Cell Biol.
<volume>205</volume>, <fpage>707</fpage>–<lpage>720</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201403026</pub-id><pub-id pub-id-type="pmid">24891604</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>P.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Robinson</surname><given-names>G.</given-names></name><name><surname>Thompson</surname><given-names>M. C.</given-names></name><name><surname>Currle</surname><given-names>D. S.</given-names></name><name><surname>Eden</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Subtypes of medulloblastoma have distinct developmental origins</article-title>. <source/>Nature
<volume>468</volume>, <fpage>1095</fpage>–<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1038/nature09587</pub-id><pub-id pub-id-type="pmid">21150899</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>S. C.</given-names></name><name><surname>Anderson</surname><given-names>K. V.</given-names></name></person-group> (<year>2010</year>). <article-title>The primary cilium: a signalling centre during vertebrate development</article-title>. <source/>Nat. Rev. Genet.
<volume>11</volume>, <fpage>331</fpage>–<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1038/nrg2774</pub-id><pub-id pub-id-type="pmid">20395968</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Estévez</surname><given-names>C.</given-names></name><name><surname>Felix</surname><given-names>D. A.</given-names></name><name><surname>Smith</surname><given-names>M. D.</given-names></name><name><surname>Paps</surname><given-names>J.</given-names></name><name><surname>Morley</surname><given-names>S. J.</given-names></name><name><surname>James</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>SMG-1 and mTORC1 act antagonistically to regulate response to injury and growth in planarians</article-title>. <source/>PLoS Genet.
<volume>8</volume>:<fpage>e1002619</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1002619</pub-id><pub-id pub-id-type="pmid">22479207</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Romero</surname><given-names>R.</given-names></name><name><surname>Rivera-Casas</surname><given-names>C.</given-names></name><name><surname>Ausio</surname><given-names>J.</given-names></name><name><surname>Mendez</surname><given-names>J.</given-names></name><name><surname>Eirin-Lopez</surname><given-names>J. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Birth-and-death long-term evolution promotes histone H2B variant diversification in the male germinal cell line</article-title>. <source/>Mol. Biol. Evol.
<volume>27</volume>, <fpage>1802</fpage>–<lpage>1812</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/msq058</pub-id><pub-id pub-id-type="pmid">20194426</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodrich</surname><given-names>L. V.</given-names></name><name><surname>Milenkovic</surname><given-names>L.</given-names></name><name><surname>Higgins</surname><given-names>K.</given-names></name><name><surname>Scott</surname><given-names>M.</given-names></name></person-group> (<year>1997</year>). <article-title>Altered neural cell fates and medulloblastoma in mouse patched mutants</article-title>. <source/>Science
<volume>277</volume>, <fpage>1109</fpage>–<lpage>1113</lpage>. <pub-id pub-id-type="pmid">9262482</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>M.</given-names></name><name><surname>Griffith</surname><given-names>O. L.</given-names></name><name><surname>Coffman</surname><given-names>A. C.</given-names></name><name><surname>Weible</surname><given-names>J. V.</given-names></name><name><surname>McMichael</surname><given-names>J. F.</given-names></name><name><surname>Spies</surname><given-names>N. C.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>DGIdb: mining the druggable genome</article-title>. <source/>Nat. Methods
<volume>10</volume>, <fpage>1209</fpage>–<lpage>1210</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2689</pub-id><pub-id pub-id-type="pmid">24122041</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilherme</surname><given-names>A.</given-names></name><name><surname>Soriano</surname><given-names>N. A.</given-names></name><name><surname>Bose</surname><given-names>S.</given-names></name><name><surname>Holik</surname><given-names>J.</given-names></name><name><surname>Bose</surname><given-names>A.</given-names></name><name><surname>Pomerleau</surname><given-names>D. P.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>EHD2 and the novel EH domain binding protein EHBP1 couple endocytosis to the actin cytoskeleton</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>10593</fpage>–<lpage>10605</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M307702200</pub-id><pub-id pub-id-type="pmid">14676205</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Signaling cross-talk between TGF-β/BMP and other pathways</article-title>. <source/>Cell Res.
<volume>19</volume>, <fpage>71</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2008.302</pub-id><pub-id pub-id-type="pmid">19002158</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>H.</given-names></name><name><surname>Wojnowski</surname><given-names>L.</given-names></name><name><surname>Zimmer</surname><given-names>A. M.</given-names></name><name><surname>Hall</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>G.</given-names></name><name><surname>Zimmer</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome</article-title>. <source/>Nat. Med.
<volume>4</volume>, <fpage>619</fpage>–<lpage>622</lpage>. <pub-id pub-id-type="pmid">9585239</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y. G.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Dlugosz</surname><given-names>A. A.</given-names></name><name><surname>Ellison</surname><given-names>D. W.</given-names></name><name><surname>Gilbertson</surname><given-names>R. J.</given-names></name><name><surname>Alvarez-Buylla</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Dual and opposing roles of primary cilia in medulloblastoma development</article-title>. <source/>Nat. Med.
<volume>15</volume>, <fpage>1062</fpage>–<lpage>1065</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2020</pub-id><pub-id pub-id-type="pmid">19701203</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbour</surname><given-names>M. E.</given-names></name><name><surname>Breusegem</surname><given-names>S. Y.</given-names></name><name><surname>Antrobus</surname><given-names>R.</given-names></name><name><surname>Freeman</surname><given-names>C.</given-names></name><name><surname>Reid</surname><given-names>E.</given-names></name><name><surname>Seaman</surname><given-names>M. N.</given-names></name></person-group> (<year>2010</year>). <article-title>The cargo-selective retromer complex is a recruiting hub for protein complexes that regulate endosomal tubule dynamics</article-title>. <source/>J. Cell Sci.
<volume>123</volume>(<issue>Pt 21</issue>), <fpage>3703</fpage>–<lpage>3717</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.071472</pub-id><pub-id pub-id-type="pmid">20923837</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>J. R.</given-names></name><name><surname>Mellor</surname><given-names>P.</given-names></name><name><surname>Eldaly</surname><given-names>H.</given-names></name><name><surname>Lennard</surname><given-names>T. W.</given-names></name><name><surname>Kirby</surname><given-names>J. A.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?</article-title>
<source/>Clin. Cancer Res.
<volume>13</volume>, <fpage>1562</fpage>–<lpage>1570</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-06-1987</pub-id><pub-id pub-id-type="pmid">17332302</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatten</surname><given-names>M. E.</given-names></name></person-group> (<year>1999</year>). <article-title>Expansion of CNS Precursor Pools</article-title>. <source/>Neuron
<volume>22</volume>, <fpage>2</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(00)80668-6</pub-id><pub-id pub-id-type="pmid">10027279</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattermann</surname><given-names>K.</given-names></name><name><surname>Mentlein</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology</article-title>. <source/>Ann. Anat.
<volume>195</volume>, <fpage>103</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.aanat.2012.10.013</pub-id><pub-id pub-id-type="pmid">23279723</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hede</surname><given-names>S. M.</given-names></name><name><surname>Savov</surname><given-names>V.</given-names></name><name><surname>Weishaupt</surname><given-names>H.</given-names></name><name><surname>Sangfelt</surname><given-names>O.</given-names></name><name><surname>Swartling</surname><given-names>F. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Oncoprotein stabilization in brain tumors</article-title>. <source/>Oncogene
<volume>33</volume>, <fpage>4709</fpage>–<lpage>4721</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.445</pub-id><pub-id pub-id-type="pmid">24166497</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hehnly</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>C.-T.</given-names></name><name><surname>Powers</surname><given-names>C. M.</given-names></name><name><surname>Liu</surname><given-names>H.-L.</given-names></name><name><surname>Doxsey</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>The Centrosome regulates the Rab11- dependent recycling endosome pathway at appendages of the mother centriole</article-title>. <source/>Curr. Biol.
<volume>22</volume>, <fpage>1944</fpage>–<lpage>1950</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2012.08.022</pub-id><pub-id pub-id-type="pmid">22981775</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heikkila</surname><given-names>T.</given-names></name><name><surname>Wheatley</surname><given-names>E.</given-names></name><name><surname>Crighton</surname><given-names>D.</given-names></name><name><surname>Schroder</surname><given-names>E.</given-names></name><name><surname>Boakes</surname><given-names>A.</given-names></name><name><surname>Kaye</surname><given-names>S. J.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Co-crystal structures of inhibitors with MRCKbeta, a key regulator of tumor cell invasion</article-title>. <source/>PLoS ONE 6:e24825. <pub-id pub-id-type="doi">10.1371/journal.pone.0024825</pub-id><pub-id pub-id-type="pmid">21949762</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldin</surname><given-names>C. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting the PDGF signaling pathway in tumor treatment</article-title>. <source/>Cell Commun. Signal.
<volume>11</volume>:<fpage>97</fpage>. <pub-id pub-id-type="doi">10.1186/1478-811X-11-97</pub-id><pub-id pub-id-type="pmid">24359404</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hippenmeyer</surname><given-names>S.</given-names></name><name><surname>Youn</surname><given-names>Y. H.</given-names></name><name><surname>Moon</surname><given-names>H. M.</given-names></name><name><surname>Miyamichi</surname><given-names>K.</given-names></name><name><surname>Zong</surname><given-names>H.</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Genetic mosaic dissection of Lis1 and Ndel1 in neuronal migration</article-title>. <source/>Neuron
<volume>68</volume>, <fpage>695</fpage>–<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.027</pub-id><pub-id pub-id-type="pmid">21092859</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>C. M.</given-names></name><name><surname>Hawes</surname><given-names>S. M.</given-names></name><name><surname>Kees</surname><given-names>U. R.</given-names></name><name><surname>Gottardo</surname><given-names>N. G.</given-names></name><name><surname>Dallas</surname><given-names>P. B.</given-names></name></person-group> (<year>2014</year>). <article-title>Gene expression analyses of the spatio-temporal relationships of human medulloblastoma subgroups during early human neurogenesis</article-title>. <source/>PLoS ONE 9:e112909. <pub-id pub-id-type="doi">10.1371/journal.pone.0112909</pub-id><pub-id pub-id-type="pmid">25412507</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horgan</surname><given-names>C. P.</given-names></name><name><surname>McCaffrey</surname><given-names>M. W.</given-names></name></person-group> (<year>2009</year>). <article-title>The dynamic Rab11-FIPs</article-title>. <source/>Biochem. Soc. Trans.
<volume>37</volume>(<issue>Pt 5</issue>), <fpage>1032</fpage>–<lpage>1036</lpage>. <pub-id pub-id-type="doi">10.1042/bst0371032</pub-id><pub-id pub-id-type="pmid">19754446</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovestadt</surname><given-names>V.</given-names></name><name><surname>Jones</surname><given-names>D. T.</given-names></name><name><surname>Picelli</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Kool</surname><given-names>M.</given-names></name><name><surname>Northcott</surname><given-names>P. A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing</article-title>. <source/>Nature
<volume>510</volume>, <fpage>537</fpage>–<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1038/nature13268</pub-id><pub-id pub-id-type="pmid">24847876</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>Y. C.</given-names></name><name><surname>Tuz</surname><given-names>K.</given-names></name><name><surname>Ferland</surname><given-names>R. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Trafficking in and to the primary cilium</article-title>. <source/>Cilia
<volume>1</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/2046-2530-1-4</pub-id><pub-id pub-id-type="pmid">23351793</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H. G.</given-names></name><name><surname>Scholten</surname><given-names>I.</given-names></name><name><surname>Gruss</surname><given-names>C.</given-names></name><name><surname>Knippers</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>The distribution of the DEK protein in mammalian chromatin</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>358</volume>, <fpage>1008</fpage>–<lpage>1014</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.05.019</pub-id><pub-id pub-id-type="pmid">17524367</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Rambaldi</surname><given-names>I.</given-names></name><name><surname>Daniels</surname><given-names>E.</given-names></name><name><surname>Featherstone</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Expression of the Wdr9 gene and protein products during mouse development</article-title>. <source/>Dev. Dyn.
<volume>227</volume>, <fpage>608</fpage>–<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1002/dvdy.10344</pub-id><pub-id pub-id-type="pmid">12889071</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Lempicki</surname><given-names>R. A.</given-names></name></person-group> (<year>2009a</year>). <article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title>. <source/>Nucleic Acids Res.
<volume>37</volume>, <fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id><pub-id pub-id-type="pmid">19033363</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Lempicki</surname><given-names>R. A.</given-names></name></person-group> (<year>2009b</year>). <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source/>Nat. Protoc.
<volume>4</volume>, <fpage>44</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jäkel</surname><given-names>S.</given-names></name><name><surname>Albig</surname><given-names>W.</given-names></name><name><surname>Kutay</surname><given-names>U.</given-names></name><name><surname>Bischoff</surname><given-names>F. R.</given-names></name><name><surname>Schwamborn</surname><given-names>K.</given-names></name><name><surname>Doenecke</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>The importin beta/importin 7 heterodimer is a functional nuclear import receptor for histone H1</article-title>. <source/>EMBO J.
<volume>18</volume>, <fpage>2411</fpage>–<lpage>2423</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/18.9.2411</pub-id><pub-id pub-id-type="pmid">10228156</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>D.</given-names></name></person-group> (<year>2009</year>). <article-title>Hedgehog signalling: emerging evidence for non-canonical pathways</article-title>. <source/>Cell. Signal.
<volume>21</volume>, <fpage>1023</fpage>–<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2009.01.033</pub-id><pub-id pub-id-type="pmid">19399989</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Williamson</surname><given-names>A.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Philipp</surname><given-names>I.</given-names></name><name><surname>Rape</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex</article-title>. <source/>Cell
<volume>133</volume>, <fpage>653</fpage>–<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.04.012</pub-id><pub-id pub-id-type="pmid">18485873</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>M. C.</given-names></name><name><surname>Caswell</surname><given-names>P. T.</given-names></name><name><surname>Norman</surname><given-names>J. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Endocytic recycling pathways: emerging regulators of cell migration</article-title>. <source/>Curr. Opin. Cell Biol.
<volume>18</volume>, <fpage>549</fpage>–<lpage>557</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2006.08.003</pub-id><pub-id pub-id-type="pmid">16904305</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadin</surname><given-names>M. E.</given-names></name><name><surname>Rubinstein</surname><given-names>L. J.</given-names></name><name><surname>Nelson</surname><given-names>J. S.</given-names></name></person-group> (<year>1970</year>). <article-title>Neonatal cerebellar medulloblastoma originating from the fetal external granular layer</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>29</volume>, <fpage>583</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="pmid">5471923</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Networking of WNT, FGF, Notch, BMP, and Hedgehog Signaling Pathways during Carcinogenesis</article-title>. <source/>Stem Cell Rev.
<volume>3</volume>, <fpage>30</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1007/s12015-007-0006-6</pub-id><pub-id pub-id-type="pmid">17873379</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>E. E.</given-names></name><name><surname>Horgan</surname><given-names>C. P.</given-names></name><name><surname>McCaffrey</surname><given-names>M. W.</given-names></name></person-group> (<year>2012</year>). <article-title>Rab11 proteins in health and disease</article-title>. <source/>Biochem. Soc. Trans.
<volume>40</volume>, <fpage>1360</fpage>–<lpage>1367</lpage>. <pub-id pub-id-type="doi">10.1042/bst20120157</pub-id><pub-id pub-id-type="pmid">23176481</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J. J.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Gardner</surname><given-names>D.</given-names></name><name><surname>Beachy</surname><given-names>P. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>107</volume>, <fpage>13432</fpage>–<lpage>13437</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1006822107</pub-id><pub-id pub-id-type="pmid">20624968</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R. S.</given-names></name><name><surname>Rubin</surname><given-names>J. B.</given-names></name><name><surname>Gibson</surname><given-names>H. D.</given-names></name><name><surname>DeHaan</surname><given-names>E. N.</given-names></name><name><surname>Alvarez-Hernandez</surname><given-names>X.</given-names></name><name><surname>Segal</surname><given-names>R. A.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells</article-title>. <source/>Development
<volume>128</volume>, <fpage>1971</fpage>–<lpage>1981</lpage>. <pub-id pub-id-type="pmid">11493520</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloet</surname><given-names>S. L.</given-names></name><name><surname>Whiting</surname><given-names>J. L.</given-names></name><name><surname>Gafken</surname><given-names>P.</given-names></name><name><surname>Ranish</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>E. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7</article-title>. <source/>Mol. Cell. Biol.
<volume>32</volume>, <fpage>3358</fpage>–<lpage>3369</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.00416-12</pub-id><pub-id pub-id-type="pmid">22711989</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knödler</surname><given-names>A.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Peranen</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Coordination of Rab8 and Rab11 in primary ciliogenesis</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>107</volume>, <fpage>6346</fpage>–<lpage>6351</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1002401107</pub-id><pub-id pub-id-type="pmid">20308558</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knox</surname><given-names>C.</given-names></name><name><surname>Law</surname><given-names>V.</given-names></name><name><surname>Jewison</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Ly</surname><given-names>S.</given-names></name><name><surname>Frolkis</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs</article-title>. <source/>Nucleic Acids Res.
<volume>39</volume>, <fpage>D1035</fpage>–<lpage>D1041</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq1126</pub-id><pub-id pub-id-type="pmid">21059682</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Komuro</surname><given-names>Y.</given-names></name><name><surname>Fahrion</surname><given-names>J.</given-names></name><name><surname>Foote</surname><given-names>K.</given-names></name><name><surname>Fenner</surname><given-names>K.</given-names></name><name><surname>Kumada</surname><given-names>T.</given-names></name><name><surname>Ohno</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Granule cell migration and differentiation</article-title>, in <source/>Handbook of the Cerebellum and Cerebellar Disorders, eds <person-group person-group-type="editor"><name><surname>Manto</surname><given-names>M.</given-names></name><name><surname>Schmahmann</surname><given-names>J. D.</given-names></name><name><surname>Rossi</surname><given-names>F.</given-names></name><name><surname>Gruol</surname><given-names>D. L.</given-names></name><name><surname>Koibuchi</surname><given-names>N.</given-names></name></person-group> (<publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name>), <fpage>107</fpage>–<lpage>125</lpage>.</mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komuro</surname><given-names>Y.</given-names></name><name><surname>Galas</surname><given-names>L.</given-names></name><name><surname>Lebon</surname><given-names>A.</given-names></name><name><surname>Raoult</surname><given-names>E.</given-names></name><name><surname>Fahrion</surname><given-names>J. K.</given-names></name><name><surname>Tilot</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>The role of calcium and cyclic nucleotide signaling in cerebellar granule cell migration under normal and pathological conditions</article-title>. <source/>Dev. Neurobiol.
<volume>75</volume>, <fpage>369</fpage>–<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1002/dneu.22219</pub-id><pub-id pub-id-type="pmid">25066767</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kool</surname><given-names>M.</given-names></name><name><surname>Koster</surname><given-names>J.</given-names></name><name><surname>Bunt</surname><given-names>J.</given-names></name><name><surname>Hasselt</surname><given-names>N. E.</given-names></name><name><surname>Lakeman</surname><given-names>A.</given-names></name><name><surname>van Sluis</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features</article-title>. <source/>PLoS ONE 3:e3088. <pub-id pub-id-type="doi">10.1371/journal.pone.0003088</pub-id><pub-id pub-id-type="pmid">18769486</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriventseva</surname><given-names>E. V.</given-names></name><name><surname>Tegenfeldt</surname><given-names>F.</given-names></name><name><surname>Petty</surname><given-names>T. J.</given-names></name><name><surname>Waterhouse</surname><given-names>R. M.</given-names></name><name><surname>Simao</surname><given-names>F. A.</given-names></name><name><surname>Pozdnyakov</surname><given-names>I. A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>OrthoDB v8: update of the hierarchical catalog of orthologs and the underlying free software</article-title>. <source/>Nucleic Acids Res.
<volume>43</volume>, <fpage>D250</fpage>–<lpage>D256</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku1220</pub-id><pub-id pub-id-type="pmid">25428351</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kular</surname><given-names>R. K.</given-names></name><name><surname>Cvetanovic</surname><given-names>M.</given-names></name><name><surname>Siferd</surname><given-names>S.</given-names></name><name><surname>Kini</surname><given-names>A. R.</given-names></name><name><surname>Opal</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuronal differentiation is regulated by leucine-rich acidic nuclear protein (LANP), a member of the inhibitor of histone acetyltransferase complex</article-title>. <source/>J. Biol. Chem.
<volume>284</volume>, <fpage>7783</fpage>–<lpage>7792</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M806150200</pub-id><pub-id pub-id-type="pmid">19136565</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachyankar</surname><given-names>M. B.</given-names></name><name><surname>Sultana</surname><given-names>N.</given-names></name><name><surname>Schonhoff</surname><given-names>C. M.</given-names></name><name><surname>Mitra</surname><given-names>P.</given-names></name><name><surname>Poluha</surname><given-names>W.</given-names></name><name><surname>Lambert</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>A role for nuclear PTEN in neuronal differentiation</article-title>. <source/>J. Neurosci.
<volume>20</volume>, <fpage>1404</fpage>–<lpage>1413</lpage>. <pub-id pub-id-type="pmid">10662831</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>V.</given-names></name><name><surname>Knox</surname><given-names>C.</given-names></name><name><surname>Djoumbou</surname><given-names>Y.</given-names></name><name><surname>Jewison</surname><given-names>T.</given-names></name><name><surname>Guo</surname><given-names>A. C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>DrugBank 4.0: shedding new light on drug metabolism</article-title>. <source/>Nucleic Acids Res.
<volume>42</volume>, <fpage>D1091</fpage>–<lpage>D1097</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1068</pub-id><pub-id pub-id-type="pmid">24203711</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Gleeson</surname><given-names>J. G.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of primary cilia in neuronal function</article-title>. <source/>Neurobiol. Dis.
<volume>38</volume>, <fpage>167</fpage>–<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2009.12.022</pub-id><pub-id pub-id-type="pmid">20097287</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S. J.</given-names></name><name><surname>Langhans</surname><given-names>S. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Anaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis</article-title>. <source/>BMC Cancer
<volume>12</volume>:<fpage>44</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-12-44</pub-id><pub-id pub-id-type="pmid">22280307</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Krauthauser</surname><given-names>C.</given-names></name><name><surname>Maduskuie</surname><given-names>V.</given-names></name><name><surname>Fawcett</surname><given-names>P.</given-names></name><name><surname>Olson</surname><given-names>J.</given-names></name><name><surname>Rajasekaran</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source/>BMC Cancer
<volume>11</volume>:<fpage>144</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-11-144</pub-id><pub-id pub-id-type="pmid">21501498</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Kim</surname><given-names>J. M.</given-names></name><name><surname>Cho</surname><given-names>S. Y.</given-names></name><name><surname>Kim</surname><given-names>H. S.</given-names></name><name><surname>Shin</surname><given-names>H. S.</given-names></name><name><surname>Jeon</surname><given-names>J. Y.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>TIMP-1 modulates chemotaxis of human neural stem cells through CD63 and integrin signalling</article-title>. <source/>Biochem. J.
<volume>459</volume>, <fpage>565</fpage>–<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20131119</pub-id><pub-id pub-id-type="pmid">24635319</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Roy</surname><given-names>C.</given-names></name><name><surname>Wrana</surname><given-names>J. L.</given-names></name></person-group> (<year>2005</year>). <article-title>Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>6</volume>, <fpage>112</fpage>–<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1038/nrm1571</pub-id><pub-id pub-id-type="pmid">15687999</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>Y. F.</given-names></name><name><surname>Ma</surname><given-names>P.</given-names></name><name><surname>Link</surname><given-names>B. A.</given-names></name><name><surname>Dowling</surname><given-names>J. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Factorial microarray analysis of zebrafish retinal development</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>12909</fpage>–<lpage>12914</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0806038105</pub-id><pub-id pub-id-type="pmid">18753621</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Saito</surname><given-names>M.</given-names></name><name><surname>Chuang</surname><given-names>J. Z.</given-names></name><name><surname>Tseng</surname><given-names>Y. Y.</given-names></name><name><surname>Dedesma</surname><given-names>C.</given-names></name><name><surname>Tomizawa</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Ciliary transition zone activation of phosphorylated Tctex-1 controls ciliary resorption, S-phase entry and fate of neural progenitors</article-title>. <source/>Nat. Cell Biol.
<volume>13</volume>, <fpage>402</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2218</pub-id><pub-id pub-id-type="pmid">21394082</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Fredriksson</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Eriksson</surname><given-names>U.</given-names></name></person-group> (<year>2003</year>). <article-title>PDGF-D is a potent transforming and angiogenic growth factor</article-title>. <source/>Oncogene
<volume>22</volume>, <fpage>1501</fpage>–<lpage>1510</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1206223</pub-id><pub-id pub-id-type="pmid">12629513</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Olson</surname><given-names>L. M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Bidder</surname><given-names>M.</given-names></name><name><surname>Nguyen</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer</article-title>. <source/>Int. J. Med. Sci.
<volume>5</volume>, <fpage>133</fpage>–<lpage>142</lpage>. <pub-id pub-id-type="doi">10.7150/ijms.5.133</pub-id><pub-id pub-id-type="pmid">18566677</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Salmonsen</surname><given-names>R. A.</given-names></name><name><surname>Turner</surname><given-names>T. K.</given-names></name><name><surname>Litofsky</surname><given-names>N. S.</given-names></name><name><surname>Di Cristofano</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation</article-title>. <source/>Mol. Cell. Neurosci.
<volume>20</volume>, <fpage>21</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1006/mcne.2002.1115</pub-id><pub-id pub-id-type="pmid">12056837</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lit</surname><given-names>L. C.</given-names></name><name><surname>Scott</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Stebbing</surname><given-names>J.</given-names></name><name><surname>Photiou</surname><given-names>A.</given-names></name><name><surname>Giamas</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>LATS2 is a modulator of estrogen receptor alpha</article-title>. <source/>Anticancer Res.
<volume>33</volume>, <fpage>53</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="pmid">23267128</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livesey</surname><given-names>F. J.</given-names></name><name><surname>Young</surname><given-names>T. L.</given-names></name><name><surname>Cepko</surname><given-names>C. L.</given-names></name></person-group> (<year>2004</year>). <article-title>An analysis of the gene expression program of mammalian neural progenitor cells</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>101</volume>, <fpage>1374</fpage>–<lpage>1379</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0307014101</pub-id><pub-id pub-id-type="pmid">14734810</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>E. E.</given-names></name><name><surname>Klein</surname><given-names>R. S.</given-names></name><name><surname>Flanagan</surname><given-names>J. G.</given-names></name></person-group> (<year>2001</year>). <article-title>Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction</article-title>. <source/>Cell
<volume>105</volume>, <fpage>69</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00297-5</pub-id><pub-id pub-id-type="pmid">11301003</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lütcke</surname><given-names>A.</given-names></name><name><surname>Parton</surname><given-names>R. G.</given-names></name><name><surname>Murphy</surname><given-names>C.</given-names></name><name><surname>Olkkonen</surname><given-names>V. M.</given-names></name><name><surname>Dupree</surname><given-names>P.</given-names></name><name><surname>Valencia</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>1994</year>). <article-title>Cloning and subcellular localization of novel rab proteins reveals polarized and cell type-specific expression</article-title>. <source/>J. Cell Sci.
<volume>107</volume>(<issue>Pt 12</issue>), <fpage>3437</fpage>–<lpage>3448</lpage>. <pub-id pub-id-type="pmid">7706395</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>W. M.</given-names><suffix>Jr.</suffix></name><name><surname>Gunaje</surname><given-names>J.</given-names></name><name><surname>Daum</surname><given-names>G.</given-names></name><name><surname>Dong</surname><given-names>X. R.</given-names></name><name><surname>Majesky</surname><given-names>M. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Regulator of G-protein signaling - 5 (RGS5) is a novel repressor of hedgehog signaling</article-title>. <source/>PLoS ONE 8:e61421. <pub-id pub-id-type="doi">10.1371/journal.pone.0061421</pub-id><pub-id pub-id-type="pmid">23637832</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manchado</surname><given-names>E.</given-names></name><name><surname>Eguren</surname><given-names>M.</given-names></name><name><surname>Malumbres</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>The anaphase-promoting complex/cyclosome (APC/C): cell-cycle-dependent and -independent functions</article-title>. <source/>Biochem. Soc. Trans.
<volume>38</volume>(<issue>Pt 1</issue>), <fpage>65</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1042/BST0380065</pub-id><pub-id pub-id-type="pmid">20074037</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangal</surname><given-names>M.</given-names></name><name><surname>Sagar</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>H.</given-names></name><name><surname>Raghava</surname><given-names>G. P. S.</given-names></name><name><surname>Agarwal</surname><given-names>S. M.</given-names></name></person-group> (<year>2013</year>). <article-title>NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database</article-title>. <source/>Nucleic Acids Res.
<volume>41</volume>, <fpage>D1124</fpage>–<lpage>D1129</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1047</pub-id><pub-id pub-id-type="pmid">23203877</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manoranjan</surname><given-names>B.</given-names></name><name><surname>Venugopal</surname><given-names>C.</given-names></name><name><surname>McFarlane</surname><given-names>N.</given-names></name><name><surname>Doble</surname><given-names>B. W.</given-names></name><name><surname>Dunn</surname><given-names>S. E.</given-names></name><name><surname>Scheinemann</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Medulloblastoma stem cells: where development and cancer cross pathways</article-title>. <source/>Pediatr. Res.
<volume>71</volume>(<issue>4 Pt 2</issue>), <fpage>516</fpage>–<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1038/pr.2011.62</pub-id><pub-id pub-id-type="pmid">22430388</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>R. C.</given-names></name><name><surname>Gale</surname><given-names>N. W.</given-names></name><name><surname>Morrison</surname><given-names>M. E.</given-names></name><name><surname>Mason</surname><given-names>C. A.</given-names></name><name><surname>Yancopoulos</surname><given-names>G. D.</given-names></name></person-group> (<year>1996</year>). <article-title>Eph family receptors and their ligands distribute in opposing gradients in the developing mouse retina</article-title>. <source/>Dev. Biol.
<volume>180</volume>, <fpage>786</fpage>–<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1006/dbio.1996.0347</pub-id><pub-id pub-id-type="pmid">8954746</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marillat</surname><given-names>V.</given-names></name><name><surname>Sabatier</surname><given-names>C.</given-names></name><name><surname>Failli</surname><given-names>V.</given-names></name><name><surname>Matsunaga</surname><given-names>E.</given-names></name><name><surname>Sotelo</surname><given-names>C.</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>The Slit Receptor Rig-1/Robo3 controls midline crossing by hindbrain precerebellar neurons and axons</article-title>. <source/>Neuron
<volume>43</volume>, <fpage>69</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2004.06.018</pub-id><pub-id pub-id-type="pmid">15233918</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martí</surname><given-names>E.</given-names></name><name><surname>Bovolenta</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Sonic hedgehog in CNS development: one signal, multiple outputs</article-title>. <source/>Trends Neurosci.
<volume>25</volume>, <fpage>89</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/S0166-2236(02)02062-3</pub-id><pub-id pub-id-type="pmid">11814561</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Driessen</surname><given-names>K.</given-names></name><name><surname>Nixon</surname><given-names>S. J.</given-names></name><name><surname>Zerial</surname><given-names>M.</given-names></name><name><surname>Parton</surname><given-names>R. G.</given-names></name></person-group> (<year>2005</year>). <article-title>Regulated localization of Rab18 to lipid droplets: effects of lipolytic stimulation and inhibition of lipid droplet catabolism</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>42325</fpage>–<lpage>42335</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M506651200</pub-id><pub-id pub-id-type="pmid">16207721</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzluff</surname><given-names>W. F.</given-names></name><name><surname>Gongidi</surname><given-names>P.</given-names></name><name><surname>Woods</surname><given-names>K. R.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Maltais</surname><given-names>L. J.</given-names></name></person-group> (<year>2002</year>). <article-title>The human and mouse replication-dependent histone genes</article-title>. <source/>Genomics
<volume>80</volume>, <fpage>487</fpage>–<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1006/geno.2002.6850</pub-id><pub-id pub-id-type="pmid">12408966</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClintock</surname><given-names>T. S.</given-names></name><name><surname>Glasser</surname><given-names>C. E.</given-names></name><name><surname>Bose</surname><given-names>S. C.</given-names></name><name><surname>Bergman</surname><given-names>D. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Tissue expression patterns identify mouse cilia genes</article-title>. <source/>Physiol. Genomics
<volume>32</volume>, <fpage>198</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1152/physiolgenomics.00128.2007</pub-id><pub-id pub-id-type="pmid">17971504</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIlwain</surname><given-names>D. R.</given-names></name><name><surname>Pan</surname><given-names>Q.</given-names></name><name><surname>Reilly</surname><given-names>P. T.</given-names></name><name><surname>Elia</surname><given-names>A. J.</given-names></name><name><surname>McCracken</surname><given-names>S.</given-names></name><name><surname>Wakeham</surname><given-names>A. C.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decay</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>107</volume>, <fpage>12186</fpage>–<lpage>12191</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1007336107</pub-id><pub-id pub-id-type="pmid">20566848</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKean</surname><given-names>D. M.</given-names></name><name><surname>Sisbarro</surname><given-names>L.</given-names></name><name><surname>Ilic</surname><given-names>D.</given-names></name><name><surname>Kaplan-Alburquerque</surname><given-names>N.</given-names></name><name><surname>Nemenoff</surname><given-names>R.</given-names></name><name><surname>Weiser-Evans</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>FAK induces expression of Prx1 to promote tenascin-C-dependent fibroblast migration</article-title>. <source/>J. Cell Biol.
<volume>161</volume>, <fpage>393</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200302126</pub-id><pub-id pub-id-type="pmid">12741393</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinney</surname><given-names>N.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>Y. J.</given-names></name><name><surname>Rushing</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>EphrinB1 expression is dysregulated and promotes oncogenic signaling in medulloblastoma</article-title>. <source/>J. Neurooncol.
<volume>121</volume>, <fpage>109</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-014-1618-8</pub-id><pub-id pub-id-type="pmid">25258252</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellor</surname><given-names>P.</given-names></name><name><surname>Harvey</surname><given-names>J. R.</given-names></name><name><surname>Murphy</surname><given-names>K. J.</given-names></name><name><surname>Pye</surname><given-names>D.</given-names></name><name><surname>O'Boyle</surname><given-names>G.</given-names></name><name><surname>Lennard</surname><given-names>T. W.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells <italic>in vivo</italic></article-title>. <source/>Br. J. Cancer
<volume>97</volume>, <fpage>761</fpage>–<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6603928</pub-id><pub-id pub-id-type="pmid">17726466</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memi</surname><given-names>F.</given-names></name><name><surname>Abe</surname><given-names>P.</given-names></name><name><surname>Cariboni</surname><given-names>A.</given-names></name><name><surname>MacKay</surname><given-names>F.</given-names></name><name><surname>Parnavelas</surname><given-names>J. G.</given-names></name><name><surname>Stumm</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>CXC chemokine receptor 7 (CXCR7) affects the migration of GnRH neurons by regulating CXCL12 availability</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>17527</fpage>–<lpage>17537</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0857-13.2013</pub-id><pub-id pub-id-type="pmid">24174685</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micheli</surname><given-names>L.</given-names></name><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Farioli-Vecchioli</surname><given-names>S.</given-names></name><name><surname>Tirone</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>Control of the normal and pathological development of neural stem and progenitor cells by the PC3/Tis21/Btg2 and Btg1 Genes</article-title>. <source/>J. Cell. Physiol.
<volume>230</volume>, <fpage>2881</fpage>–<lpage>2890</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.25038</pub-id><pub-id pub-id-type="pmid">25967096</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micheli</surname><given-names>L.</given-names></name><name><surname>D'Andrea</surname><given-names>G.</given-names></name><name><surname>Leonardi</surname><given-names>L.</given-names></name><name><surname>Tirone</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>HDAC1, HDAC4 and HDAC9 Bind to PC3/Tis21/Btg2 and Are Required for its Inhibition of Cell Cycle Progression and Cyclin D1 Expression</article-title>. <source/>J. Cell. Physiol. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1002/jcp.25467</pub-id><pub-id pub-id-type="pmid">27333946</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mimeault</surname><given-names>M.</given-names></name><name><surname>Batra</surname><given-names>S. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies</article-title>. <source/>Brain Pathol.
<volume>21</volume>, <fpage>479</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.2011.00505.x</pub-id><pub-id pub-id-type="pmid">21615592</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>A. L.</given-names></name><name><surname>Friedman</surname><given-names>M. D.</given-names></name><name><surname>Ormond</surname><given-names>D. R.</given-names></name><name><surname>Tobias</surname><given-names>M.</given-names></name><name><surname>Murali</surname><given-names>R.</given-names></name><name><surname>Jhanwar-Uniyal</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>PI3K/mTOR signaling pathways in medulloblastoma</article-title>. <source/>Anticancer Res.
<volume>32</volume>, <fpage>3141</fpage>–<lpage>3146</lpage>. <pub-id pub-id-type="pmid">22843885</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriwaki</surname><given-names>K.</given-names></name><name><surname>Bertin</surname><given-names>J.</given-names></name><name><surname>Gough</surname><given-names>P. J.</given-names></name><name><surname>Orlowski</surname><given-names>G. M.</given-names></name><name><surname>Chan</surname><given-names>F. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death</article-title>. <source/>Cell Death Dis.
<volume>6</volume>, <fpage>e1636</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2015.16</pub-id><pub-id pub-id-type="pmid">25675296</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriwaki</surname><given-names>K.</given-names></name><name><surname>Chan</surname><given-names>F. K.</given-names></name></person-group> (<year>2013</year>). <article-title>RIP3: a molecular switch for necrosis and inflammation</article-title>. <source/>Genes Dev.
<volume>27</volume>, <fpage>1640</fpage>–<lpage>1649</lpage>. <pub-id pub-id-type="doi">10.1101/gad.223321.113</pub-id><pub-id pub-id-type="pmid">23913919</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Pershad</surname><given-names>R.</given-names></name><name><surname>Hsieh</surname><given-names>T. F.</given-names></name><name><surname>Scarpa</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>S. W.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Gene expression in the developing mouse retina by EST sequencing and microarray analysis</article-title>. <source/>Nucleic Acids Res.
<volume>29</volume>, <fpage>4983</fpage>–<lpage>4993</lpage>. <pub-id pub-id-type="doi">10.1093/nar/29.24.4983</pub-id><pub-id pub-id-type="pmid">11812828</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mühlhäusser</surname><given-names>P.</given-names></name><name><surname>Muller</surname><given-names>E. C.</given-names></name><name><surname>Otto</surname><given-names>A.</given-names></name><name><surname>Kutay</surname><given-names>U.</given-names></name></person-group> (<year>2001</year>). <article-title>Multiple pathways contribute to nuclear import of core histones</article-title>. <source/>EMBO Rep.
<volume>2</volume>, <fpage>690</fpage>–<lpage>696</lpage>. <pub-id pub-id-type="doi">10.1093/embo-reports/kve168</pub-id><pub-id pub-id-type="pmid">11493596</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>The golgin coiled-coil proteins of the Golgi apparatus</article-title>. <source/>Cold Spring Harb. Perspect. Biol.
<volume>3</volume>:<fpage>a005256</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a005256</pub-id><pub-id pub-id-type="pmid">21436057</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muto</surname><given-names>A.</given-names></name><name><surname>Aoki</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Mouse Rab11-FIP4 regulates proliferation and differentiation of retinal progenitors in a Rab11-independent manner</article-title>. <source/>Dev. Dyn.
<volume>236</volume>, <fpage>214</fpage>–<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1002/dvdy.21009</pub-id><pub-id pub-id-type="pmid">17089410</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muto</surname><given-names>A.</given-names></name><name><surname>Arai</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Rab11-FIP4 is predominantly expressed in neural tissues and involved in proliferation as well as in differentiation during zebrafish retinal development</article-title>. <source/>Dev. Biol.
<volume>292</volume>, <fpage>90</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2005.12.050</pub-id><pub-id pub-id-type="pmid">16457799</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naslavsky</surname><given-names>N.</given-names></name><name><surname>Boehm</surname><given-names>M.</given-names></name><name><surname>Backlund</surname><given-names>P. S.</given-names><suffix>Jr.</suffix></name><name><surname>Caplan</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Rabenosyn-5 and EHD1 interact and sequentially regulate protein recycling to the plasma membrane</article-title>. <source/>Mol. Biol. Cell
<volume>15</volume>, <fpage>2410</fpage>–<lpage>2422</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E03-10-0733</pub-id><pub-id pub-id-type="pmid">15020713</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neth</surname><given-names>P.</given-names></name><name><surname>Ries</surname><given-names>C.</given-names></name><name><surname>Karow</surname><given-names>M.</given-names></name><name><surname>Egea</surname><given-names>V.</given-names></name><name><surname>Ilmer</surname><given-names>M.</given-names></name><name><surname>Jochum</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion</article-title>. <source/>Stem Cell Rev.
<volume>3</volume>, <fpage>18</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1007/s12015-007-0001-y</pub-id><pub-id pub-id-type="pmid">17873378</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nigg</surname><given-names>E. A.</given-names></name><name><surname>Raff</surname><given-names>J. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Centrioles, centrosomes, and cilia in health and disease</article-title>. <source/>Cell
<volume>139</volume>, <fpage>663</fpage>–<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.10.036</pub-id><pub-id pub-id-type="pmid">19914163</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northcott</surname><given-names>P. A.</given-names></name><name><surname>Jones</surname><given-names>D. T.</given-names></name><name><surname>Kool</surname><given-names>M.</given-names></name><name><surname>Robinson</surname><given-names>G. W.</given-names></name><name><surname>Gilbertson</surname><given-names>R. J.</given-names></name><name><surname>Cho</surname><given-names>Y. J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Medulloblastomics: the end of the beginning</article-title>. <source/>Nat. Rev. Cancer
<volume>12</volume>, <fpage>818</fpage>–<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3410</pub-id><pub-id pub-id-type="pmid">23175120</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northcott</surname><given-names>P. A.</given-names></name><name><surname>Korshunov</surname><given-names>A.</given-names></name><name><surname>Witt</surname><given-names>H.</given-names></name><name><surname>Hielscher</surname><given-names>T.</given-names></name><name><surname>Eberhart</surname><given-names>C. G.</given-names></name><name><surname>Mack</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Medulloblastoma comprises four distinct molecular variants</article-title>. <source/>J. Clin. Oncol.
<volume>29</volume>, <fpage>1408</fpage>–<lpage>1414</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.27.4324</pub-id><pub-id pub-id-type="pmid">20823417</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northcott</surname><given-names>P. A.</given-names></name><name><surname>Shih</surname><given-names>D. J.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>Y. J.</given-names></name><name><surname>Kool</surname><given-names>M.</given-names></name><name><surname>Hawkins</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2012c</year>). <article-title>Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples</article-title>. <source/>Acta Neuropathol.
<volume>123</volume>, <fpage>615</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-011-0899-7</pub-id><pub-id pub-id-type="pmid">22057785</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocaña</surname><given-names>O. H.</given-names></name><name><surname>Corcoles</surname><given-names>R.</given-names></name><name><surname>Fabra</surname><given-names>A.</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G.</given-names></name><name><surname>Acloque</surname><given-names>H.</given-names></name><name><surname>Vega</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1</article-title>. <source/>Cancer Cell
<volume>22</volume>, <fpage>709</fpage>–<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2012.10.012</pub-id><pub-id pub-id-type="pmid">23201163</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohshima-Hosoyama</surname><given-names>S.</given-names></name><name><surname>Davare</surname><given-names>M.</given-names></name><name><surname>Hosoyama</surname><given-names>T.</given-names></name><name><surname>Nelon</surname><given-names>L.</given-names></name><name><surname>Keller</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma</article-title>. <source/>J. Neurooncol.
<volume>105</volume>, <fpage>475</fpage>–<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-011-0619-0</pub-id><pub-id pub-id-type="pmid">21633906</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omori</surname><given-names>Y.</given-names></name><name><surname>Araki</surname><given-names>F.</given-names></name><name><surname>Chaya</surname><given-names>T.</given-names></name><name><surname>Kajimura</surname><given-names>N.</given-names></name><name><surname>Irie</surname><given-names>S.</given-names></name><name><surname>Terada</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Presynaptic dystroglycan-pikachurin complex regulates the proper synaptic connection between retinal photoreceptor and bipolar cells</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>6126</fpage>–<lpage>6137</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.0322-12.2012</pub-id><pub-id pub-id-type="pmid">22553019</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozeki</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Tauchi-Sato</surname><given-names>K.</given-names></name><name><surname>Hatano</surname><given-names>N.</given-names></name><name><surname>Taniguchi</surname><given-names>H.</given-names></name><name><surname>Fujimoto</surname><given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Rab18 localizes to lipid droplets and induces their close apposition to the endoplasmic reticulum-derived membrane</article-title>. <source/>J. Cell Sci.
<volume>118</volume>(<issue>Pt 12</issue>), <fpage>2601</fpage>–<lpage>2611</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.02401</pub-id><pub-id pub-id-type="pmid">15914536</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>A. K.</given-names></name><name><surname>Lee</surname><given-names>S. J.</given-names></name><name><surname>Phi</surname><given-names>J. H.</given-names></name><name><surname>Wang</surname><given-names>K. C.</given-names></name><name><surname>Kim</surname><given-names>D. G.</given-names></name><name><surname>Cho</surname><given-names>B. K.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation</article-title>. <source/>Neuro Oncol.
<volume>14</volume>, <fpage>203</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nor196</pub-id><pub-id pub-id-type="pmid">22090452</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawar</surname><given-names>S. A.</given-names></name><name><surname>Sarkar</surname><given-names>T. R.</given-names></name><name><surname>Balamurugan</surname><given-names>K.</given-names></name><name><surname>Sharan</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>C/EBPδ targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>107</volume>, <fpage>9210</fpage>–<lpage>9215</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0913813107</pub-id><pub-id pub-id-type="pmid">20439707</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peifer</surname><given-names>M.</given-names></name><name><surname>Polakis</surname><given-names>P.</given-names></name></person-group> (<year>2000</year>). <article-title>Wnt Signaling in oncogenesis and embryogenesis–a look outside the nucleus</article-title>. <source/>Science
<volume>287</volume>, <fpage>1606</fpage>–<lpage>1609</lpage>. <pub-id pub-id-type="doi">10.1126/science.287.5458.1606</pub-id><pub-id pub-id-type="pmid">10733430</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>K.</given-names></name><name><surname>Sjoblom</surname><given-names>T.</given-names></name><name><surname>Rubin</surname><given-names>K.</given-names></name><name><surname>Heldin</surname><given-names>C. H.</given-names></name><name><surname>Ostman</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>PDGF receptors as cancer drug targets</article-title>. <source/>Cancer Cell
<volume>3</volume>, <fpage>439</fpage>–<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/S1535-6108(03)00089-8</pub-id><pub-id pub-id-type="pmid">12781361</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilz</surname><given-names>A.</given-names></name><name><surname>Schaap</surname><given-names>D.</given-names></name><name><surname>Hunt</surname><given-names>D.</given-names></name><name><surname>Fitzgibbon</surname><given-names>J.</given-names></name></person-group> (<year>1995</year>). <article-title>Chromosomal localization of three mouse diacylglycerol kinase (DAGK) genes: genes sharing sequence homology to the Drosophila retinal degeneration A (rdgA) gene</article-title>. <source/>Genomics
<volume>26</volume>, <fpage>599</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="pmid">7607687</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plass</surname><given-names>C.</given-names></name><name><surname>Pfister</surname><given-names>S. M.</given-names></name><name><surname>Lindroth</surname><given-names>A. M.</given-names></name><name><surname>Bogatyrova</surname><given-names>O.</given-names></name><name><surname>Claus</surname><given-names>R.</given-names></name><name><surname>Lichter</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer</article-title>. <source/>Nat. Rev. Genet.
<volume>14</volume>, <fpage>765</fpage>–<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3554</pub-id><pub-id pub-id-type="pmid">24105274</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotnikova</surname><given-names>O. V.</given-names></name><name><surname>Golemis</surname><given-names>E. A.</given-names></name><name><surname>Pugacheva</surname><given-names>E. N.</given-names></name></person-group> (<year>2008</year>). <article-title>Cell cycle-dependent ciliogenesis and cancer</article-title>. <source/>Cancer Res.
<volume>68</volume>, <fpage>2058</fpage>–<lpage>2061</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5838</pub-id><pub-id pub-id-type="pmid">18381407</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poliakov</surname><given-names>A.</given-names></name><name><surname>Cotrina</surname><given-names>M.</given-names></name><name><surname>Wilkinson</surname><given-names>D. G.</given-names></name></person-group> (<year>2004</year>). <article-title>Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly</article-title>. <source/>Dev. Cell
<volume>7</volume>, <fpage>465</fpage>–<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2004.09.006</pub-id><pub-id pub-id-type="pmid">15469835</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Privette Vinnedge</surname><given-names>L. M.</given-names></name><name><surname>Kappes</surname><given-names>F.</given-names></name><name><surname>Nassar</surname><given-names>N.</given-names></name><name><surname>Wells</surname><given-names>S. I.</given-names></name></person-group> (<year>2013</year>). <article-title>Stacking the DEK: from chromatin topology to cancer stem cells</article-title>. <source/>Cell Cycle
<volume>12</volume>, <fpage>51</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.4161/cc.23121</pub-id><pub-id pub-id-type="pmid">23255114</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quesada</surname><given-names>V.</given-names></name><name><surname>Díaz-Perales</surname><given-names>A.</given-names></name><name><surname>Gutiérrez-Fernández</surname><given-names>A.</given-names></name><name><surname>Garabaya</surname><given-names>C.</given-names></name><name><surname>Cal</surname><given-names>S.</given-names></name><name><surname>Lopez-Otin</surname><given-names>C.</given-names></name></person-group> (<year>2004</year>). <article-title>Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>314</volume>, <fpage>54</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2003.12.050</pub-id><pub-id pub-id-type="pmid">14715245</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raman</surname><given-names>D.</given-names></name><name><surname>Sai</surname><given-names>J.</given-names></name><name><surname>Hawkins</surname><given-names>O.</given-names></name><name><surname>Richmond</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Adaptor protein2 (AP2) orchestrates CXCR2-mediated cell migration</article-title>. <source/>Traffic
<volume>15</volume>, <fpage>451</fpage>–<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1111/tra.12154</pub-id><pub-id pub-id-type="pmid">24450359</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rask-Andersen</surname><given-names>M.</given-names></name><name><surname>Almén</surname><given-names>M. S.</given-names></name><name><surname>Schiöth</surname><given-names>H. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Trends in the exploitation of novel drug targets</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>10</volume>, <fpage>579</fpage>–<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3478</pub-id><pub-id pub-id-type="pmid">21804595</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riobo</surname><given-names>N. A.</given-names></name><name><surname>Saucy</surname><given-names>B.</given-names></name><name><surname>Dilizio</surname><given-names>C.</given-names></name><name><surname>Manning</surname><given-names>D. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Activation of heterotrimeric G proteins by Smoothened</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>103</volume>, <fpage>12607</fpage>–<lpage>12612</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0600880103</pub-id><pub-id pub-id-type="pmid">16885213</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>T. L.</given-names></name><name><surname>Ho</surname><given-names>U.</given-names></name><name><surname>Luff</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>C. S.</given-names></name><name><surname>Apte</surname><given-names>S. H.</given-names></name><name><surname>MacDonald</surname><given-names>K. P.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Smg1 haploinsufficiency predisposes to tumor formation and inflammation</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>110</volume>, <fpage>E285</fpage>–<lpage>E294</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1215696110</pub-id><pub-id pub-id-type="pmid">23277562</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodini</surname><given-names>C. O.</given-names></name><name><surname>Suzuki</surname><given-names>D. E.</given-names></name><name><surname>Nakahata</surname><given-names>A. M.</given-names></name><name><surname>Pereira</surname><given-names>M. C.</given-names></name><name><surname>Janjoppi</surname><given-names>L.</given-names></name><name><surname>Toledo</surname><given-names>S. R.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Aberrant signaling pathways in medulloblastomas: a stem cell connection</article-title>. <source/>Arq. Neuropsiquiatr.
<volume>68</volume>, <fpage>947</fpage>–<lpage>952</lpage>. <pub-id pub-id-type="doi">10.1590/S0004-282X2010000600021</pub-id><pub-id pub-id-type="pmid">21243257</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romer</surname><given-names>J. T.</given-names></name><name><surname>Curran</surname><given-names>T.</given-names></name></person-group> (<year>2004</year>). <article-title>Medulloblastoma and retinoblastoma: oncology recapitulates ontogeny</article-title>. <source/>Cell Cycle
<volume>3</volume>, <fpage>917</fpage>–<lpage>919</lpage>. <pub-id pub-id-type="doi">10.4161/cc.3.7.1011</pub-id><pub-id pub-id-type="pmid">15254429</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>A.</given-names></name><name><surname>Schraegle</surname><given-names>S. J.</given-names></name><name><surname>Stahlberg</surname><given-names>E. A.</given-names></name><name><surname>Meier</surname><given-names>I.</given-names></name></person-group> (<year>2005</year>). <article-title>Coiled-coil protein composition of 22 proteomes–differences and common themes in subcellular infrastructure and traffic control</article-title>. <source/>BMC Evol. Biol.
<volume>5</volume>:<fpage>66</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2148-5-66</pub-id><pub-id pub-id-type="pmid">16288662</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussel</surname><given-names>M. F.</given-names></name><name><surname>Hatten</surname><given-names>M. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Cerebellum development and medulloblastoma</article-title>. <source/>Curr. Top. Dev. Biol.
<volume>94</volume>, <fpage>235</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-380916-2.00008-5</pub-id><pub-id pub-id-type="pmid">21295689</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>A. K.</given-names></name><name><surname>Kappes</surname><given-names>F.</given-names></name><name><surname>Mundade</surname><given-names>A.</given-names></name><name><surname>Deutzmann</surname><given-names>A.</given-names></name><name><surname>Rosmarin</surname><given-names>D. M.</given-names></name><name><surname>Legendre</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Intercellular trafficking of the nuclear oncoprotein DEK</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>110</volume>, <fpage>6847</fpage>–<lpage>6852</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1220751110</pub-id><pub-id pub-id-type="pmid">23569252</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saletta</surname><given-names>F.</given-names></name><name><surname>Wadham</surname><given-names>C.</given-names></name><name><surname>Ziegler</surname><given-names>D. S.</given-names></name><name><surname>Marshall</surname><given-names>G. M.</given-names></name><name><surname>Haber</surname><given-names>M.</given-names></name><name><surname>McCowage</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Molecular profiling of childhood cancer: biomarkers and novel therapies</article-title>. <source/>BBA Clin.
<volume>1</volume>, <fpage>59</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbacli.2014.06.003</pub-id><pub-id pub-id-type="pmid">26675306</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>A.</given-names></name><name><surname>Sekine</surname><given-names>Y.</given-names></name><name><surname>Saruta</surname><given-names>C.</given-names></name><name><surname>Nishibe</surname><given-names>H.</given-names></name><name><surname>Morita</surname><given-names>N.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Cerebellar development transcriptome database (CDT-DB): profiling of spatio-temporal gene expression during the postnatal development of mouse cerebellum</article-title>. <source/>Neural Netw.
<volume>21</volume>, <fpage>1056</fpage>–<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1016/j.neunet.2008.05.004</pub-id><pub-id pub-id-type="pmid">18603407</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schüller</surname><given-names>U.</given-names></name><name><surname>Heine</surname><given-names>V. M.</given-names></name><name><surname>Mao</surname><given-names>J.</given-names></name><name><surname>Kho</surname><given-names>A. T.</given-names></name><name><surname>Dillon</surname><given-names>A. K.</given-names></name><name><surname>Han</surname><given-names>Y. G.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma</article-title>. <source/>Cancer Cell
<volume>14</volume>, <fpage>123</fpage>–<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2008.07.005</pub-id><pub-id pub-id-type="pmid">18691547</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M. A.</given-names></name><name><surname>Ginsberg</surname><given-names>M. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Networks and crosstalk: integrin signalling spreads</article-title>. <source/>Nat. Cell Biol.
<volume>4</volume>, <fpage>E65</fpage>–<lpage>E68</lpage>. <pub-id pub-id-type="doi">10.1038/ncb0402-e65</pub-id><pub-id pub-id-type="pmid">11944032</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>S. B.</given-names></name><name><surname>McNamara</surname><given-names>P.</given-names></name><name><surname>Heo</surname><given-names>S.</given-names></name><name><surname>Turner</surname><given-names>A.</given-names></name><name><surname>Lane</surname><given-names>W. S.</given-names></name><name><surname>Chakravarti</surname><given-names>D.</given-names></name></person-group> (<year>2001</year>). <article-title>Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein</article-title>. <source/>Cell
<volume>104</volume>, <fpage>119</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00196-9</pub-id><pub-id pub-id-type="pmid">11163245</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhan</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>M.</given-names></name><name><surname>Satoh</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth</article-title>. <source/>Nat. Commun.
<volume>5</volume>, <fpage>5425</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6425</pub-id><pub-id pub-id-type="pmid">25370275</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shikama</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>C. W.</given-names></name><name><surname>France</surname><given-names>S.</given-names></name><name><surname>Delavaine</surname><given-names>L.</given-names></name><name><surname>Lyon</surname><given-names>J.</given-names></name><name><surname>Krstic-Demonacos</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>A novel cofactor for p300 that regulates the p53 response</article-title>. <source/>Mol. Cell
<volume>4</volume>, <fpage>365</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="pmid">10518217</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sicinski</surname><given-names>P.</given-names></name><name><surname>Donaher</surname><given-names>J. L.</given-names></name><name><surname>Parker</surname><given-names>S. B.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Fazeli</surname><given-names>A.</given-names></name><name><surname>Gardner</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>Cyclin D1 provides a link between development and oncogenesis in the retina and breast</article-title>. <source/>Cell
<volume>82</volume>, <fpage>621</fpage>–<lpage>630</lpage>. <pub-id pub-id-type="pmid">7664341</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spassky</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>Y. G.</given-names></name><name><surname>Aguilar</surname><given-names>A.</given-names></name><name><surname>Strehl</surname><given-names>L.</given-names></name><name><surname>Besse</surname><given-names>L.</given-names></name><name><surname>Laclef</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Primary cilia are required for cerebellar development and Shh-dependent expansion of progenitor pool</article-title>. <source/>Dev. Biol.
<volume>317</volume>, <fpage>246</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2008.02.026</pub-id><pub-id pub-id-type="pmid">18353302</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupfler</surname><given-names>B.</given-names></name><name><surname>Birck</surname><given-names>C.</given-names></name><name><surname>Séraphin</surname><given-names>B.</given-names></name><name><surname>Mauxion</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation</article-title>. <source/>Nat. Commun.
<volume>7</volume>:<fpage>10811</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms10811</pub-id><pub-id pub-id-type="pmid">26912148</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>C. H.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Ciliary resorption modulates G1 length and cell cycle progression</article-title>. <source/>Cell Cycle
<volume>10</volume>, <fpage>2825</fpage>–<lpage>2826</lpage>. <pub-id pub-id-type="doi">10.4161/cc.10.17.16943</pub-id><pub-id pub-id-type="pmid">21964298</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takanashi</surname><given-names>M.</given-names></name><name><surname>Oikawa</surname><given-names>K.</given-names></name><name><surname>Fujita</surname><given-names>K.</given-names></name><name><surname>Kudo</surname><given-names>M.</given-names></name><name><surname>Kinoshita</surname><given-names>M.</given-names></name><name><surname>Kuroda</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Heterochromatin protein 1γ epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers</article-title>. <source/>Am. J. Pathol.
<volume>174</volume>, <fpage>309</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2009.080148</pub-id><pub-id pub-id-type="pmid">19056850</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takash</surname><given-names>W.</given-names></name><name><surname>Canizares</surname><given-names>J.</given-names></name><name><surname>Bonneaud</surname><given-names>N.</given-names></name><name><surname>Poulat</surname><given-names>F.</given-names></name><name><surname>Mattei</surname><given-names>M. G.</given-names></name><name><surname>Jay</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling</article-title>. <source/>Nucleic Acids Res.
<volume>29</volume>, <fpage>4274</fpage>–<lpage>4283</lpage>. <pub-id pub-id-type="doi">10.1093/nar/29.21.4274</pub-id><pub-id pub-id-type="pmid">11691915</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>I.</given-names></name><name><surname>Lai</surname><given-names>J.</given-names></name><name><surname>Yong</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S. F.</given-names></name><name><surname>Leung</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase</article-title>. <source/>FEBS Lett.
<volume>585</volume>, <fpage>1260</fpage>–<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2011.03.054</pub-id><pub-id pub-id-type="pmid">21457715</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>I.</given-names></name><name><surname>Yong</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>J. M.</given-names></name><name><surname>Lim</surname><given-names>L.</given-names></name><name><surname>Leung</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>A tripartite complex containing MRCK modulates lamellar actomyosin retrograde flow</article-title>. <source/>Cell
<volume>135</volume>, <fpage>123</fpage>–<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.09.018</pub-id><pub-id pub-id-type="pmid">18854160</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanikawa</surname><given-names>C.</given-names></name><name><surname>Espinosa</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Masuda</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Tsuchiya</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Regulation of histone modification and chromatin structure by the p53-PADI4 pathway</article-title>. <source/>Nat. Commun.
<volume>3</volume>:<fpage>676</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1676</pub-id><pub-id pub-id-type="pmid">22334079</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M. D.</given-names></name><name><surname>Northcott</surname><given-names>P. A.</given-names></name><name><surname>Korshunov</surname><given-names>A.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>Y.-J.</given-names></name><name><surname>Clifford</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Molecular subgroups of medulloblastoma: the current consensus</article-title>. <source/>Acta Neuropathol.
<volume>123</volume>, <fpage>465</fpage>–<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-011-0922-z</pub-id><pub-id pub-id-type="pmid">22134537</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teicher</surname><given-names>B. A.</given-names></name><name><surname>Fricker</surname><given-names>S. P.</given-names></name></person-group> (<year>2010</year>). <article-title>CXCL12 (SDF-1)/CXCR4 pathway in cancer</article-title>. <source/>Clin. Cancer Res.
<volume>16</volume>, <fpage>2927</fpage>–<lpage>2931</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-2329</pub-id><pub-id pub-id-type="pmid">20484021</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiveron</surname><given-names>M. C.</given-names></name><name><surname>Cremer</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>CXCL12/CXCR4 signalling in neuronal cell migration</article-title>. <source/>Curr. Opin. Neurobiol.
<volume>18</volume>, <fpage>237</fpage>–<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2008.06.004</pub-id><pub-id pub-id-type="pmid">18644448</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trichonas</surname><given-names>G.</given-names></name><name><surname>Murakami</surname><given-names>Y.</given-names></name><name><surname>Thanos</surname><given-names>A.</given-names></name><name><surname>Morizane</surname><given-names>Y.</given-names></name><name><surname>Kayama</surname><given-names>M.</given-names></name><name><surname>Debouck</surname><given-names>C. M.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>107</volume>, <fpage>21695</fpage>–<lpage>21700</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1009179107</pub-id><pub-id pub-id-type="pmid">21098270</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triplett</surname><given-names>J. W.</given-names></name><name><surname>Feldheim</surname><given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Eph and ephrin signaling in the formation of topographic maps</article-title>. <source/>Semin. Cell Dev. Biol.
<volume>23</volume>, <fpage>7</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2011.10.026</pub-id><pub-id pub-id-type="pmid">22044886</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unbekandt</surname><given-names>M.</given-names></name><name><surname>Croft</surname><given-names>D. R.</given-names></name><name><surname>Crighton</surname><given-names>D.</given-names></name><name><surname>Mezna</surname><given-names>M.</given-names></name><name><surname>McArthur</surname><given-names>D.</given-names></name><name><surname>McConnell</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>A novel small-molecule MRCK inhibitor blocks cancer cell invasion</article-title>. <source/>Cell Commun. Signal.
<volume>12</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/s12964-014-0054-x</pub-id><pub-id pub-id-type="pmid">25288205</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanden Berghe</surname><given-names>T.</given-names></name><name><surname>Linkermann</surname><given-names>A.</given-names></name><name><surname>Jouan-Lanhouet</surname><given-names>S.</given-names></name><name><surname>Walczak</surname><given-names>H.</given-names></name><name><surname>Vandenabeele</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Regulated necrosis: the expanding network of non-apoptotic cell death pathways</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>15</volume>, <fpage>135</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3737</pub-id><pub-id pub-id-type="pmid">24452471</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinnakota</surname><given-names>S.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Egal</surname><given-names>H.</given-names></name><name><surname>Sarthy</surname><given-names>V.</given-names></name><name><surname>Sarkar</surname><given-names>H. K.</given-names></name></person-group> (<year>1997</year>). <article-title>Molecular characterization and <italic>in situ</italic> localization of a mouse retinal taurine transporter</article-title>. <source/>J. Neurochem.
<volume>69</volume>, <fpage>2238</fpage>–<lpage>2250</lpage>. <pub-id pub-id-type="pmid">9375654</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>V. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Purkinje-cell-derived Sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum</article-title>. <source/>Curr. Biol.
<volume>9</volume>, <fpage>445</fpage>–<lpage>448</lpage>. <pub-id pub-id-type="pmid">10226030</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>V. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Proliferative and cell fate effects of Hedgehog signaling in the vertebrate retina</article-title>. <source/>Brain Res.
<volume>1192</volume>, <fpage>61</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2007.06.018</pub-id><pub-id pub-id-type="pmid">17655833</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wechsler-Reya</surname><given-names>R. J.</given-names></name></person-group> (<year>2014</year>). <article-title>The role of stem cells and progenitors in the genesis of medulloblastoma</article-title>. <source/>Exp. Neurol.
<volume>260</volume>, <fpage>69</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2012.11.014</pub-id><pub-id pub-id-type="pmid">23178582</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>V. Y.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2001</year>). <article-title>Genetic regulation of cerebellar development</article-title>. <source/>Nat. Rev. Neurosci.
<volume>2</volume>, <fpage>484</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1038/35081558</pub-id><pub-id pub-id-type="pmid">11433373</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>JimMY on the stage: Linking DNA damage with cell adhesion and motility</article-title>. <source/>Cell Adh. Migr.
<volume>4</volume>, <fpage>166</fpage>–<lpage>168</lpage>. <pub-id pub-id-type="doi">10.4161/cam.4.2.11368</pub-id><pub-id pub-id-type="pmid">20574148</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Dakubo</surname><given-names>G. D.</given-names></name><name><surname>Thurig</surname><given-names>S.</given-names></name><name><surname>Mazerolle</surname><given-names>C. J.</given-names></name><name><surname>Wallace</surname><given-names>V. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Retinal ganglion cell-derived sonic hedgehog locally controls proliferation and the timing of RGC development in the embryonic mouse retina</article-title>. <source/>Development
<volume>132</volume>, <fpage>5103</fpage>–<lpage>5113</lpage>. <pub-id pub-id-type="doi">10.1242/dev.02096</pub-id><pub-id pub-id-type="pmid">16236765</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X. A.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>25941</fpage>–<lpage>25953</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.375725</pub-id><pub-id pub-id-type="pmid">22605338</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wysocka</surname><given-names>J.</given-names></name><name><surname>Sayegh</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>Y. H.</given-names></name><name><surname>Perlin</surname><given-names>J. R.</given-names></name><name><surname>Leonelli</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Human PAD4 regulates histone arginine methylation levels via demethylimination</article-title>. <source/>Science
<volume>306</volume>, <fpage>279</fpage>–<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1126/science.1101400</pub-id><pub-id pub-id-type="pmid">15345777</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warskulat</surname><given-names>U.</given-names></name><name><surname>Heller-Stilb</surname><given-names>B.</given-names></name><name><surname>Oermann</surname><given-names>E.</given-names></name><name><surname>Zilles</surname><given-names>K.</given-names></name><name><surname>Haas</surname><given-names>H.</given-names></name><name><surname>Lang</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Phenotype of the taurine transporter knockout mouse</article-title>. <source/>Meth. Enzymol.
<volume>428</volume>, <fpage>439</fpage>–<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1016/S0076-6879(07)28025-5</pub-id><pub-id pub-id-type="pmid">17875433</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wechsler-Reya</surname><given-names>R. J.</given-names></name><name><surname>Scott</surname><given-names>M. P.</given-names></name></person-group> (<year>1999</year>). <article-title>Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog</article-title>. <source/>Neuron
<volume>22</volume>, <fpage>103</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="pmid">10027293</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehr</surname><given-names>M. C.</given-names></name><name><surname>Holder</surname><given-names>M. V.</given-names></name><name><surname>Gailite</surname><given-names>I.</given-names></name><name><surname>Saunders</surname><given-names>R. E.</given-names></name><name><surname>Maile</surname><given-names>T. M.</given-names></name><name><surname>Ciirdaeva</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila</article-title>. <source/>Nat. Cell Biol.
<volume>15</volume>, <fpage>61</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2658</pub-id><pub-id pub-id-type="pmid">23263283</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werbowetski-Ogilvie</surname><given-names>T. E.</given-names></name><name><surname>Seyed Sadr</surname><given-names>M.</given-names></name><name><surname>Jabado</surname><given-names>N.</given-names></name><name><surname>Angers-Loustau</surname><given-names>A.</given-names></name><name><surname>Agar</surname><given-names>N. Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Inhibition of medulloblastoma cell invasion by Slit</article-title>. <source/>Oncogene
<volume>25</volume>, <fpage>5103</fpage>–<lpage>5112</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1209524</pub-id><pub-id pub-id-type="pmid">16636676</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>J. E.</given-names></name><name><surname>Brown</surname><given-names>R. E.</given-names></name><name><surname>Buryanek</surname><given-names>J.</given-names></name><name><surname>Pfister</surname><given-names>S.</given-names></name><name><surname>Vats</surname><given-names>T. S.</given-names></name><name><surname>Rytting</surname><given-names>M. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Preliminary experience with personalized and targeted therapy for pediatric brain tumors</article-title>. <source/>Pediatr. Blood Cancer
<volume>59</volume>, <fpage>27</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/pbc.23402</pub-id><pub-id pub-id-type="pmid">22162424</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>K.</given-names></name><name><surname>Ren</surname><given-names>X.-R.</given-names></name><name><surname>Huang</surname><given-names>Y.-Z.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Saito</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the slit-robo pathway</article-title>. <source/>Cell
<volume>107</volume>, <fpage>209</fpage>–<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00530-X</pub-id><pub-id pub-id-type="pmid">11672528</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wuyts</surname><given-names>A.</given-names></name><name><surname>Govaerts</surname><given-names>C.</given-names></name><name><surname>Struyf</surname><given-names>S.</given-names></name><name><surname>Lenaerts</surname><given-names>J. P.</given-names></name><name><surname>Put</surname><given-names>W.</given-names></name><name><surname>Conings</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Isolation of the CXC chemokines ENA-78, GRO α and GRO γ from tumor cells and leukocytes reveals NH2-terminal heterogeneity</article-title>. <source/>Funct. Compar. Differ. Nat. Isoforms
<volume>260</volume>, <fpage>421</fpage>–<lpage>429</lpage>. <pub-id pub-id-type="pmid">10095777</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yabuta</surname><given-names>N.</given-names></name><name><surname>Okada</surname><given-names>N.</given-names></name><name><surname>Ito</surname><given-names>A.</given-names></name><name><surname>Hosomi</surname><given-names>T.</given-names></name><name><surname>Nishihara</surname><given-names>S.</given-names></name><name><surname>Sasayama</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Lats2 is an essential mitotic regulator required for the coordination of cell division</article-title>. <source/>J. Biol. Chem.
<volume>282</volume>, <fpage>19259</fpage>–<lpage>19271</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M608562200</pub-id><pub-id pub-id-type="pmid">17478426</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Minoshima</surname><given-names>S.</given-names></name><name><surname>Shimizu</surname><given-names>N.</given-names></name></person-group> (<year>2007</year>). <article-title>Identification of three novel proteins (SGSM1, 2, 3) which modulate small G protein (RAP and RAB)-mediated signaling pathway</article-title>. <source/>Genomics
<volume>90</volume>, <fpage>249</fpage>–<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygeno.2007.03.013</pub-id><pub-id pub-id-type="pmid">17509819</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Edman</surname><given-names>L. C.</given-names></name><name><surname>Sánchez-Alcañiz</surname><given-names>J. A.</given-names></name><name><surname>Fritz</surname><given-names>N.</given-names></name><name><surname>Bonilla</surname><given-names>S.</given-names></name><name><surname>Hecht</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Cxcl12/Cxcr4 signaling controls the migration and process orientation of A9-A10 dopaminergic neurons</article-title>. <source/>Development
<volume>140</volume>, <fpage>4554</fpage>–<lpage>4564</lpage>. <pub-id pub-id-type="doi">10.1242/dev.098145</pub-id><pub-id pub-id-type="pmid">24154522</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z. J.</given-names></name><name><surname>Ellis</surname><given-names>T.</given-names></name><name><surname>Markant</surname><given-names>S. L.</given-names></name><name><surname>Read</surname><given-names>T. A.</given-names></name><name><surname>Kessler</surname><given-names>J. D.</given-names></name><name><surname>Bourboulas</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells</article-title>. <source/>Cancer Cell
<volume>14</volume>, <fpage>135</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2008.07.003</pub-id><pub-id pub-id-type="pmid">18691548</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yim</surname><given-names>E. K.</given-names></name><name><surname>Peng</surname><given-names>G.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Rak functions as a tumor suppressor by regulating PTEN protein stability and function</article-title>. <source/>Cancer Cell
<volume>15</volume>, <fpage>304</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2009.02.012</pub-id><pub-id pub-id-type="pmid">19345329</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Lei</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Craft</surname><given-names>C. M.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>KASH protein Syne-2/Nesprin-2 and SUN proteins SUN1/2 mediate nuclear migration during mammalian retinal development</article-title>. <source/>Hum. Mol. Genet.
<volume>20</volume>, <fpage>1061</fpage>–<lpage>1073</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq549</pub-id><pub-id pub-id-type="pmid">21177258</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Rubin</surname><given-names>J. B.</given-names></name><name><surname>Cho</surname><given-names>Y. J.</given-names></name><name><surname>Shu</surname><given-names>H. K.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration</article-title>. <source/>Mol. Cancer
<volume>12</volume>:<fpage>18</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-12-18</pub-id><pub-id pub-id-type="pmid">23497290</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Yeung</surname><given-names>P. L.</given-names></name><name><surname>Li</surname><given-names>C. W.</given-names></name><name><surname>Tsai</surname><given-names>S. C.</given-names></name><name><surname>Dinh</surname><given-names>G. K.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>33799</fpage>–<lpage>33805</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M403997200</pub-id><pub-id pub-id-type="pmid">15184363</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Woodford</surname><given-names>N.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name><name><surname>Hamburger</surname><given-names>A. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases</article-title>. <source/>Nucleic Acids Res.
<volume>31</volume>, <fpage>2168</fpage>–<lpage>2177</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkg318</pub-id><pub-id pub-id-type="pmid">12682367</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Hua</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling</article-title>. <source/>J. Neurooncol.
<volume>110</volume>, <fpage>9</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-012-0933-1</pub-id><pub-id pub-id-type="pmid">22790444</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>CXCL12 Enhances Human Neural Progenitor Cell Survival Through a CXCR7- and CXCR4-Mediated Endocytotic Signaling Pathway</article-title>. <source/>Stem Cells
<volume>30</volume>, <fpage>2571</fpage>–<lpage>2583</lpage>. <pub-id pub-id-type="doi">10.1002/stem.1239</pub-id><pub-id pub-id-type="pmid">22987307</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X. C.</given-names></name><name><surname>Nagasawa</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>J. Y.</given-names></name><name><surname>Rao</surname><given-names>Y.</given-names></name></person-group> (<year>2002</year>). <article-title>Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons</article-title>. <source/>Nat. Neurosci.
<volume>5</volume>, <fpage>719</fpage>–<lpage>720</lpage>. <pub-id pub-id-type="doi">10.1038/nn881</pub-id><pub-id pub-id-type="pmid">12080344</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinke</surname><given-names>J.</given-names></name><name><surname>Schneider</surname><given-names>F. T.</given-names></name><name><surname>Harter</surname><given-names>P. N.</given-names></name><name><surname>Thom</surname><given-names>S.</given-names></name><name><surname>Ziegler</surname><given-names>N.</given-names></name><name><surname>Toftgard</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma</article-title>. <source/>Mol. Cancer
<volume>14</volume>, <fpage>17</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-015-0294-4</pub-id><pub-id pub-id-type="pmid">25645196</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlotnik</surname><given-names>A.</given-names></name><name><surname>Yoshie</surname><given-names>O.</given-names></name><name><surname>Nomiyama</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>The chemokine and chemokine receptor superfamilies and their molecular evolution</article-title>. <source/>Genome Biol.
<volume>7</volume>:<fpage>243</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2006-7-12-243</pub-id><pub-id pub-id-type="pmid">17201934</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuchero</surname><given-names>J. B.</given-names></name><name><surname>Belin</surname><given-names>B.</given-names></name><name><surname>Mullins</surname><given-names>R. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Actin binding to WH2 domains regulates nuclear import of the multifunctional actin regulator JMY</article-title>. <source/>Mol. Biol. Cell
<volume>23</volume>, <fpage>853</fpage>–<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E11-12-0992</pub-id><pub-id pub-id-type="pmid">22262458</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuchero</surname><given-names>J. B.</given-names></name><name><surname>Coutts</surname><given-names>A. S.</given-names></name><name><surname>Quinlan</surname><given-names>M. E.</given-names></name><name><surname>Thangue</surname><given-names>N. B.</given-names></name><name><surname>Mullins</surname><given-names>R. D.</given-names></name></person-group> (<year>2009</year>). <article-title>p53-cofactor JMY is a multifunctional actin nucleation factor</article-title>. <source/>Nat. Cell Biol.
<volume>11</volume>, <fpage>451</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1852</pub-id><pub-id pub-id-type="pmid">19287377</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>